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Colorectal cancer (CRC) is the second most common cancer in both men and 
women. Approximately 3-5% of CRCs show microsatellite instability (MSI) caused by 
germline defects in mismatch repair genes. In addition, 12% of sporadic CRCs show 
MSI. Currently, MSI is tested using a fragment analysis based assay not suitable for 
high throughput testing. Knowledge of microsatellite instability affects prognosis, 
surveillance and treatment of CRCs and MSI testing is now recommended for all 
newly diagnosed CRCs. As a result, development of high throughput approaches is 
desirable. The focus of my work was to develop and validate a high throughput 
sequence based MSI assay. 
Initially, I tested 25 (7-9bp) mononucleotide markers, previously identified from 
in silico analyses, using a cohort of 55 CRCs, and selected 8 markers which 
collectively could discriminate between MSI-high (MSI-H) and microsatellite stable 
(MSS) cases. To define the optimal parameters to discriminate between MSI-H and 
MSS samples, I tested these 8 markers and 9 long (8-12bp) mononucleotide markers 
identified in a parallel study, across a panel of 141 CRC samples. This allowed 
development of a scoring scheme for the 17 markers, which achieved 96% sensitivity 
and 100% specificity. I validated this scheme using an independent cohort of 70 
CRCs without knowing their MSI status. The assay achieved a 100% sensitivity and 
specificity.  
Finally, I assessed the ability of short repeats to allow inference of the clonal 
variation within both FFPE (7) and fresh (4) MSI-H CRCs by analysing multiple 
samples from each cancer. I was able to infer the lineage relationship between 
primary tumour and lymph node metastasis in three cases and to construct 
phylogenetic trees for all cancers for which multiple samples were available 
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Chapter 1. Introduction 
1.1. Colorectal Cancer and microsatellite instability 
Colorectal cancer (CRC) is the third most common cancer both in men and 
women. Every year, approximately 40,000 new colorectal cancer cases are 
diagnosed in the UK and one person out of 20 is estimated to develop colorectal 
cancer at  some point in the life (Cancer-Research-UK, 2015). 
Like other types of cancer, CRC is accompanied by the emergence of many 
genetic and epigenetic alterations. In about 15% of early stages CRCs, a specific 
form of genetic alteration, called microsatellite instability (MSI), is observed (Ward et 
al., 2001, Kim et al., 1994). Microsatellites are short, repetitive DNA sequences 
scattered across Eukaryotic genomes. Microsatellites are more liable to length 
changes as a result of suboptimal fidelity of DNA polymerase in replicating these 
sequences. 
Under normal circumstances, errors that happen during DNA replication of 
microsatellites are corrected by a special family of proteins known as mismatch repair 
proteins encoded by mismatch repair genes (MMR). Germline mutations of MMR 
genes are the hallmark of the most common hereditary type of CRC, which is known 
as Lynch syndrome. It is expected, therefore, to find a certain level of microsatellite 
instability in the context of mutated MMR genes (Lynch and de la Chapelle, 2003, De 
la Chapelle, 2004). 
  Microsatellite instability (MSI) has a biological and clinical impact in CRC. It has 
been found that MSI positive CRCs (MSI-H) have better outcomes than microsatellite 
stable (MSS) CRC in terms of survival, response to certain chemotherapies and low 
recurrence rate (Sinicrope et al., 2011, Saridaki et al., 2014). Furthermore, MSI 
positive CRCs are less likely to distantly metastasize and more prone to reside in the 
right side of the colon (Caecum and Ascending colon) compared to MSS CRCs (Kim 
et al., 1994). 
As a result of the aforementioned importance, finding a reliable laboratory test 
to detect microsatellite instability is desirable. This need has been addressed using a 
variety of methods over the last 2 decades and a consensus guidelines were 
published in 1997 (Rodriguez-Bigas et al., 1997) and amended in 2004 (Umar et al., 
2004) to guide diagnosis of microsatellite instability. In practice, MSI testing has been 
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applied in the form of a widely used commercial kit sold by Promega (Promega, 
Madison, WI, USA). This MSI test is based on a multiplex amplification of 5 
quasimonomorphic long (more than 20 nucleotides in length) mononucleotide 
markers followed by a fragment analysis. Although it is the most commonly used one, 
this test has several drawbacks such as the reliance on long repetitive tracts, 
convoluted interpretation, low throughput and a suboptimal sensitivity and specificity 
in cancers with MSH6 mutations and tumours other than CRCs (Lynch et al., 2009, 
Berg et al., 2009). 
As a result of the clinical benefits of MSI detection and its impact on the 
subsequent choice of treatment, seminal guidelines have recently recommended 
offering the MSI test for all newly diagnosed CRCs (Berg et al., 2009, de la Chapelle 
and Hampel, 2010, Vasen et al., 2013, Loughrey et al., 2014). It is desirable, 
therefore, to develop a new MSI testing approach accurate and robust enough to 
satisfy these evolving needs on a large-scale basis. 
The advent of massive parallel sequencing techniques (also known as Next 
Generation Sequencing (NGS)) has opened the way for new research and diagnostic 
developments. This has made it feasible to use the multiplexing potential of NGS to 
analyse thousands of targets in the same sequencing run with a relatively short 
turnaround time. It may be possible, therefore, to develop an NGS based MSI assay 
robust and sensitive enough to be used in clinical laboratories. 
1.2. MMR Genes  
1.2.1. MMR Function 
Every day, millions of cells in a human body are lost and replaced by new cells 
from skin, hair follicles and other organs. This replacement (which is achieved by 
compensatory cell division) is accompanied by millions of DNA replication events that 
are essential to ensure the newly synthesized cells get the exact copy of the parental 
DNA and thus maintain viability of the organism. Due to the huge number of cell 
divisions, nucleotide errors during DNA replications are inevitable events, and under 
normal circumstances, these occur at a low rate of approximately 1.3×10-8 base pairs 
per generation in humans (Scally and Durbin, 2012, Nachman and Crowell, 2000). In 
most eukaryotes, the rate of mutation is controlled by the characteristic 3’-5’ 
exonuclease activity of DNA polymerase which is responsible for proofreading of the 
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newly synthesized DNA strand to ensure an accurate DNA replication. However, in 
repetitive sequences, in vivo studies showed that this proofreading function is 
efficient with short sequences only (Tran et al., 1997). 
A further level of controlling DNA errors is achieved by a group of specialized 
proteins, which function within the Mismatch Repair system encoded by the 
Mismatch Repair genes. Mismatch Repair (MMR) genes that are involved in 
predisposition to human cancers include MLH1 (mutL Homolog1), MSH2 (mutS 
Homolog 2), MSH6 (mutS Homolog 6) and PMS2 (Postmieotic Segregation 
increased 2).  
Roles of MMR genes in DNA repair have a sequential pattern (as shown in the 
Figure  1-1 comprising: 
1) Recognition of the DNA error: This is primarily achieved by the human 
homologue of the MSH family (hMSH). hMSHα heterodimer (composed of one 
molecule of MSH2 and one molecule of MSH6) which recognizes small 
insertion/deletion loops (IDLs) and base mismatches, while hMSHβ (MSH2 
and MSH3) are capable of recognizing larger IDLs (Jascur and Boland, 2006). 
There is evidence indicating that recognition of the mismatch in the newly 
synthesized strand requires the finding of a nick (e.g. that created by Okazaki 
fragments) which in turn can be used as an access point for subsequent 
enzymes involved in repair (e.g. Exonuclease I) (Jascur and Boland, 2006). 
2) Recruitment of the repair enzyme machinery: This involves the hMutL 
complex (which is composed of hMLH1 and hPMS2) which modifies the 
enzymatic activity of DNA polymerase, displacing the proliferating cell nuclear 
antigen (PCNA) and recruiting Exonuclease I (Exo 1), which in turn is required 
for excision of mismatched sequences.  
3) Removal (excision) of the incorrectly matched bases: This step is 
mediated by Exo 1 which excises a single strand (may reach up to 1000 
nucleotides) from a nick, to the position of the mismatch in 5’-3’ or 3’-5’ 
direction (Genschel et al., 2002).  
4) Resynthesis of the required bases by DNA polymerase: This step is 
achieved by DNA polymerase δ (Wilson et al., 2005, Jascur and Boland, 
2006). 




Figure ‎1-1: The sequential action of MMR genes in DNA repair (Martin and Scharff, 2002). 
MMR genes are also involved in several other cellular functions (other than 
mismatch repair) which include repairing of double strand breaks, induction of 
apoptosis, anti-recombination effect, and destabilzation of DNA (Hegde et al., 2014). 
1.2.2. MMR Defects 
Based on the MMR functions outlined above, it is clear how defective MMR 
genes (whether complete absence of a protein or just a defective protein) could 
initiate events leading to the accumulation of genomic mutations. Lynch syndrome 
(LS, also called hereditary non polyposis colorectal cancer), is a hereditary disorder 
where inherited mutations in MMR genes increase the susceptibility to certain 
cancers, particularly CRCs. In LS, germline mutations in MMR genes are most often 
detected in MLH1 and MSH2 (about 90%) and less frequently in MSH6 and PMS2 
(10%) (Lynch and de la Chapelle, 2003). 
The most common mutations in the MMR genes are substitutions followed by 
deletions (Li et al., 2013a). However, MMR gene defects can also be found in other 
forms than point mutation, including the following: 
- Genomic rearrangements of MLH1 and MSH2: This kind of mutation 
represents a proportion of MMR gene mutations. Large genomic 
rearrangement extends from a single exon to a full gene deletion. In a study 
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conducted on 365 suspected LS patients, prevalence of large genomic 
rearrangements was reported to be 17.9% and 45.3% in MLH1 and MSH2, 
respectively in mutation positive cases (=153 cases) (Baudhuin et al., 2005).  
- Epigenetic changes: 60%-90% of the CpG islands in the human genome are 
methylated in the 5th carbon atom of cytosine bases. In the majority of 
expressed genes, these CpG islands are located in the promoter region, thus 
methylation leads to alterations in the function of these genes (Gazzoli et al., 
2002). MLH1 promoter hypermethylation has been reported in sporadic 
colorectal cancer cases with microsatellite instability (Kane et al., 1997). Li et 
al. (2013b) observed MLH1 promoter hypermethylation in 20.3% of unselected 
colorectal cancer cases. Interestingly, the prevalence of MLH1 
hypermethylation was reported to be as high as 80% of all MSI-H carriers 
(Lynch et al., 2009). Simultaneous methylation of MLH1 promoter and p16 in 
CRCs have recently been analysed and found to be associated with 
prognostic and clinicopathological features like right sided CRC, poorly 
differentiated, BRAF mutation positive and MSI-H phenotype (Veganzones et 
al., 2015). This kind of combined methylation has an impact on the disease 
free survival and might help in determination of new therapeutic approaches in 
MSI-H CRCs. 
- Promoter abnormalities: MSH2 promoter mutations have been investigated 
and a specific SNP (- 80 A insertion) has been found to change the binding 
activity of MSH2 and form a novel binding complex. However, these mutations 
seem to have a limited role in the initiation of carcinogenesis in both Lynch 
syndrome and early CRCs (Shin et al., 2002). 
1.3. Molecular testing of MMR defects 
1.3.1. Immunohistochemistry Analysis 
Routinely, MMR gene defects are often tested first by immunohistochemistry 
to check the functionality of these genes by targeting their protein products. This is 
usually done using commercially available antibodies against MMR proteins to test 
for expression in tissue samples. MMR immunohistochemistry (IHC) is a sensitive 
testing strategy and it detects MMR gene dysfunctions in colorectal cancer cases 
with sensitivity up to 100%. Its low cost and simplicity have made it a widely used 
testing option for MMR function. IHC, however, requires experienced personnel to 
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perform and to interpret the results, and can show a relatively low specificity (as low 
as 82%) (Stormorken et al., 2005). Furthermore, the existence of two independent 
somatic MMR gene mutations had been observed in up to 70% of MMR defective 
cases where no germline mutation is present. This is important to be detected as it 
will affect the subsequent surveillance options (Haraldsdottir et al., 2014). As a result 
of these limitations, IHC cannot be considered as the gold standard test to identify 
patients with defective MMR genes. 
1.3.2. Sequencing of MMR genes to detect point mutations  
PCR amplification of all coding exons and flanking sequences followed by 
direct gene scanning represents the gold standard testing strategy to detect point 
mutations of MMR genes. However, direct PMS2 gene sequencing can be 
complicated by the fact that this gene is located on chromosome 7 where several 
homologous copies also exist (i.e. PMS2 psuedogenes) (Nakagawa et al., 2004).  
The results of the preceding MMR IHC test can guide the decision of which 
gene needs to be tested, thus cutting the time and cost. Furthermore, with the advent 
of next generation sequencing, it has become possible to sequence all coding 
sequences of MMR genes in a single run. Nevertheless, both sequencing 
approaches (i.e. Sanger sequencing and next generation sequencing) would not be 
able to detect full exon or multi- exon deletions/ duplications. 
1.3.3. Detection of large genomic rearrangements (deletion and duplication) 
Multiplex Ligation-dependent Probe Amplification (MLPA) is the method of 
choice to detect large genomic rearrangements which are too small to be detected by 
standard cytogenetic methods. The existence of 2 or more sequentially deleted 
exons could be considered as a dependable result. However, when there is a 
deletion in a single exon (or a single probe deletion when multiple probes are 
designed for a single exon), results need to be confirmed by other techniques (e.g. 
sanger sequencing to check for a SNP at site of probe binding or Southern Blotting) 
(Hegde et al., 2013).  
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1.3.4. Other tests 
Other tests can be selectively performed in targeted cases. MLH1 promoter 
hypermethylation can be tested using bisulfite conversion followed by real time PCR 
to compare both wildtype and methylated plot graphs.  
In 10-40% of tumours with defective MSH2/MSH6 protein in IHC with no MMR 
germline mutations, the underlying reason is a deletion in the epithelial cell adhesion 
molecule (EpCAM) gene (Ligtenberg et al., 2009, Kovacs et al., 2009, Niessen et al., 
2009, Guarinos et al., 2010). EpCAM (also known as TACSTD1 gene) deletions 
usually lead to loss of the most 3’ exons (2 or 4 exons) in addition to the 
polyadenlation signal of the gene. This ,consequently, impairs the proper termination 
of transcription and leads to promoter methylation of the downstream gene, which is 
MSH2 (in tissues that express EpCAM) (Ligtenberg et al., 2009). EPCAM mutation 
status is tested for either by MLPA or Southern blot. 
Other less common genetic alterations might be involved in loss of MMR 
function, such as: 
1) Inversion of MSH2 (exons 1-7): In a study conducted in 2014, this inversion 
was observed in 6 out of 10 CRC patients with unexplained defective MSH2 
expression (Rhees et al., 2014).  
2) MMR germline mutations are usually associated with MSI, but in some cases 
where no germline mutation in MMR is existed, other genes might be 
responsible. Polymerase E (POLE) mutations have been found to be 
associated with MSI-H with the absence of MMR germline mutations (but was 
associated with MSH2 and MSH6 somatic mutations) (Elsayed et al., 2014). 
1.4. Microsatellite Instability 
1.4.1. Repetitive DNA  
Repetitive DNA refers to DNA sequences that are repeated many times 
(multiple copies) throughout the genome. These repetitive DNA sequences can be 
subdivided into: 
- Interspersed repeats: These are sequences that are repeated in different 
genomic positions, due to replication by transposition. Interspersed sequences 
can be further divided into long interspersed nuclear elements (LINEs) (more 
     
8 
 
than 300bp in length) such as L1 repeats or short interspersed nuclear 
elements (SINEs) (100-300bp) such as Alu elements. 
- Short tandem repeats (also known as microsatellites): DNA repeats of 2 
bases or more repeated 2- million times adjacent to each other. Some 
chromosomal regions have more abundance of these tandem repeats than 
others, e.g. centromere and telomere.   
- Segmental duplications: These are arbitrarily defined as any complex 
sequence tract of 1kb or more, which shares >90% identity to another region 
of the genome. These constitute 1-14% of different human chromosomes and 
highly enriched in pericentromeric and subtelomric regions (Zhang et al., 
2005, Treangen and Salzberg, 2012). 
Satellite is a “catch all” term for all non-mobile, highly repetitive sequences 
with a clear repeat periodicity within complex genomes. These repeats can be 
classified based on repeat periodicity into Satellites (>20 bases), Minisatellites (7-20 
bases) and Microsatellites (1-6 bases) (Ellegren, 2004).  
1.4.2. Microsatellites 
Microsatellites constitute about 3% of the human genome and can be 
classified in different ways. Based on repeat length, microsatellites can be 
subclassified into those with a single nucleotide (mononucleotide repeat), two 
(dinucleotides), three (trinucleotides), four (tetranucleotides), five (pentanucleoide) or 
6 (hexanucleotide). Alternatively, microsatellites can be classified based on the tract 
structure into perfect (or simple) microsatellites (in which the tract is continuous and 
made up of a single repetitive unit), imperfect (or complex) microsatellites (where the 
tract is interrupted by another sequences) or compound, where 2 or more 
microsatellite units coexist together (Urquhart et al., 1994, Sharma et al., 2007). 
However, microsatellites might undergo mutations, e.g. transition/transversion, which 
lead to a single event causing an interruption in the microsatellite tract. This 
interruption is usually increases the stability of the microsatellite. 
The vast majority of microsatellites (MSs) are located in the non-coding 
regions, however, about 8% of them can also exist within coding sequences 
(Ellegren, 2000) where the majority of them are tri- and hexanucleotides MSs 
(Subramanian et al., 2003). On the chromosomal level, microsatellites are unevenly 
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distributed in different human chromosomes, but chromosome 19 has the greatest 
population of these sequences (Subramanian et al., 2003). 
Mononucleotides are an abundant form of microsatellites across all 
chromosomes but comparatively more abundant in coding regions of chromosome 7 
and 16 while the least abundance is in the exonic regions of the Y chromosome. Poly 
A and poly T tracts are about 300- fold more abundant than Poly G and poly C 
across the genome (Subramanian et al., 2003).  
The exact function of microsatellites is not clearly understood, and they have 
historically been considered as junk DNA for this reason. However, some functions 
have been ascribed to specific microsatellites in a number of analyses: 
1- A highly conserved feature of many proteins involved in transcription 
regulation is that they contain glutamine- rich domains (Glutamine is 
encoded by a triplet sequence) (Escher et al., 2000). These glutamine rich 
activation domains were found to behave very similarly in both yeast and 
mammals in regulating gene expression. They are activated by the binding 
of acidic activators to remote enhancers.  
2- It has been suggested that microsatellites are involved in regulation of 
transcription of several genes such as early growth response 1 (EGR1), 
where increase in the length of polymorphic CA microsatellites in the first 
intron was found to be associated with reduced expression (Gebhardt et 
al., 1999), tyrosine hydroxylase, where a tetranucleotide microsatellite in 
the first intron was found to impact upon the gene expression and be 
associated with predisposition to schizophrenia (Meloni et al., 1995, Meloni 
et al., 1998) and P53 inducible gene 3 (PIG3), where a pentanucleotide 
microsatellite in the PIG3 promoter is necessary to facilitate the binding of 
the wildtype P53 and thus induce apoptosis  (Contente et al., 2002). 
3- Microsatellites may also have an effect on recombination (Wahls et al., 
1990), nucleosome positioning (Wang and Griffith, 1995) and chromatin 
structure (Heale and Petes, 1995). 
4- It has recently found that repetitive DNA sequences play a role in 
determination of the 3 dimensional structure of the genome in different 
organisms including human (Axel Cournac, 2015). 
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1.4.3. Multistep Evolution of Microsatellites 
The mechanisms of microsatellite development have been extensively 
studied. It has been suggested that microsatellites are developed initially from a 
specific sequences called ‘proto-STR’. These sequences have the ability to mutate 
and acquire instability. A threshold number of repeats need to be crossed prior to 
developing into a full-blown microsatellite. It has been proposed that 4 for di- and 2 
for tetranucleotides are the minimum number of repeats that are required for pro-STR 
to develop into microsatellites (Messier et al., 1996). 
1.4.4. Coding Microsatellites 
 Microsatellites (MS) are distributed randomly in the genome, thus they can 
be located in the coding, regulatory, intronic or intergenic sequences. When they are 
found in coding or regulatory sequences, microsatellite alterations are most likely to 
have functional consequences. Mononucleotide microsatellite instability in some 
target genes (e.g. TGFBRII, BAX, MSH3 and MSH6) has been found to be 
associated with the transition from early to late cancer stage (Yashiro et al., 2010). 
Recently, alterations of dinucleotide MSs in the 3’UTR of the microsomal 
prostaglandin E synthase-1 (mPGES-1) gene were shown to alter the expression of 
this gene in CRC (Cherukuri et al., 2015).  
1.4.5. Microsatellite instability 
Under normal circumstances, the mutation rate of the human genome is very 
low (down to 1.3 x 10-8 per nucleotide per generation). The mutation rate can be 
defined as the number of mutations per a specific genomic region with a specified 
length (e.g. megabase) or per time (e.g. cell generation) (Roberts and Gordenin, 
2014). The mutation rate in microsatellites is higher than normal sequences (up to 
1.2 x 10-3 per locus per gamete per generation) due to the high frequency of DNA 
polymerase slippage (Weber and Wong, 1993, Fan and Chu, 2007).  
Initially, Ionov and colleagues observed that colorectal cancer patients who 
have somatic mutations in particular poly (dA, dT) sequences have additional 
mutations in other simple DNA repeats. They initially named this condition as  
“mutator mutation” or “mutator phenotype” (Ionov et al., 1993). These terms 
correspond to what is currently known as “Microsatellite instability”.  
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Microsatellite instability first became implicated in hereditary colorectal cancer 
when an anonymous repetitive marker on chromosome 2p was genetically linked to 
the occurrence of early onset colorectal cancer (Peltomaki et al., 1993). At the same 
time, another related locus on chromosome 3p was mapped by another group of 
researchers (Lindblom et al., 1993). These findings were contributory to the 
discovery of MSH2 and MLH1 genes, respectively. 
Microsatellite instability (MSI) has been observed in up to 96-100% (Moslein et 
al., 1996, Mueller et al., 2009) of hereditary non polyposis colorectal cancer 
(HNPCC) where one or more of the MMR genes (MLH1, MSH2, MSH6 and PMS2) is 
mutated. It has also been detected in up to 15% of sporadic colorectal cancers, but in 
these cases, contrary to HNPCC, MSI is almost always caused by promoter 
hypermethylaion of the MLH1 gene (Boland, 2000). However, MSI was reported to 
be a rare event in rectal cancers and when found, most likely refers to hereditary 
background (i.e. Lynch syndrome) (Nilbert et al., 1999, de Rosa et al., 2016).  
1.4.6. Mechanisms of microsatellite instability 
 It is not clearly understood what is the exact mechanism that lies behind the 
development of microsatellites, however 4 possible mechanisms have been 
proposed: 
1- Unequal crossing over: This results in transfer of large tracts of satellite DNA 
between homologous chromosomes during recombination (Schug et al., 
1998). 
2- Poly A extension of Retrotranscripts: Some microsatellites are likely to be 
products of the extension of the 3’ poly A tail retrotranscripts after 
retroposition. This suggestion has been supported by the association of poly A 
microsatellites and transposable elements. However, this is not always true 
and at best, it only explains a single type of microsatellite (Nadir et al., 1996). 
3- Repetitive DNA usually assumes a non B DNA conformation; which is more 
mutation-labile (Wang et al., 2008). 
4- Replication slippage: It was postulated that slippage of DNA polymerase 
over a repetitive sequence is more likely to happen. This slippage leads to 
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generation of extra bases that form a loop and, if not eliminated, will be 
incorporated in the subsequent replication (Kornberg et al., 1964). 
Usually, mismatches occur during DNA replication by inserting a different 
(mismatched) base into the new DNA strand and, driven by the proofreading function 
of DNA polymerase and MMR proteins, these mismatches are corrected and the 
proper base inserted into the DNA strand. In the presence of intact MMR genes, 
these trivial changes are eliminated. If, for any reason, these erroneous bases are 
not corrected, the accumulation of these errors in repetitive sequences results in 
microsatellite instability. It has been found that MMR gene mutations (specifically, 
MLH1, MSH2 and PMS1) increase instability 100-700 fold. Moreover, loss of the 
proofreading function of DNA polymerase has been found to have less impact on the 
instability than MMR mutations (Strand et al., 1993).  
1.4.7. Factors affecting the microsatellite mutation rate  
Several factors have been suggested to influence the mutation rate of 
microsatellites. These are: 
1- Repeat number: In human, the slippage rate is exponentially increased with 
the repeat number (Lai and Sun, 2003). 
2- Repeat unit: Dinucleotides have been found to mutate more frequently than 
other kinds of microsatellites. Dinucleotides have also been found to undergo 
expansion more than contraction compared to tetranucleotides. This may, 
partly, explain the higher abundance of dinucleotide repeats (Ellegren, 2000). 
Non-disease causing dinucleotide repeats have higher mutation rates than 
trinucleotide microsatellites, while disease relevant trinucleotide repeats show 
mutation rates of up to 7 times higher than tetranucleotides (Chakraborty et 
al., 1997).  
3- Base composition of repeat unit: It has been shown that Poly G/C 
homopolymers have a higher mutation rate, even in the context of intact MMR 
genes (Boyer et al., 2002). 
4- Flanking sequences: The mutation rate of microsatellites is also affected by 
the sequence context within which the microsatellite is located e.g. high GC in 
the surrounding sequences reduces the mutation rate (Glenn et al., 1996). 
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5- Age: microsatellite instabilities can accumulate with time resulting in higher 
incidence in older age groups (Brinkmann et al., 1998).  
6- Sex: microsatellite mutations were found to behave in a sex-dependant 
manner with a higher mutation rate in male than female (this might be due to 
the higher number of replication in spermatogenesis than oogenesis) 
(Brinkmann et al., 1998, Ellegren, 2000). 
1.4.8. MSI testing: 
Direct MSI testing is performed using a PCR based technique to compare the 
fragment lengths of target microsatellites in cancer tissues with those of matched 
normal tissues. From 1997, MSI testing in diagnostic settings depended on a 
consensus panel, called the Bethesda panel, which was composed of two 
mononucleotide markers (BAT-25 and BAT-26) and three dinucleotide markers 
(D2S123, D5S346 and D17S250). Using that panel, tumours with 2 or more unstable 
markers were classified as MSI-High (MSI-H), those with one unstable marker are 
classified as MSI-Low (MSI-L) and those with no unstable marker are classified as 
MS- Stable (MSS) (Rodriguez-Bigas et al., 1997). To improve sensitivity of the 
Bethesda panel, revised guidelines have suggested the expansion of that panel to 
include more markers that are known to be less polymorphic (quasimonomorphic 
markers) (Umar et al., 2004). Currently, in diagnostic practice, most centers rely on a 
commercially available panel of quasimonomorphic mononucleotide markers sold by 
Promega (Promega, Madison, WI, USA). The fact that most people are homozygous 
at these markers means that tumours can be tested without the need for normal 
control tissue, thereby cutting costs.  
1.5. MSI and its impact on prognosis in CRCs 
In addition to the role of MSI status in diagnosis, it has a role in prognosis. 
MSI-H CRCs are found to be poorly differentiated, less aggressive and have a better 
prognosis (Saridaki et al., 2014). Moreover, MSI-H CRCs have been found to have a 
high risk of loco-regional recurrence (Søreide et al., 2009) and stage I MSI-H CRCs 
are unlikely to show lymph node metastasis (Kang et al., 2015). Therefore, 
stratification of patients for MSI status could affect the post-resection surveillance 
(endoscopy vs radioimaging) and prediction of lymph node involvement. 
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In a meta-analysis, MSI- H colorectal cancers were found to have a 15% 
better prognosis compared to MSS tumours (Popat et al., 2005). It has been reported 
that MSI-H status is an independent positive prognostic factor in stage II CRCs 
following surgical removal (Merok et al., 2013). In 2011, a large study concluded that 
a previously treated patients with stage II and III MSI-H CRCs have a better 
prognosis with improved disease free and overall survival (DFS and OS) (Sinicrope 
et al., 2011). The exact aetiology underpinning the better prognosis in MSI-H patients 
is not well understood, however, DCC, TP53 and KRAS gene mutations (which are 
all known to be associated with poorer prognosis in CRCs) are less common in MSI-
H cancers (Klump et al., 2004). Moreover, MSI-H associated CRCs have been shown 
to be heavily infiltrated by lymphocytes that might reflect immune-mediated 
mechanisms which may contribute to the favourable prognosis (Linnebacher et al., 
2001).  
The prognostic importance of MSI status appears to depend upon cancer 
stage. MSI-H is observed in 14-21% of stage II CRC and is associated with a good 
prognosis (Merok et al., 2013, Klingbiel et al., 2015), 7-12% of stage III CRCs with 
less prognostic benefit (Klingbiel et al., 2015) and only 4% of stage IV CRCs where it 
is associated with a poor prognosis (Hoffmeister et al., 2013, de Cuba et al., 2015).  
Based on these findings, it seems that there is an inverse relationship between the 
prognosis and stage of disease in MSI-H CRCs. The co-existence of other genetic 
mutations with MSI-H CRCs might be an underlying reason for this difference. BRAF 
mutations occur in about 40% of MSI-H CRC and it infers a poor prognosis. The 
coexistence of BRAF mutations might be the reason for the poor survival prediction 
in advanced MSI-H CRCs (Tran et al., 2011). It has been recommended therefore to 
test both KRAS and BRAF in MSI-H CRCs when a prognostic stratification is required 
(de Cuba et al., 2015).  
Elevated microsatellite alterations at selected tetranucleotide repeats 
(EMAST) was found to be elevated in MSI-H metastatic CRCs, and its existence 
associated with poor prognosis (worse overall survival) (Birgisson et al., 2015). 
Moreover, the existence of other genetic alterations (e.g. 1p36 deletion) was found to 
be associated with higher risk of dissemination in MSS, rather than MSI-H, CRCs 
(Mayrhofer et al., 2014). 
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Finally, as MMR gene mutations have been suggested to be an early event 
during colorectal carcinogenesis, it has been suggested that testing the colorectal 
adenomas obtained from routine follow up colonoscopy for MSI might be a useful tool 
for early detection and determination of surveillance option (Loukola et al., 1999).  
1.6. MSI and its impact on treatment of CRCs 
MSI status, to some extent, plays a role in choosing effective and safe 
chemotherapies in specific cancers. From the molecular point of view, it has been 
suggested that an intact MMR system is required to effectively induce apoptosis on 
exposure to 5-fluorouracil (5-FU) (Carethers et al., 1999). The MSI status has long 
been used to be a limiting factor of responsiveness to 5-FU (no response, or it may 
worsen the condition). Ribic et al (2003) concluded that Flourouracil (5-FU) based 
chemotherapy was effective in stage II or stage III MSS or MSI-Low, but not MSI-H 
colorectal cancers. In a meta-analysis conducted in 2009, stage I and II MSI-H CRC 
patients did not show a significant difference in both recurrence free and overall 
survival, whether or not they received chemotherapy (Des Guetz et al., 2009). In 
practice, all patients with stage III CRC, and some high risk stage II CRCs, receive 
FU-based adjuvant therapy, but in view of the above data, it has been proposed that 
MSI-H stage II CRCs should be excluded from this therapeutic scheme (de la 
Chapelle and Hampel, 2010). 
Some drugs seem to be selectively active in MSI-H CRCs. Methotrexate 
(MTX), a dihydrofolate reductase (DHFR) inhibitor, is a chemotherapeutic agent that 
is used to treat many human cancers including CRCs. MTX was found to be an 
effective therapeutic choice, particularly in those with mutated MSH2 (Martin et al., 
2009). Moreover, the addition of bevacizumab (antiangiogenic therapy) to the 
standard oxaliplatin-based therapy  has significantly improved survival in stage II & III 
MMR deficient CRCs (Pogue-Geile et al., 2013). 
The finding that MSI-H CRCs have a high density of lymphocyte infiltration has 
been suggested to be a basis for a promising immune–mediated, MSI-targeted 
therapy for HNPCC patients and their at risk relatives (Linnebacher et al, 2001). A 
recent study suggested that the accumulation of coding microsatellite instabilities 
results in synthesis of neoantigens which attract more CD8 tumour infiltrating 
lymphocytes (TILs), opening the window for immune-modulating therapies, both in 
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Lynch syndrome and sporadic MSI-H CRCs (Maby et al., 2015). Despite the fact that 
MSI-H CRCs usually show heavy lymphocytic infiltrations, they are not naturally 
eradicated, perhaps due to the associated immune checkpoint upregulations e.g. 
(Programmed death receptor-1) PD-1, (Programmed death ligand -1) PDL-1. Thus, 
developing new immune modulator therapies was suggested to be useful for MSI-H 
CRCs (Xiao and Freeman, 2015, Llosa et al., 2015). 
 A further potential impact of MSI testing is that knowing the MMR status prior 
to surgery might change surgical intervention because of the associated high 
possibility of metachronous cancer in dMMR CRCs. Extended resection (rather than 
segmental resection) in such patients has been found to reduce the risk of 
recurrence (Aronson et al., 2015). 
In approximately 80% of MSI-H CRCs, the underlying reason is 
hypermethylation of the MLH1 promoter (Lynch et al., 2009), giving rise to a distinct 
type of CRCs called CIMP (Cytosine Islands Methylation Phenotype) positive CRCs. 
The development of metachronous CRC after right hemicolectomy is uncommon in 
CIMP+ MSI-H CRC, while Lynch patients (who are CIMP- MSI-H) are still at 
increased risk of metachronous cancer after segmental resection (Messick et al., 
2014). Thus, classifying patients according to MSI status could have a significant 
impact on subsequent surgical decision. 
Quite recently, a landmark study concluded that the use of pembrolizumab 
(PD-1 blocking agent) showed observable clinical benefit in MMR deficient tumours 
(Le et al., 2015). This will likely open the window to development of a more target 
therapy in this particular group of tumours in the near future. Furthermore, the 
ongoing trials to develop a frameshift peptide (FSP) vaccines in MSI-H tumours 
represent a unique preventive scenario in this well-defined group of patients (Kloor et 
al., 2015). 
Although the current testing strategy performs well in classifying CRCs into 
MSI-H, MSI-L and MSS, it has several notable limitations: 
1) It is done now using a low throughput approach and usually complicated by a 
convoluted subjective interpretation based mainly on the visual inspection of 
fragment profiles.  
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2) It shows suboptimal sensitivity and specificity in detecting patients with MLH1 
and MSH2 gene mutations (91% and 90%, respectively) (Berg et al., 2009). 
3)  MSI-H is not detected in a number of colorectal cancer cases with MSH6  (or 
PMS2) germline mutations (55-77% sensitivity and 90% specificity) (Lynch et 
al., 2009, Berg et al., 2009). 
4) The low sensitivity to detect MSI in MMR deficient tumours other than CRC 
(85.7%) (Kuismanen et al., 2002). 
The majority of colorectal cancers are MSS, but a substantial body of evidence 
suggests that all colorectal cancers have some degree of instability which cannot be 
detected unless a satisfactory number of markers is used at least to differentiate 
between the MSI-L and MSS groups of CRCs (Laiho et al., 2002). A study conducted 
in 2013 showed that using a hexapanel has a superior sensitivity compared to the 
currently used pentaplex panel in terms of both detecting MSH6 mutated tumours 
(96.7% vs 84%) and MMR deficient non-colonic tumours (92.9% vs 85.7%) (Pagin et 
al., 2013). 
As a result of the clinical benefits of MSI detection and its impact on the 
subsequent choice of treatment, several studies and guidelines have recently 
recommended offering the MSI test for all newly diagnosed CRCs (Berg et al., 2009, 
de la Chapelle and Hampel, 2010, Vasen et al., 2013, Loughrey et al., 2014, Kloor et 
al., 2015). It is desirable, therefore, to develop a new MSI testing strategy accurate 
enough to satisfy these evolving needs on a large-scale basis. 
The advent of next generation sequencing (NGS) has opened new research 
and diagnostic avenues to adopt genetic tests on a large scale. In the last few years, 
researchers have started to look at the possibility of using high throughput 
techniques to test for MSI. In 2012, a comprehensive analysis conducted by the 
cancer genome atlas network (TCGA), showed, in part, that microsatellite instability 
can be detected using the NGS approach (Cancer Genome Atlas, 2012). One year 
later, a large-scale genome and transcriptome-wide study (Yoon et al., 2013) 
demonstrated the impact of MSI on the expression profile (it was associated with 
downregulation of 139 genes) in human gastric cancers, despite the majority of these 
instabilities (90.5%) being localized to the noncoding regions (UTRs). This study also 
showed that MSI could be detected at a huge number of repeats of varying length, 
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suggesting that sequence typing of short repeats may be a viable alternative option 
to current MSI testing techniques.  
The main aim of this study is to develop and validate an NGS based MSI test 
that can be used efficiently as a screening tool to fulfil the increasing demand for MSI 
screening. The development of such a test is promising because: 
1) It could be significantly cheaper due to the high number of cases being 
analysed, simplification of methodology, and removal of the need for manual 
visual analysis of raw data.  
2) It could potentially enable MSI testing to be offered routinely as a screening 
tool.  
3) It could help to improve the management of MSI-H tumours, as it would enable 
efficient identification of Lynch syndrome families (as the current method has 
suboptimal sensitivity and specificity in diagnosing Lynch patients).  
4) It could also have important implications in terms of surveillance of at risk 
individuals.  
5) Being offered in an NGS- based version, it could provide more options in the 
future to be collated with mutation testing of relevant genes in the same test 
(e.g. BRAF, MMR or KRAS) 
1.7. Clonality and Microsatellite Instability 
Cancer cells are usually known to share common features collectively known 
as “the hallmarks of cancer” like uncontrolled cell division, angiogenesis, evasion of 
the growth suppression, antiapoptotic features and others (Hanahan and Weinberg, 
2011). However, individual cancers are genetically heterogeneous and this 
heterogeneity reflects its variable biological features. Cancers are usually composed 
of more than one clone, cells within each clone share the same phenotypic and 
genotypic characteristics which might be different from those of other clones, creating 
a state of intratumour heterogeneity (ITH). This intrinsic intratumour variability 
imposes burdens in terms of both proper diagnosis and management (Michor and 
Polyak, 2010). 
It has been postulated that tumours are initiated from a vulnerable cell after 
exposure to a carcinogen. Genetic instability of that progenitor cell produces cells 
with a growth advantage and thus allows the clonal propagation. Most of the 
     
19 
 
produced cells die due to metabolic or environmental pressure, but occasionally, one 
cell survives that pressure (because it has additional selective advantage) and, with 
further division, results in a clone that has the same biological characteristics of the 
original progenitor cell in addition the acquired selective advantage mutations 
(Nowell, 1976). According to Nowell’s assumption, the tumour mass is derived solely 
from a single progenitor cell (unicellular origin). However, some tumours might be 
considered as exceptions from Nowell’s model like viral induced tumours e.g. 
condylomata acuminata (where viral infection might affect the surrounding cells) and 
hereditary cancers e.g. Neurofibromatosis where a familial gene mutation affects all 
cells and increase susceptibility to cancer. This concept has been extended later into 
linear and branched evolution. In linear evolution, it has been proposed that cancer 
cells will acquire genetic mutations with time and the fittest cell will create the 
dominant clone. According to the linear approach, most cancer cells belong to a 
single clone (the fittest clone) and that clone will carry all mutations that happened 
during the evolution of tumour. The branched model, on the other hand, states that 
cancer cells acquire different mutations resulting in different individual clones that 
develop concomitantly, but independently, in the tumour (Polyak, 2008, de Bruin et 
al., 2013). Consistent with the branched model, tumour genomic analyses revealed 
the coexistence of many independent clones and at the time of diagnosis, one 
becomes the dominant subclone. These dominant cell populations were estimated to 
constitute more than 50% of the tumour mass while other subdominant subclones 
equally or unequally share the rest of tumour cell populations (Nik-Zainal et al., 
2012).  
To assess the genetic heterogeneity, a clonal marker needs to be used to 
trace a cell or a group of cells and compare them with other cells within the same 
tumour mass or with different tumour lesions. X- Chromosome inactivation was used 
in preliminary trials. One of the X chromosomes in female mammals would be 
randomly inactivated during embryonic life in a phenomenon called Lyonization 
(Lyon, 1961). On propagation, daughter cells will inherit the same pattern of X 
chromosome inactivation from the parental cells. This concept was used to trace 
clonal characteristics in tumours. However, this approach is limited to females and 
would not give further information about the genetic characteristics of tumour cells 
(Wang et al., 2009). 
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The clonal development of cancer is associated with mutations in different 
genes. Mutations that confer phenotypic effect on cancer cells and are positively 
selected during cancer development are defined as driver mutations, while those that 
have no clear effect (or neutral) are named as passenger mutations (Stratton et al., 
2009). The vast majority of cancer associated mutations are passenger while the 
minority belonging to the driver class (Vogelstein et al., 2013). A genome wide 
screening of drivers and passengers was used to assess ITH in many human 
tumours (Futreal et al., 2004, McFarland et al., 2013, Carreira et al., 2014). However, 
the distribution of driver mutations does not reflect the proper phylogenetic 
relationship as these mutations impose selective advantage to cells bearing them 
(Naxerova et al., 2014). Passenger mutations, on the other hand, represent useful 
markers to detect early lesions that develop prior to tumour development, but a 
notable drawback of screening the passengers is the need to screen hundreds of 
thousands of genomic loci. However, the advent of massive parallel sequencing 
might help to make such an approach doable in the future (Salk and Horwitz, 2010). 
Analysis of specific genomic regions was used as an alternative approach to 
construct phylogenetic trees. A study conducted in 2014 utilised deep sequencing of 
X chromosome to assess the phylogenetic relationship in MMR-deficient colorectal 
adenomas (De Grassi et al., 2014). In that assay, all protein-coding genes in addition 
to selected intergenic segments in X chromosome were analysed in four male 
patients with colorectal adenomas with matched normal tissues to compare the 
mutational profile. It was possible, with this approach, to construct lineage 
relationship in each adenoma, however, such an approach is limited to markers that 
are located in chromosome X only. 
The rapid proliferation of cancer cells is associated with increased DNA 
replication. In repetitive sequences (microsatellites), the replication fidelity decreases 
due to the high possibility of polymerase slippage during replication (Lai and Sun, 
2003). Microsatellites can, therefore, be used as a genome wide approach to assess 
the intratumour heterogeneity. 
1.7.1. The role of microsatellites in assessment of clonality 
The successive accumulation of genetic and epigenetic alterations is crucial 
for the development of cancer and it has been suggested that the normal mutation 
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rate together with clonal expansion is enough to allow emergence of these alterations 
(Tomlinson et al., 1996). However, additional genomic instabilities (whether at the 
chromosomal or nucleotide levels) were found to be existed in most tumours 
(Lengauer et al., 1998). 
Microsatellites can be used as a biological clock to count the genetic events 
that occur during tumour development. Replication slippage is the most likely reason 
for the development of microsatellite instability. Therefore, instability (whether a 
deletion or insertion) develops during DNA replication, which happens with each cell 
division. During each slippage, a single base either deleted or inserted, but with intact 
repair genes, these slippage events are corrected and errors are eradicated from the 
genome. Based on that one division-one event concept, microsatellite instability can 
be used to document the time since MMR genes mutations have happened.  
It is believed that one of the first kind of microsatellites to mutate following 
MMR mutations is the mononucleotide (poly A and poly T) repeats (Ionov et al., 
1993, Blake et al., 2001). In yeast, the (A) homopolymers of > 8 bases length are 
more prone to mutations than shorter tracts. It has been suggested that both 
polymerase proofreading and MMR are able to deal with the alteration of short 
repeats, while only MMR proteins are able to repair mutation in the longer repeats. 
Therefore, genes containing coding homopolymers are at risk of inactivation when 
MMR genes are mutated (Tran et al., 1997).  
Most tumours appear thousands of replications after the loss of MMR function. 
Assuming a rate of 1 division per day, an MSI-H tumour requires a decade to develop 
after the loss of MMR genes compared to sporadic CRCs which requires more than a 
decade to evolve (Blake et al., 2001). It has been suggested that tumour clones with 
earlier MMR mutations acquire more MSI events and the longer the duration since 
MMR mutations have happened, the higher the frequency of microsatellite mutations. 
However, different cells, and hence different clones, will have different timing of MMR 
gene mutations. Therefore, these cells manifest variable microsatellites profiles. 
Moreover, both deletions and insertions could result in an allelic variation for each 
individual cell and this allelic variation can be used to discriminate between different 
cells (and hence, different clones) within the same tumour. Shibata et al (1996) have 
suggested that recently developed and adjacent clones are more likely to have a 
similar (or nearly similar) allelic profile, while the older and spatially distant clones are 
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likely to show more allelic diversity owing to the accumulations of different 
microsatellite mutational events. 
Microsatellite instability has been used to test the intratumour heterogeneity 
(ITH) in different human cancers. Dinucleotide microsatellite instability was 
successfully utilised to investigate the multileneage development in benign and 
tumour samples from Cutaneous T-cell lymphoma (CTCL) (Rübben et al., 2004). In 
intestinal metaplasia (IM), which is a premalignant condition of the intestinal type 
gastric cancer, microsatellite instability was used to investigate the genetic 
heterogeneity in different lesions from the same patient. Different allelic profiles of the 
tested microsatellites were observed in the spatially different lesions (Guo et al., 
2015). Beggs et al (2013), has extensively investigated the heterogeneity in MSI 
status in sporadic polyps using a unique approach (gland by gland approach). The 
study found a heterogenous MSI profile within the same polyp. The MSI in a 
heterogeneous polyp (MSI +/-) are thought to develop later during progression, while 
MSI+ polyps were thought to develop MSI earlier in the original adenomatous crypt. 
The existence of MSI clones within MSS polyps might accelerate carcinogenesis (as 
the MSI clone will be positively selected) (Beggs et al., 2013). 
Similarly, microsatellite instability can be used to compare the clonal 
characteristics between primary tumours and their metastases. One study tested the 
MS alterations both in the primary human tumours (lung and bladder cancers) and 
their distant foci, found that the alterations observed in the cytopathological samples 
(urine and sputum) and tumour edges, were identical to those in the primary site 
(Mao et al., 1994).   
The existence of genetic heterogeneity in terms of microsatellite instability can 
be indirectly used to distinguish between benign tumours and those which are 
potentially malignant lesions. PolyG monnucleoides, for instance, have been used to 
detect clonal lineages in preneoplastic conditions like ulcerative colitis (Salk et al., 
2009). 
A secondary aim of this study is to assess the utility of short mononucleotide 
microsatellites in determining the clonal changes between different specimens of 
MSI-H CRCs. This will help to determine the lineage relationship between the tested 
samples and assessing the tumour age since the event of MMR loss. 
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1.8. Aims of study and chapters outlines 
 This study aims to develop a high throughput MSI testing approach 
convenient to be used in routine clinical diagnostics. This panel is ultimately aiming to 
efficiently discriminate between MSI-H and MSS CRC cases. As a secondary aim, 
part of the study aimed to assess the utility of a panel of short mononucleotides to 
assess the clonal characteristics in MSI-H CRCs. 
In the first result chapter (Chapter 3), a panel of 25 short (7-9bp) 
mononucleotide markers was assessed across a cohort of 55 CRCs, of them 25 are 
MSI-H. The aim of this chapter is to assess the most informative markers in terms of 
differentiation between MSS and MSI-H cases. This chapter also includes my 
contribution in an initial assessment of a panel of 120 short repeats to find out the 
informative markers in assessing the MSI status. 
In the second result chapter (Chapter 4), the most informative markers from 
Chapter 3 in addition to informative mononucloetide markers from a parallel study (17 
markers in total, 7-12bp in length) are assessed using a large cohort composed of 
141 CRC samples (referred from Spain). The work of this Chapter aims to assess the 
degree of discrimination of that panel of markers, and to establish an informative 
calling system for classifying samples into MSI-H and MSS. 
In the third result chapter (Chapter 5), the calling system that was developed 
in chapter 4 is validated across an independent cohort composed of 70 CRC 
samples referred from Edinburgh. The utility of neighbouring SNPs to establish allele 
specificity is assessed as an additional informative criterion. 
In the fourth result chapter (Chapter 6), a panel of 23 short mononucleotide 
markers and the calling system developed and validated in previous chapters are 
used to assess the clonal characteristics of both fresh and FFPE MSI-H CRC 
tumours. For that purpose, different specimens from the same tumour were used. 
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Chapter 2. Methods 
2.1. Ethical approvals 
Samples for MSI analysis have been collected under the ethical approval 
referenced IRAS project ID: 99148 (REC reference: 13/LO/1514) entitled “The use of 
rapid DNA extraction and genetic testing on silicone nanowires to screen for 
microsatellite instability in tumour tissue as a matter of routine”. The clinical and 
pathological data of the collected cases were retrospectively checked, aided by the 
NHS passport under the reference number REF: LOA/CP.  
Amendment of the original approval was applied in order to cover the 
collection and processing of colorectal cancer fresh tissue (CRC) samples from the 
Royal Victoria Infirmary (RVI). The amendment was approved on the 10th of March 
2015.  
The samples that have been referred from abroad were covered by ethical 
approvals from the original referring laboratories. 
2.2. Clinical samples 
2.2.1. Tumour samples for MSI assay  
1) Eleven tumour DNA samples (5 MSI-H, 6 MSS and one matched normal 
sample) were used to assess the variability of 120 short repeats. These 
samples were processed by Dr Lisa Redford (Newcastle University, UK). The 
5 MSI-H samples were obtained from the Cancer Prevention Program 2 
(CAPP2) Biobank. Microsatellite instability was assessed using MSI Analysis 
System, Version 1.2 kit (Promega, Madison, WI, USA). 
2) A group of 248 formalin fixed- paraffin embedded (FFPE) tissue curls from 
different tumours were obtained from the Northern Genetics Service 
(Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK) in 2014. These 
tumours have previously been MSI tested using MSI Analysis System, Version 
1.2 kit (Promega, Madison, WI, USA), and their MSI status, clinical and 
pathological data were obtained from the National Health Service (NHS) 
database. These samples were classified into microsatellite instability-High 
(MSI-H) and microsatellite stable (MSS) accordingly. To increase the number 
of MSI-H tumours, 9 additional DNA samples from MSI-H CRC tumours were 
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provided from the Northern Genetics Service (Newcastle Upon Tyne Hospitals 
NHS Foundation Trust, UK). 
3) A batch of 201 CRC DNA samples (labelled as S1-201) was provided by the 
Genetics Service, Complejo Hospitalario de Navarra and the Oncogenetics 
and Hereditary Cancer Group, IDISNA (Biomedical Research Institute of 
Navarre, 31008 ESPANA). MSI status was determined for these samples 
using MSI Analysis System, Version 1.2 kit (Promega, Madison, WI, USA) and 
MMR IHC. From them, 141 CRC samples were chosen to be analysed and I 
was kept blind for their MSI status during analysis. 
4) A batch of 100 CRC DNA samples was provided by collaborators in Edinburgh 
(Dr Mark Arends, Department of Molecular Pathology, University of Edinburgh, 
UK). These samples were extracted and quantified in the original laboratory 
and, therefore, sent to us in the form of extracted DNA. The MSI status was 
determined based on MSI Analysis System, Version 1.2 kit (Promega, 
Madison, WI, USA) and MMR IHC. Our research group remained blind for the 
clinical and pathological data of these samples, but the cohort had 
approximately equal number of MSI-H and MSS samples. 
2.2.2. Tumour samples for clonality assay 
1) Thirteen groups of fresh CRC tissue samples were obtained from the 
Department of Cellular Pathology (RVI, Newcastle Upon Tyne Hospitals NHS 
Foundation Trust, UK). Each group was composed of 8 fresh tissue samples 
retrieved from different locations in clockwise orientations within the same 
CRC tumour. The samples were taken from locations corresponding to 3, 6, 9 
and 12 o’clock both by fine needle aspiration using BD Microlance 21-gage 
needles (BD, New Jersey, United States of America) (to retrieve deep samples 
from within the tumour mass) and scalpel (to retrieve more superficial tissue 
samples). The closest margin to the antimesentric border represents the 12 
o’clock position. Each tumour sample was accompanied by matched normal 
tissue sample from the same patient for the purpose of downstream analysis. 
The normal tissue samples were retrieved from normal mucosa 7-10cm away 
from the tumour mass to avoid tumour cell contamination. The retrieval of 
these samples was carried out by Dr Stephanie Needham (Department of 
Cellular Pathology, RVI, Newcastle Upon Tyne Hospitals NHS Foundation 
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Trust, UK). In addition, 3 fresh MSI-H CRC tumours were obtained from Dr 
Lisa Redford (Newcastle university, UK) to increase the number of MSI-H 
tumours. MSI status of these 3 additional MSI-H tumours was determined 
based on MSI Analysis System, Version 1.2 kit (Promega, Madison, WI, USA). 
2) The NHS database was mined to identify MSI-H CRC tumours (using MSI 
Analysis System, Version 1.2 kit (Promega, Madison, WI, USA)) with lymph 
node involvement (or those with a multiple tumour samples) that had been 
referred from the RVI in the time from 2000-2015. The search was limited to 
the RVI referred cases due to technical and ethical issues. The criteria I was 
looking for, were to get at least 2 different tumour samples for each patient 
and/or an involved lymph node (when possible). Eighteen MSI-H CRC’s 
tumours were found to have adequate pathological information (their 
histopathological reports were examined) and all were referred from the RVI. 
Overall, a total of 7 FFPE CRC tumours were collected and for each of them, 
there was at least one additional sample from an involved lymph node or from 
a different colonic location (caecal, ascending, transverse, descending, 
sigmoid or rectal). The corresponding slides were requested from the 
department of cellular pathology and reviewed by a candidate pathologist (Dr 
Helen Turner, Department of Cellular Pathology, RVI, Newcastle Hospitals 
NHS Foundation Trust, UK). The pathologist reviewed the slides and selected 
the appropriate slides fulfilling the requested criteria. The corresponding 
blocks (from which the nominated slides were retrieved) were then requested 
and collected from the Department of Cellular Pathology. Four slices of 10µM 
thickness were cut from each block by our in house microtome (Leica 
Microsystems GmbH, Wetzlar, Germany) for DNA extraction. 
The clinical samples included in this study and their details are 
summarized in Table  2-1. 






 Year Group 
No. of 
cases 
Description Provider Form 
Samples used in the MSI assay 
1 2014 CRC tumours  11 
5 MSI-H tumour sample obtained from CAPP2 and 6 
MSS tumours in addition to a single normal sample  
CAPP2 DNA 
2 2014 Tumours 248 
Composed of different cancers and all have been MSI 
tested previously 
NGS/ NUTH FFPE curls 
3 2014 MSI-H CRCs 9 
These are 9 additional samples to increase the number 
of MSI-H tumours. 
NGS/ NUTH DNA 
4 2015 CRC tumours 201 
141 samples were chosen for analysis. Almost half of 
them are MSI-H and the rest are MSS samples 
Spain DNA 
5 2015 CRC tumours 100 50 MSI-H and 50 MSS samples Edinburgh DNA 
Samples used in the clonality assay 
1 2015 CRC tumours 13 
Each group represents a single CRC tumour. For each 
CRC tumour, 8 specimens in addition to 1 matching 
normal sample were provided. 
RVI/ NUTH Fresh tissue 
2 2015 MSI-H CRC tumours  3 
These are 3 MSI-H tumours prepared and extracted 
previously 
NU DNA 
3 2016 MSI-H CRC tumours 7 
At least 2 samples from 2 different locations were 
provided for each tumour 
RVI/ NUTH FFPE blocks 
Table ‎2-1: Colorectal cancer tumours that were analysed in this study and their provider.   CAPP2= Cancer Prevention Program, NGS= Northern 
Genetic Service, NUTH= Newcastle Upon Tyne Hospitals, RVI= Royal Victoria Infirmary hospital, NU= Newcastle University. 
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2.3. DNA Extraction 
2.3.1. DNA extraction from FFPE tissue samples using the BiOstic FFPE Tissue 
DNA Isolation Kit 
FFPE samples were provided either as sliced curls or as paraffin blocks. 
Tissue blocks were sliced using microtome (Leica Microsystems GmbH, Wetzlar, 
Germany) to prepare the required slices. For both groups, DNA was extracted using 
the BiOstic FFPE Tissue DNA Isolation Kit (MO BIO Laboratories, CA, USA) 
following the manufacturer’s instructions. Briefly, samples were incubated with an 
optimised wax melting solution and proteinase K at 55°C for 2 hours, then the lysate 
was incubated in 90°C for an hour to remove the cross links and allow for successful 
PCR. Finally, DNA was eluted in 100µl of elution buffer (10 mM Tris pH 8.0) and the 
extracted DNA was stored at -20°C until it was used in subsequent analysis. 
2.3.2. DNA extraction from Fresh tissue samples using the ReliaPrepTM gDNA 
Tissue Miniprep System kit 
 Immediately upon collection, fresh tissue samples were kept at -20°C until 
they were processed for DNA extraction. The time from collection to DNA extraction 
was kept as short as possible (ranging from 1 hour-1 week). DNA was extracted from 
the fresh tissue samples using the ReliaPrepTM gDNA Tissue Miniprep System kit 
(Promega, Madison, WI, USA) according to the manufacturer’s instructions. Briefly, 
the frozen tissue sections were placed in a 1.5ml tube containing Phosphate Buffer 
Solution (PBS) and lysed by 20µl Proteinase K. The lysate was then incubated in 
56°C for 2 hours and finally, eluted in 100µl of Nuclease-free water. The extracted 
DNA was kept at -20°C until it was used in subsequent analysis. 
2.4. DNA Quantity and Quality Assessment 
2.4.1. Quantitative Assessment 
2.4.1.1. Qubit Fluorometer 
DNA was quantified using a Qubit 2.0 Fluorometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) using the high sensitivity dsDNA assay kit (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s 
instructions. Briefly, 2µl of DNA was mixed with 198µl of a dsDNA HS reagent and 
Qubit dsDNA HS buffer to determine the DNA concentration.  
     
30 
 
2.4.1.2. QIAxcel Automated Electrophoresis 
The PCR products were quantified by a QIAxcel® automated capillary 
electrophoresis system (Qiagen, Hilden, Germany). The quantification was performed 
using a QIAxcel DNA screening kit (2400) according to manufacturer’s instructions.  
2.4.2. Qualitative Assessment 
DNA quality was assessed using the Agilent® Bioanalyser (Agilent 
Technologies, CA, USA). The quality assessment was carried out using the Agilent 
High Sensitivity DNA Kit (Agilent Technologies, CA, USA) following the 
manufacturers’ instructions. To check DNA integrity, DV100 and DV200 (which refer 
to the percentage of DNA with a size ≥100 and 200 respectively in the tested sample) 
were used. 
2.5. Primer Design 
Primer design was performed using a combination of Primer-BLAST: 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/ and Primer 3 (Rozen and Skaletsky, 
1999). All primers were checked for sequence specificity using UCSC Genome 
Browser’s in silico PCR online tool (Kent et al., 2002).  
Primers were designed to be compatible with one of 2 library protocols: 
1) Tagmentation based library preparation: The first set of primers was 
specifically designed to amplify a genomic segment of about 300bp that is 
compatible with the tagmentation based library preparation protocol. All 
primers were tested using a normal control DNA sample to assess their 
function. 
2) Tagmentation free library preparation or direct amplicon sequencing: The 
second set of primers was optimized to amplify a genomic sequence of about 
150bp and was used in the Tagmentation- free library preparation protocol. 
For these primers, overhanging adapter sequences were directly incorporated 
into the 3’ end of primers. The adapters sequences were designed based on 
the technical data listed by Illumina 
(https://support.illumina.com/content/dam/illuminal support/documents/ 
documentation/ chemistry_documentation/16s/16s-metagenomic-library-prep-
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guide-15044223-b.pdf) (Illumina, California, USA). Both the primers and their 
incorporated adapter sequences were then ordered from Metabion (Metabion 
international AG, Steinkirchen, Germany). 
2.6. PCR 
2.6.1. Amplicon generation by PCR for MiSeq analysis 
Monoplex PCR was carried out to generate all amplicons from all samples in 
this work. The high fidelity Herculase II Fusion DNA polymerase (Agilent 
Technologies, CA, USA) was used for that purpose because it can replicate repetitive 
sequences with a very low error rate (Fazekas et al., 2010). For each reaction, a total 
reaction volume of 25μl was used which included 17.25μl of dH2O, 5μl 5X reaction 
buffer, 0.25μl of dNTP (100 mM), 0.25μl Herculase II polymerase, 0.63μl of both 
forward and reverse primers (10μM) and 1μl of genomic DNA in 10 mM Tris pH 8.0 
elution buffer (10-50 ng/μl). PCR was performed using a SensoQuest® thermal cycler 
(Sensoquest, Goettingen, Germany) with an initial denaturation at 95oC for 2 
minutes, followed by 35 cycles of 95oC for 20 seconds, 58oC for 20 seconds and 
72oC for 30 seconds and a final extension at 72oC for 3 minutes. The annealing 
temperature of 58°C was used for all primer pairs except two primer pairs; IM16-9 
and GM14-11, in which 57°C was used as an optimal annealing temperature. 
2.6.2. PCR amplification for fragment analysis 
 Genomic DNA from fresh tissue samples was amplified using the MSI 
Analysis System, Version 1.2 kit (Promega, Madison, WI, USA). For each PCR 
reaction, 5.85μl of dH2O was mixed with 1μl  of Gold STAR 10X Buffer, 1μl  of MSI 
10X Primer Pair Mix, 0.15μl  of  AmpliTaq Gold® DNA polymerase (5u/ μl) and 2 μl  of 
genomic DNA (1-2 ng/μl). The PCR amplification was run on a SensoQuest thermal 
cycler (Sensoquest, Goettingen, Germany) following the PCR program shown in 
Table  2-2. 
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PCR program Temperature Time Cycles 
Preinitiation denaturation 95
o
C 11 min. 1 
Preinitiation denaturation 96°C 1 min 1 




Stage 2 (Annealing) 68°C- 58°C (0.53°C/sec) hold for 30 sec. 
Stage 3 (Extension) ramp to 70°C in 50 seconds 
(0.24°C/sec) 
hold for 1 min. 
Stage 1 (denaturation) 90
o




Stage 2 (Annealing) Ramp to 58
o




Hold for 30 Sec. 
Stage 3 (Extension) Ramp to 70
o




Hold for 1 min. 
Delay (Post extension) 60
o
C 30 min. 1 
Hold 4
o
C   
Table ‎2-2: The PCR program that used to generate products for fragment analysis.  
2.7. Post-PCR detection 
2.7.1. Gel Electrophoresis: 
Agarose gel electrophoresis was used to check PCR products when the 
number of products is low. PCR products were run in 1.5% agarose gel, which was 
prepared by dissolving 1.5 g of agarose (NBS Biologicals, Cambridgeshire, UK) in 
100ml of 1X Tris Acetate buffer (which is prepared from 0.04M TRIS acetate and 
0.001M EDTA in water) and melted in the microwave for 2 minutes. 10μl of GelRed 
Nucleic Acid Gel Stain 10,000x (Biotium, California, USA) was mixed with the gel to 
visualise the products. 7μl of 2X loading dye (Promega, Madison, USA) was mixed 
with 7μl of PCR product prior to loading into the gel wells. DNA ladder was prepared 
by mixing 10μl of 1Kb DNA ladder (Promega, Madison, WI, USA) with 15μl of dH2O 
and 25μl of 2X Blue/Orange loading dye (Promega, Madison, WI, USA). The gel was 
run at 90 volts for 1 hour using electrophoresis system (BIO-RAD, CA, USA). PCR 
products were visualised using a GelDoc-It™ (UVP, CA, USA) documentation 
system.  
2.7.2. QIAxcel Electrophoresis 
QIAxcel automated electrophoresis system (Qiagen, Hilden, Germany) was 
used according to the manufacturer’s instructions to check PCR products when the 
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number of products is high. All PCR amplicons in this study were visualised on the 
QIAxcel system, which adds further advantage of product quantification. 
2.8. Fragment Analysis 
 For MSI testing by fragment analysis, 2µl of PCR products from section  2.6.2 
were mixed with 11µl of Hi-Di Formamide (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) and 1µl of Internal Lane System 600 (ILS 600). The whole mix 
was denatured at 95°C for 3 minutes, followed by an immediate chilling for another 3 
minutes. The products were then analysed by the Genetic Analyzer 3130xl (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). When run is finished, the data 
were exported and analysed by the Gene Mapper (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) or GeneMarker (Softgenetics, State College, PA, 
USA) software. 
2.9. Library preparation and High Throughput MiSeq Sequencing  
2.9.1. Amplicon Pooling 
All amplicons for each sample were quantified by QIAxcel electrophoresis 
system and pooled at approximately equal concentrations. For some amplicons with 
very low concentrations, the entire product volume was used for pooling. Amplicons 
that failed to be generated by PCR were not pooled. 
2.9.2. Clean-Up of pooled amplicons 
The pooled PCR products from each sample were purified using AMPure 
clean up kit (Beckman Coulter, CA, USA) following the manufacturer’s instructions.  
Briefly, a specific volume of AMPure magnetic beads (=pooled amplicon volume x 
1.8) was used for each sample. This was followed by incubation at room temperature 
for 5 minutes and wash with 70% ethanol. Finally, the purified products were eluted 
in 50µl of dH2O. AMPure clean-up is the recommended clean up method by both the 
Nextera XT DNA and 16S metagenomic sample preparation protocols which are the 
library preparation protocols that used in this study.  
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2.9.3. Size determination 
The lengths of purified products were measured using QIAxcel automated 
electrophoresis (Qiagen, Hilden, Germany). This initial size determination was used 
for comparison with the product length in the subsequent steps.  
2.9.4. Barcoding of pooled amplicons 
Each sample was tagged with a unique set of 8 base indexes (index i7 and 
index i5) by a reduced cycle PCR following the Nextera XT DNA library preparation 
protocol (Illumina, San Diego, CA, USA) for the longer amplicons (~300bp) and 
following the 16S metagenomic sample preparation protocol for the shorter 
amplicons (~150bp). For both protocols, library was prepared as recommended by 
manufacturer with minor modifications such as using QIAxcel instead of the Agilent 
Bioanalyzer to compare the change in band sizes of pooled amplicons before and 
after barcoding.  
Two sets of indexes were used; the first set is Nextera XT index kit FC-131-
1001 (96 index, 384 samples) (Illumina, San Diego, CA, USA) which consisted of the 
i5 indexes (S502- S508 and S517) and the i7 indexes (N701-N712). 5µl of each 
index (i5 and i7) were mixed with 15µl of the Nextera proprietary master mix and 5µl 
of the cleaned amplicons. These indexes were distributed so that to give a 96 unique 
combinations of barcodes and incorporated with the amplicons by a 12 cycle PCR 
program with a pre-heating at 72°C for 3 minutes, followed by an initial denaturation 
at 95°C for 30 seconds, 12 cycles of 95°C for 10 seconds, 55°C for 30 seconds and 
72°C for 30 seconds, and a final extension at 72°C for 5 minutes.  
The second index set was the Nextera XT Index Kit v2 Set D FC-131-2004 (96 
indexes, 384 samples) (Illumina, San Diego, CA, USA). This kit was composed of i5 
indexes (S513, 515-518,520-522 and 508) and i7 indexes (N701-712). In the PCR 
reaction, Herculase II Fusion DNA polymerase (Agilent Technologies, CA, USA) was 
used instead of the 2x HiFi Kappa enzyme (which is the recommended enzyme both 
in the Nextera and 16S Metagenomic protocols) for its superior fidelity and its 
relatively low cost. For each individual sample, the Herculase PCR mix was prepared 
by combining 0.5µl of the Herculase II Fusion enzyme solution, 0.5µl dNTPs 
(100mM), 10µl of the Herculase PCR buffer and 24µl of dH2O. 5µl of both i5 and i7 
indexes were mixed with 35µl of the Herculase PCR mix and 5µl of the cleaned 
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amplicon. The whole mix was then amplified using a reduced cycle PCR with an 
initial denaturation at 95°C for 1 minute, then a 10 cycles of 95°C for 30 seconds, 
55°C for 30 seconds and 72°C for 30 seconds with a final extension at 72°C for  5 
minutes. 
2.9.5. Clean Up of the barcoded amplicons and QIAxcel electrophoresis 
The PCR products from  2.9.4 were then washed and cleaned up using an 
AMPure clean up kit (Beckman Coulter, CA, USA) and the success of the barcoding 
procedure was checked by QIAxcel automated electrophoresis (Qiagen, Hilden, 
Germany) to visually check for shift in bands sizes compared to the band profiles 
observed before adding the indexes from section  2.9.3.   
2.9.6. DNA Quantitaficaton and Dilution  
The DNA concentrations of the pooled products were quantified using the 
Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) as 
recommended by the library preparation protocols using 2µl from each pooled 
sample. The concentrations of the barcoded amplicons were measured in ng/µl, 
while it is recommended that it be calculated in nM. The conversion from ng/µl to nM 
was done by the following equation: 
Concentration (ng/µl) X 106 / 660 (g/mol) X (average Library size) = [nM] 
The average library size was calculated by combining the average product 
sizes for all amplicons after adding the overhang (50bp), adapters (60) and indexes 
(8) = 118bp). The average library size was estimated to be 430bp (in the 
tagmentation based protocol) and 260bp (in the tagmentation free protocol). All 
samples were then diluted to a DNA concentration of about 0.7ng/µl using elution 
buffer to achieve the required 4nM concentration as recommended in protocols. 
2.9.7. Library preparation and MiSeq sequencing 
 After normalisation of all indexed samples at the required concentration, 5µl 
of each sample (with an optimised concentration of 4 nM of the barcoded amplicons) 
was added to a 1.5ml eppendorf tube to create the pooled library, which contained all 
the amplicons of the all pooled samples. The pooled amplicon library was then 
chemically denatured (using a freshly prepared 0.2N NaOH) and diluted to an optimal 
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concentration of 4pM in the first and second experiments and 10pM in the third 
experiment. 
The control PhiX library was prepared in a similar way by dilution to the same 
amplicon library final concentration (i.e. 4pM and 10pM). Both libraries (pooled 
amplicon library and PhiX library) were then pooled together and prior to be loaded 
into the sequencing machine, they were denatured at 96°C for 3 minutes and chilled 
on ice until analysed by the MiSeq. 
Sequencing of pooled amplicons was done on the Illumina MiSeq platform 
(Illumina, San Diego, CA, USA) using the MiSeq Reagent kit V3 (600 cycles) 
(Illumina, San Diego, CA, USA) for targeted resequencing with paired end read 
sequencing (251 cycles for both read 1 and read 2). The Basespace® web based 
cloud on-site informatics tool (http://www.illumina.com/informatics 
/research/sequencing-data-analysis-management/basespace.html) was used to 
monitor NGS data in real time and to store and retrieve the data later on. 
2.10. Data analysis 
2.10.1. Sequencing data  
 Initial analysis was done by the MiSeq reporter system. This includes adapter 
trimming (the removal of the adapter sequences) and demultiplexing. Sequences 
were then aligned using BWA aligner against GRCh37/hg19 assembly as reference. 
Sequencing data were retrieved from the Illumine MiSeq machine in the form of 
FASTQ files and analysed primarily by Dr Mauro Santibanez Koref (Institute of 
Genetic Medicine, Newcastle University). The data were then processed using the R 
studio environment (R-Core-Team) to generate the text file format.  
2.10.2. Data visualization 
Alignment files (as BAM files) were visualized using the Integrated Genomics 
Viewer software (IGV) (Robinson et al., 2011). 
2.10.3. Variant calling 
For variant calling, an in-house caller called Concordant Overlapping Paired 
Reads Caller (COPReC), was designed and run by Dr Mauro Santibanez-Koref 
(Institute of Genetic Medicine, Newcastle University). This software was used to 
retrieve insertions and deletions in the concordant overlapping paired end reads. The 
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COPReC generates an output data in the form of a table for each homopolymer and 
its adjacent SNP, which shows sequencing reads for each homopolymer length 
(variant and wildtype) and the called base of the SNP for each sequencing read that 
span both the homopolymers and SNP.  
2.10.4. Deletion frequency 
 Deletion frequency for each amplicon was calculated by comparing the 
sequencing reads of each variant genotype to the total reads from each SNP allele. 
This was done for all amplicons that have at least 100 paired end sequencing reads 
from all SNP alleles. 
2.10.5. Fisher’s Exact test 
 A 2x2 contingency table was constructed for each amplicon to assess the 
allelic distribution of the deletion. This was called as deletion with allelic bias. Allelic 
bias was used as an additional criterion to assess instability. Calculations were made 
manually by using an online tool to calculate the Fisher’s Exact 
(http://scistatcalc.blogspot.co.uk/2013/11/fishers-exact-test-calculator). Values below 
0.0001 were considered as extremely significant, between 0.0001-0.001 were very 
significant, 0.001-0.05 are significant and those more than 0.05 were considered as 
not significant. 
2.10.6. Threshold setting 
 Deletion frequencies for each marker were plotted across all MSS and MSI-H 
samples to generate deletion curves. For each marker, deletion curves in the MSI-H 
and MSS samples represent sensitivity and specificity curves respectively. Threshold 
sets were arbitrarily selected, starting from low deletion frequency (0.01) and 
gradually increased. For each threshold set, the performance of results of our MSI 
assay was compared to the reported phenotype done by the gold standard assay 
(MSI Analysis System, Version1.2: Promega, Madison, USA). This yielded in 
recognition of true positive, true negative, false positive and false negative samples. 
True positives (TP) are defined as samples that were reported as MSI-H and 
predicted as MSI-H as well, true negatives (TN) which are samples that have been 
reported and predicted as MSS, false negatives (FN) which are samples that were 
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reported as MSI-H and predicted as MSS and false positives (FP) which are samples 
that were reported as MSS and predicted as MSI-H. 
These values were used to generate sensitivity and specificity for each 
threshold set as follows: 
Sensitivity= True Positives / (True Positives + False Negatives) 
Specificity= True Negatives / (True Negatives + False Positives) 
The false positive and false negative rates were calculated as explained 
below:  
FPR= False positives (FP) / False positives (FP) + True negatives (TN) 
FNR= False negatives (FN)/ False negatives (FN) + True positives (TP) 
2.10.7. Determination of MSI status 
For purposes of classifications, markers that showed deletion frequencies 
above the threshold value and having an allelic bias were considered unstable.  
In the subsequent validation assays, in addition to the aforementioned 
classification, a new scoring system was applied by giving a score of 1 for the marker 
that showed a deletion above the length-specific threshold and a score of 2 for those 
with both a deletion frequency above the threshold and an allelic bias. Samples that 
have an overall score equal or more than 3 were called as MSI-H and those with an 
overall score below 3 were considered as MSS. 
2.10.8. Constructing the phylogenetic tree for clonality assay 
 The phylogenetic tree for samples that were assessed in the clonality assay 
was constructed using the Mesquite software 
(http://mesquiteproject.wikispaces.com/). The following steps were used to construct 
a tree: 
1) Data input: the system requires inputs of Taxa and characters. Tumour 
specimens were considered as Taxa and the markers were considered as 
characters in the character matrix. The number of both taxa and characters 
were specified accordingly. In the project window, a value of 0 was entered for 
ancestral character and 1 for a derived one. In accordance with this scheme, 0 
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value was representing stable and 1 represents unstable markers in that 
particular specimen. The file needs to be saved in order to be used in the 
subsequent tree construction. 
2) Constructing phylogenetic trees: after entering the inputs, the software is 
now ready to construct a phylogenetic tree. This was done by the option (Taxa 
& Trees> Make New Trees Block from> Tree search> Mesquite Heuristic 
Search (Add & Rearrange) > Tree length> SPR rearrange> OK> the MAX 
number of trees was set to 100. Then the tree was constructed based on the 
data entered in the character matrix. The first tree is usually unrooted, 
therefore it needs to be manually re-rooted to a specific outgroup (ancestral 
taxon). The outgroup was selected to be the normal specimen or tumour 
specimen that has the least number of unstable markers. The rooted tree then 
was saved by: Tree> store tree. 
3) Construction of a consensus tree: The high number of constructed trees 
needs to be reduced to a single representative tree, this is done by 
constructing a consensus tree. The consensus tree was constructed as 
follows: Taxa & Trees> Make New Trees Block from> Consensus Tree> store 
trees> OK> Majority Rule Consensus> Ok> tick the options of consider tree 
weights and write group frequency list and treat trees as rooted as specified in 
the first tree> OK. This will bring the consensus tree window, which is again 
unrooted, so it should be rooted manually by choosing an outgroup as 
described earlier. 
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Chapter 3. Establishing a consensus short mononucleotide repeat 
panel for NGS-based MSI testing 
3.1. Introduction and aims 
3.1.1. Introduction 
3.1.1.1. Microsatellite instability of mononucleotide repeats 
Microsatellites (also called simple repeat sequences) are short repetitive 
sequences scattered throughout the genomes of most complex eukaryotes including 
human. They can be classified into mono, di, tri, tetra, penta or hexanucloetides 
depending on the length of the repeat unit. In MMR deficient cells, these sequences 
are susceptible to length alteration leading to a phenotype called Microsatellite 
Instability (MSI), which represents the hallmark of the mismatch repair gene 
mutations (MMR). Di and Tetranucleotide microsatellites are more polymorphic than 
other kinds of microsatellites, therefore, they are less suitable for use in the detection 
of the microsatellite instability (Umar et al., 2004, Sutter et al., 1999). 
Mononucleotides, on the other hand, show the lowest degree of variability and thus 
represent a sensitive target to be used in the assessment of microsatellite instability 
(Sutter et al., 1999, Zhou et al., 1998, Cicek et al., 2011). The earliest finding of 
mononucleotide repeat mutations in colorectal cancers was reported in 1993 (Ionov 
et al.), where they found that polyA monotonous repeats mutations were present in 
up to 12% of colorectal cancers (CRC) and, interestingly, they were associated with a 
distinct pathological and molecular phenotype. These mutations were found to be 
inversely correlated to mutations in other genes like KRAS and P53 and metastasis 
at time of diagnosis, while they were positively correlated with poorly differentiated 
histology, right sided localisation and tumours in blacks. They concluded that this 
special kind of alterations in mononucleotide repeats is mediated by mutations that 
compromise DNA replication fidelity.  
Subsequent analyses have established that the frequency of mononucleotide 
mutations was dependent upon both the length and sequence content of the repeat. 
(A) homopolymers were found to be more prone to mutation when the number of 
bases are more than 20bp and their susceptibility to mutation decreases gradually 
with the shortening of repeat length to become less likely when a repeat is less than 
10bp (Parsons et al., 1995). Moreover, In vivo studies showed that the polymerase 
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proofreading function is length sensitive, as this proofreading is highly effective in 
dealing with errors in short homopolymers, while having a marginal effect on long 
runs. Mismatch repair genes (MMR) seem to be the only proofreaders that can 
effectively deal with errors in long homopolymers (Tran et al., 1997). 
Microsatellite instability has several clinical advantages, colorectal cancers 
with  microsatellite instability was found to have a better prognosis compared to MSS 
CRCs (Popat et al., 2005). Furthermore, the detection of microsatellite instability 
carries additional advantage of determining the convenient kind of therapy. MSI-H 
CRCs are less sensitive to 5 Fluoro-Uracil (5-FU) based therapy (Ribic et al., 2003), 
while there is evidence of a relatively high sensitivity to methotrexate in those with 
MSH2 mutations (Martin et al., 2009). Recently, MMR mutated colorectal cancers 
showed a clinical benefit of immunotherapy pembrolizumab (Le et al., 2015). 
Additional advantages of assessing the microsatellite instability is the stratification of 
cancer risk and then screening those with high risk for hereditary cancers (Lynch 
syndrome). 
For all the above mentioned advantages of MSI testing, it is imperative to 
develop a laboratory test sensitive and specific enough to assess the microsatellite 
instability. 
3.1.1.2. Development and evolution of the MSI testing  
MSI was initially tested by using the original panel recommended by the 
National Cancer Institute (NCI) workshop held at 1998 and it was composed of 2 
mononucleotide and 3 dinucleotide markers (Boland et al., 1998). However, 
additional alternative markers were proposed in the same workshop including long 
mononucleotide and dinucleotide repeats. The adoption of this panel was based on a 
validation assay conducted by Ruschoff and colleagues (1997) that assessed the 
utility of 31 markers. They suggested that whatever the number of the markers used 
in the assay, instability in ≥ 40% of the markers used is enough to call the case as 
microsatellite instability- High (MSI-H). However, when a single marker exhibits 
instability, it was recommended to test an extra five markers to confirm the diagnosis.  
Over the next decade, three main caveats were observed in the performance 
of the original NCI panel, these are: 
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1) Dinucleotides are highly polymorphic and less sensitive than 
mononucleotides in detecting MSI-H, thus it was mandatory to test 
matched normal samples for correct MSI phenotyping. 
2) The need to test extra-markers in those with a single unstable marker. 
3) The existence of instability in two dinucleotides with absence of 
mononucleotide instability may result in misclassification of MSI-H cases. 
In 2002, a new panel composed of 5 long (>20 bp) mononucleotide markers 
(BAT26, BAT25, NR-21, NR-22 and NR-24) was tested and found to have a high 
sensitivity and specificity (Suraweera et al., 2002). Two years later, the NCI held 
another workshop and recommended a 5 mononucleotide panel as the most 
sensitive panel compared to the previous NCI panel (Umar et al., 2004). 
The current trend of MSI testing relies mainly on PCR amplification of 5 
mononucleotide microsatellite (BAT26, BAT25, NR-21, MONO27 and NR-24) panel, 
followed by a fragment analysis to examine the electropherogram profiles in tumours 
compared to its matched normal tissue samples. These 5 mononucleotide markers 
were validated by Bacher et al (2004) and based on this panel, three distinct 
phenotypes can be concluded, microsatellite instability- High (MSI-H) when 2 or more 
of the markers shows instability, microsatellite –Low (MSI-L) when a single marker 
shows instability and microsatellite stable (MSS) when none of the 5 markers show 
instability. Commercially, those 5 mononucleotide markers were gathered in a single 
multiplex PCR kit sold by Promega (MSI Analysis System, Version 1.2 kit, Promega, 
Madison, WI, USA) and this has led to a wide adoption of that panel (Boyle et al., 
2014). The modified NCI panel showed a very high sensitivity (95.6-100%) (Goel et 
al., 2010, Suraweera et al., 2002, Bacher et al., 2004) in detecting microsatellite 
instability. However, the ultimate gold standard for MSI assay should ideally be the 
detection of a pathogenic mutation in the MMR genes. 
Despite the fact that this mononucleotide panel has a high sensitivity and 
specificity and has improved the practice of MSI testing, it has its own limitations. The 
use of these longer homopolymers has long been associated with generation of 
PCR- induced errors that likely complicate the downstream phenotype interpretation. 
These errors occur due the inefficiency of commercial polymerases to faithfully 
replicate these longer repeats and manifested in the electropherogram in the form of 
stutter peaks (Shinde et al., 2003). Another limitation of the current MSI test is the 
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convoluted and subjective interpretation as it is solely based on the visual inspection 
of the fragment profile in the electropherogram rather than exploration of the 
sequence contents within the fragment.  
Given the importance of microsatellite instability in diagnosis, prognosis and 
determination of therapeutic options especially in colorectal cancer, several studies 
started to recommend MSI testing for all newly diagnosed CRC cases (Julié et al., 
2008, de la Chapelle and Hampel, 2010, Vasen et al., 2013, Medscape, 2015). This 
means testing around 40,000 new CRC cases each year in the UK alone (and more 
than 1,300,000 new CRC cases worldwide) (Cancer-Research-UK, 2015). It would 
not be possible to fulfil these recommendations with the current test with its inherent 
limitations of low throughput and the generation of the polymerase induced errors in 
the long homopolymers. Therefore, it is becoming increasingly important to develop 
an MSI assay robust and accurate enough to be able to cover the huge number of 
cases that need to be tested. 
3.1.1.3. The development of a sequence based MSI test 
The advent of next generation sequencing (NGS) has opened new research 
and diagnostic avenues to adopt genetic tests on a large scale. Repetitive sequences 
(like microsatellites) potentially represent a caveat in NGS applications as they are 
more prone to generate sequencing errors and their low sequence diversity might 
compromise the subsequent analysis (Clarke et al., 2001). However, PCR induced 
errors have been shown to be dramatically reduced or obliterated by using the 
commercial polymerases with non- specific dsDNA binding domain (Herculase II 
Fusion polymerase). This kind of enzymes was shown to have the best proofreading 
function in homopolymers, approaching error free replication for mononucleotide 
repeats ≤13bp in length after 35 PCR cycles (Fazekas et al., 2010) 
In the last few years, researchers have started to look at the possibility of 
using high throughput techniques to test for MSI. In 2012, a comprehensive analysis 
conducted by the cancer genome atlas network (TCGA) to explore the somatic 
mutations and classification of CRC. That study, showed, in part, that microsatellite 
instability can be detected using the NGS approach (Cancer Genome Atlas, 2012). 
Since that time, an emerging body of studies attempted to apply this technique to 
MSI testing (Salipante et al., 2014, Zhao et al., 2014, Gan et al., 2015). In 2014, our 
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group has analysed the sequencing data form the low depth whole genome 
sequencing conducted by TCGA (unpublished data) to investigating the difference in 
the deletion of short homopolymers only (7-12bp) both in MSI-H, MSS and matched 
normal samples. This analysis showed that it was possible to infer the microsatellite 
alterations by NGS platforms and there was a clear difference in the instability 
between MSI-H tumours and their matched normal counterparts and MSS samples 
as well.  
One of the major obstacles associated with the sequencing of microsatellites 
is the generation of sequence errors (Clarke et al., 2001). The existence of high 
frequency single nucleotide polymorphisms (SNP) in the nearby sequences (about 
30bp on either side) of the target homopolymers can be used to assess instability. In 
heterozygous cases, the variant reads that span both the homopolymers and the 
adjacent high frequency SNP were used to assess the distribution of instability with 
SNP alleles. The instability that is significantly biased toward one of the SNP alleles 
is, therefore, more likely to be a real instability compared to sequencing error that is 
not. This feature is called allelic bias and was considered by our team as an 
additional classifier for subsequent selection of informative polymorphic repeats. 
Our lab extensively mined the data generated from that whole genome 
analysis undertaken by TCGA to look for the most unstable short repetitive 
sequences in a selected subset of MSI-H samples compared to matched normal and 
MSS samples. The initial huge list of the variable repeats was then narrowed down to 
create a short list containing those markers that were not polymorphic, most variable 
in the MSI-H cases, have an adjacent high frequency SNP and were sequenced to 
adequate depth (≥20 reads) both in MSS and MSI-H groups. About 200,000 short (7-
12bp) repeats were found to fulfil the above mentioned criteria, of them, 120 markers 
which primers could be easily generated were used in the subsequent analysis. 
These 120 markers were initially assessed to examine their variability both in MSS 
and MSI-H samples and, ultimately, determine the most informative markers among 
them. These 120 markers were randomly divided between 3 researchers. I have 
been involved in designing and amplification of 29 markers using 5 MSI-H and 6 
MSS tumour samples. The rest of the 120 markers were analysed by Dr Lisa Redford 
(Newcastle University, UK) and Iona Middleton (Newcastle University). That initial 
analysis revealed that short homopolymers, sequence based- MSI test is feasible 
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and, subsequently, a panel of 66 (out of the 120 tested repeats) highly variable 
repeats was identified for further analysis against a larger group of CRC samples to 
consolidate the initial finding and find out the most unstable markers amongst them. 
3.1.2. Aims 
The whole genome analysis revealed a huge number of polymorphic markers, 
of them, 120 (7-12bp) for which primers could be generated were assessed in the 
MSI-H samples compared to both MSS and normal samples. This assay established 
that instability can be assessed in homopolymers and 66 markers were found to be 
the most variable among them. However, longer (10-12bp) homopolymers were more 
variable, but associated with more sequencing errors compared to short (7-9bp) 
repeats. To further investigate the utility of both short and long repeats, the 66 
markers were split into two groups with the plan that I would analyse the short ones 
(7-9bp) using a cohort composed of 55 CRC samples, of which 25 samples are MSI-
H, 25 MSS and 5 MSI-L. The overall aims of this chapter are: 
 Design and amplify primers for 29 markers (derived from the 120 markers) 
to be analysed against a small cohort of CRC samples.  
 To test a cohort of CRC samples composed of 25 MSI-H, 25 MSS and 5 
MI-L samples using the 25 short (7-9bp) repeats identified from the whole 
genome analysis. 
 Establish and assess convenient length- specific thresholds for calling 
instability based on analysis of sensitivity and specificity for each individual 
marker. 
 Assess the utility of the allelic bias as an additional parameter could be 
utilised to call instability. 
 Determine the minimal number of the most informative markers that can 
efficiently discriminate between MSI-H and MSS samples. 
3.2. Results 
3.2.1. Assessment of 29 mononucleotide repeats to identify the most variable 
repeats 
As a part of 120 variable markers retrieved from the whole genome analysis, I 
initially designed and amplified 29 of these markers using a cohort composed of 5 
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MSI-H lynch syndrome tumours, 6 MSS and one normal tissue samples as explained 
above and shown in Table  3-1 and Figure  3-1.  
 
Figure ‎3-1: Illustration of the overall number of markers and the study workflow. In the 








T1 U029 N1 169259 NR U096T 
T3 U179H03 N2 169736   
T4 U179 H12 N3 170146   
T5 U303 N4 170402   
T6 U312 N5 171223   
  N6 169836   
Table ‎3-1: DNA samples that were used in the initial assessment.  5 MSI-H, 6 MSS and one 
normal samples were used to be assessed by the 120 markers. 
All primers were designed to generate amplicons of around 300bp in size as 
this is the recommended amplicon length by the Nextera XT DNA library preparation 
protocol (Illumina, San Diego, CA, USA) which is the kit that was used for library 
preparation in this experiment. The 300bp amplicons were designed to span both the 
homopolymer of interest (the marker) and an adjacent high frequency SNP. The 
minor allele frequency (MAF) of the included SNPs was ranging between 0.05-0.9, 
and a MAF near to 0.5 was preferred when possible. Approximately 15ng of DNA 
from each sample was used to generate PCR amplicons using the Herculase II 
Fusion DNA polymerase (Agilent, Santa Clara, CA, USA). The amplified products 
were then visualized and quantified by QIAxcel (Qiagen, Limburg, Netherlands). 
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Amplicons for all 120 markers were subsequently pooled, sequenced and analysed. 
Out of 120 repeats, 66 showed evidence of instability in 1 or more tumours. The 
results were then analysed by Dr Lisa Redford (Newcastle University, UK). The 
results of the 29 markers that were designed and amplified by myself showed that for 
the 7bp markers, there was no clear instability both in MSI-H and MSS tumours as 
shown in Figure  3-2. 
 
Figure ‎3-2: The frequencies of variant reads of 6 short (7bp) homopolymers. MSI-H (red 
bars), MSS tissue samples (green bars) and normal tissue sample (U096T). Sequencing reads were 
plotted for the wildtype (0), -1 (deletion of a single base) and 1 (insertion of a single base). There is no 
clear deletion in all markers. (Y-axis: The relative frequency of the variant reads, X-axis: Allele length, 
sample IDs are shown in the upper row, the marker IDs are shown in the rightmost column). 
 For the 8bp group, five markers were designed and tested. Only a single 
marker (GM09) showed a clear degree of instability in a single MSI-H tumour 
(U029T) compared to MSS tumours as shown in Figure  3-3. 




Figure ‎3-3: The frequencies of variant reads of 5 short (8bp) homopolymers. MSI-H (red 
bars), MSS tissue samples (green bars) and normal tissue sample (U096T). Sequencing reads were 
plotted for the wildtype (0), -1 (deletion of a single base) and 1 (insertion of a single base). The marker 
GM09 shows 1bp deletion in sample U029T (blue square). (Y-axis: The relative frequency of the 
variant reads, X-axis: Allele length, sample IDs are shown in the upper row, the marker IDs are shown 
in the rightmost column). 
For the 9bp group, among the 9 markers that were designed and tested, 2 
markers (GM11 and GM17) showed a deletion frequency of up to 25% in 2 MSI-H 
tumours while another 4 markers (GM06, GM10, GM15 and GM23) showed deletion 
up to 20% in a single MSI-H tumour as shown in Figure  3-4. The remaining 3 
markers (GM05, GM21 and M28) did not show deletion in any of the tested samples. 
None of the markers showed deletion frequency greater than 10% in both MSS 
tumours and the normal tissue sample. 




Figure ‎3-4: The frequencies of variant reads of 9 short (9bp) homopolymers  in MSI-H (red 
bars), MSS tissue samples (green bars) and normal tissue sample (U096T).Sequencing reads were 
plotted for the wildtype (0), -1 (deletion of a single base) and 1 (insertion of a single base). The 
markers (GM11 and GM17) show clear (up to 25%) 1bp deletion in 2 MSI-H samples and another 4 
markers (GM06, GM10, GM15 and GM23) showed 1bp deletion frequency (up to 20%) in a single 
MSI-H sample (blue squares). None of the markers show a clear instability in MSS tumours or in 
normal sample. (Y-axis: The relative frequency of the variant reads, X-axis: Allele length, sample IDs 
are shown in the upper row, the marker IDs are shown in the rightmost column). 
For the 10bp group of markers, all the tested markers (4 markers) exhibited 
instability (up to 20% deletion frequency) in at least 2 MSI-H samples, but on the 
other hand, all markers showed a low level of instability in the MSS tumours and 
even in the normal tissue sample as shown in Figure  3-5.   




Figure ‎3-5: The frequencies of variant reads of 4 long (10bp) homopolymers  in MSI-H (red 
bars), MSS tissue samples (green bars) and normal tissue sample (U096T). Sequencing reads were 
plotted for the wildtype (0), -1 (deletion of a single base) and 1 (insertion of a single base). The marker 
GM29 show instability up to 15% in 4 MSI-H samples and the other 3 markers (GM01, GM22, GM26) 
showed deletion frequency (up to 20%) in 2 MSI-H samples (blue squares). Al markers show a low 
level of instability in MSS tumours and the normal tissue. (Y-axis: The relative frequency of the variant 
reads, X-axis: Allele length, sample IDs are shown in the upper row, the marker IDs are shown in the 
rightmost column). 
For the 11bp group of markers, 4 markers were tested. One of the markers 
(GM07), showed a high degree of instability (up to 70% deletion frequency) in MSI-H 
samples. Although GM07 showed instability in the MSS tumours as well (up to 15%), 
instability was higher in the MSI-H samples (up to 70%). The other 2 markers (GM13 
and GM14) showed instability in the MSI-H samples (up to 40% deletion frequency) 
while they didn’t show such a high degree of deletions in the MSS group as shown in 
Figure  3-6. The last marker (GM02) showed instability in both MSI-H group (up to 
40% deletion frequency) and MSS and normal group as well (up to 20% deletion 
frequency). Although the deletion frequency in the MSI-H group is higher than that in 
the MSS group, the existence of such behaviour indicates that this marker is unlikely 
to be useful in discriminating between MSI- H and MSS samples. 




Figure ‎3-6: The frequencies of variant reads of 4 long (11bp) homopolymers  MSI-H (red 
bars), MSS tissue samples (green bars) and normal tissue sample (U096T).Sequencing reads were 
plotted for the wildtype (0), -1 (deletion of a single base), 1 (insertion of a single base), -2= deletion of 
2bp, 1: insertion of 1bp and 2: insertion of 2bp. The markers (GM07, GM13 and GM14) show 
instability up to 80% in at least 2 MSI-H samples (blue squares) and they were relatively stable in the 
MSS samples. The marker (GM02) showed instability both in MSI-H and MSS groups (blue squares). 
(Y-axis: The relative frequency of the variant reads, X-axis: Allele length, sample IDs are shown in the 
upper row, the marker IDs are shown in the rightmost column). 
 A single 12bp marker (GM18) has been designed and tested. It showed a 
clear instability (more than 50% deletion frequency) in all MSI-H samples and up to 
20% in both MSS tumours and normal tissue as shown in Figure  3-7 indicating that 
this marker would unlikely to be useful to specifically detect MSI-H samples. 
 
Figure ‎3-7: The frequencies of variant reads of the 12bp long homopolymers (GM18).  MSI-
H (red bars), MSS tissue samples (green bars) and normal tissue sample (U096T).Sequencing reads 
were plotted for the wildtype (0), -1 (deletion of a single base), 1 (insertion of a single base), -2= 
deletion of 2bp, 1: insertion of 1bp and 2: insertion of 2bp. The markers show instability in all samples 
(MSI-H, MSS and even the normal tissue) but the instability was higher in the MSI-H samples (more 
than 50%). (Y-axis: The relative frequency of the variant reads, X-axis: Allele length, sample IDs are 
shown in the upper row, the marker IDs are shown in the rightmost column). 
From the above results, it was obvious that the variability was length 
dependant as the short repeats were stable both in MSI-H and MSS groups. The 
longer repeats (10-12bp), on the other hand, were more variable in the MSI-H 
samples, but at the same time, were associated with noticeable instability in MSS 
samples and even in normal tissue. This variability (in MSS and normal samples) is 
most likely to be PCR induced errors and it is clearly associated with longer repeats 
compared to the short ones. 
By the end of this part of the study, it has been found that 39% of shorter 
repeats (7-9bp) showed evidence of microsatellite instability in MSI-H samples, 
compared to 80% of longer repeats (10-12bp). However, longer repeats also 
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generated more variant reads in normal and stable tumour samples, indicative of 
sequence error. 
The results obtained from this part of the study established that: 
1) A short homopolymer sequence-based MSI test is potentially feasible, and a 
subset of 66 variable repeats was identified, which could be used as a basis 
for such a test.  
2) There is a length-related variation in both instability and sequence error rates. 
3) This analysis confirmed that both MSS and normal samples were tested 
stable, suggesting that sequence-based test may not require matched normal 
on a routine basis.  
4) Extending the analysis using a larger number of tumours would be required to 
define the optimal combination of repeats, and the criteria for tumour 
classification.  
As the optimal size of repeat for use is unclear, and analysis would require 
multiple next generation sequencing runs, the subsequent work was split into the 
extended analysis of longer repeats (8-12bp, undertaken by Dr Lisa Redford) and 
analysis of 25 short repeats (7-9bp, undertaken by myself). 
3.2.2. Analysis of 25 variable short (7-9bp) mononucleotide repeats to assess 
the criteria for calling instability in CRCs 
Having established that it is feasible to utilise short homopolymers in MSI 
testing, it is essential to define the parameters that can be used to assess instability 
using a larger cohort of CRC samples. From the 66 most variable markers that were 
nominated from the previous part of the study (explained above), a batch of 25 of the 
most unstable short repeats (7-9bp) has been chosen for further assessment using a 
relatively larger number of samples than the previously tested cohort (which was 
composed of 5 MSI-H tumours samples, 6 MSS tumours and a single normal 
sample). The panel of 25 markers was composed of ten (7bp) markers, five (8bp) 
markers and ten (9bp) markers as shown in Table  3-2. This panel was selected 
based on the accumulated result from the previous initial analysis done by Dr Lisa 
Redford (Newcastle University, UK). All these markers showed a high discriminatory 
power between MSI-H and MSS samples in that initial assay. Out of the 29 markers 
designed and analysed initially by myself (mentioned in  3.2.1), 6 markers ended up in 
these 25 markers (1 is 8bp and 5 are 9bp in length). 
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 Amplicon Repeat 
size 
SNP1 SNP2 SNP3 Repeat Position 
1 LR49-7 7 rs80323298 rs201097746 rs12903384 Chr15: 93619048 
2 LR51-7 7 rs8474   Chr10: 51026725 
3 IM14-7 7 rs11760281   Chr7: 80104531 
4 IM19-7 7 rs72736428 rs186539440 rs4877153 Chr9: 82475001 
5 IM43-7 7 rs9981507   Chr21: 32873761 
6 IM55-7 7 rs13099818   Chr3: 143253845 
7 IM66-7 7 rs147847688 rs141474571 rs4794136 Chr17: 48433967 
8 IM67-7 7 rs67082587 rs57484333  Chr7: 22290895 
9 LR08-7 7 rs181578273 rs7117269  Chr11: 56546206 
10 LR15-7 7 rs56084507   Chr8: 92077210 
11 IM59-8 8 rs10156232   Chr8: 108359001 
12 LR20-8 8 rs146973215 rs191572633 rs217474 Chr1: 64029634 
13 LR46-8 8 rs143884078 rs182346625 rs6040079 Chr20: 10660085 
14 IM41-8 8 rs1944640 rs112075239  Chr6: 147948941 
15 GM09-8 8 rs6038623   Chr20: 6836977 
16 IM16-9 9 rs114923415 rs73367791 rs59912715 Chr18: 1108767 
17 LR10-9 9 rs111814302 rs1768398 rs1768397 Chr1: 81591388 
18 LR24-9 9 rs192329538 rs1127091  Chr1: 153779429 
19 LR21-9 9 rs182900605 rs80237898 rs2413976 Chr15: 50189465 
20 LR40-9 9 rs6432372   Chr2: 13447470 
21 GM17-9 9 rs666398   Chr11: 95551111 
22 GM21-9 9 rs185182   Chr3: 142695339 
23 GM23-9 9 rs184237728 rs32123  Chr5: 11345921 
24 GM28-9 9 rs4130799   Chr5: 29209381 
25 GM11-9 9 rs347435   Chr5: 166099891 
Table ‎3-2: The 25 primers that were used to analyse the short repeats  with their repeat 
length, associated SNPs and genomic positions. 
To develop a panel of DNAs from tumours of known MSI status, I first 
examined DNA from 248 FFPE tissues previously analysed for MSI status by the 
Northern Genetics Service (as explained in Chapter 2 section  2.2.1). Clinical, 
pathological and molecular data of the samples were checked retrospectively from 
the NHS database. 
The cases that were diagnosed with primary cancers other than colorectal 
were excluded from the cohort because I was mainly interested in colorectal cancer 
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cases. The only exceptions were 2 endometrial cancer samples which were allowed 
to be included in the study because they were MSI-H.  
After this initial filtration, 87 samples (55 MSS, 27 MSI-H and 5 MSI-L) were 
selected for further molecular work. DNA has been extracted from all tumours by 
BIOstick DNA extraction Kit (MO BIO Laboratories, CA, USA) following the 
manufacturer’s instructions. The extracted DNA was then quantified by Qubit 2.0 
Flourometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA). 
As an initial assessment of DNA quality, approximately 15 ng of DNA from 
each sample was used to generate PCR amplicons using the Herculase II Fusion 
DNA polymerase (Agilent, Santa Clara, CA, USA) as shown in Figure  3-8.  
 
Figure ‎3-8: Initial check of DNA amplifiability using a 300bp amplicon.  Samples in lanes 3, 6, 
7, 8 & 11 failed to be amplified. Samples in lanes 1 & 4 showed faint bands while the remaining 
samples were successfully amplified. (Ladd: 100bp-1kb Ladder, PC: Positive Control, NC: Negative 
Control) 
58.6% (51 out of 87) of the samples were successfully amplified using the 
300bp primer set. To investigate the possible reasons for PCR failures, I then 
amplified the failed samples (those which failed to be amplified with the 300bp primer 
set) using a 100bp amplicon. Overall, 42% (15/36) of samples which failed to amplify 
the 300bp amplicon were successfully amplified using the small primer set (100bp) 
as shown in Figure  3-9. The results of successive amplifications are summarised in 
Figure  3-10. 




Figure ‎3-9: Amplifications of DNA samples with 100bp amplicons. Samples in lanes 2,3,5,7 
&11 failed to be amplified. (Ladd: Ladder, PC: Positive Control, NC: Negative Control). 
 
Figure ‎3-10: The number of amplifiable colorectal cancer samples using the 300bp and 
100bp amplicons. 300bp amplifiable samples are those that successfully amplified 300bp amplicons 
(which should amplify 100bp amplicons as well) (represented as blue bars), 100bp amplifiable 
samples refer to those that amplify the 100bp amplicon only (represented as red bars). Most of the 
samples have successfully amplified the short amplicon. However, 6 MSI-H and 15 MSS samples 
have failed to amplify even the 100bp amplicons. 
To further investigate the possible reasons behind the variable PCR results, a 
subset of MSI-H samples were tested for DNA quality using the Agilent Bioanalyser 
(Agilent, Santa Clara, CA, USA). DV200 (percentage of DNA with a size equal and 
above 200bp in the tested sample) was used as a parameter of the DNA quality (and 
hence, the DNA integrity) in the samples. Two groups of MSI-H samples were 
subjected to quality investigation, 300bp amplifiable (samples G1, G10, and G3) and 
non-amplifiable (samples 18, 47 and 58) samples. Results showed that the first 3 
samples (the amplifiable) had a DV200 of at least 15%, which is consistent with the 
successful amplifications in these cases. In 2 out of the 3 (non-amplifiable) samples, 




























Amplifiable 300bp Amplifiable 100bp Failed
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Figure  3-11. These results are broadly consistent with the assumption that successful 
amplification of long amplicons (~300bp) is dependent upon DNA quality.  
 
Figure ‎3-11: Comparative assessment of DNA quality between 2 groups of MSI-H 
samples. Amplifiable (G1, G10 and G3) and non-amplifiable (18, 47 and 58) using the 300bp primers. 
Y-axis refers to the value of DNA concentration (for blue bars) or the value of DV200 (for red 
bars).The corresponding DNA concentrations [DNA] in ng/µl were shown for each sample. DV200: the 
percentage of DNA present in fragments equal or greater than 200bp in size. Amplifiable samples 
clearly showed higher DV200 than the non-amplifiable ones. 
Only those samples which were successfully amplified with the 300bp 
amplicons were used for the subsequent analysis because this is the amplicon length 
that is needed for library preparation using the Nextera XT protocol. 
Because of the low number of amplifiable MSI-H samples within this cohort, 
DNA from additional 9 MSI-H samples (from outside the 248 pool) were obtained 
from the northern genetics service (Newcastle Upon Tyne Hospitals NHS Foundation 
Trust, UK) as explained in Chapter 2 section  2.2.1. 
Following these stages of sample filtration and additions, the final panel of 
amplifiable CRC samples became comprised of 25 MSS, 25 MSI-H and 5 MSI-L 
samples as shown in Appendix Table  8-1. All these samples were amplified using the 
primers listed in Table  3-1. PCR amplification was done using the Herculase II Fusion 
DNA polymerase (Agilent, Santa Clara, CA, USA) and approximately 15 ng/µl of the 
genomic DNA was used for amplification. However, if initial PCR failed, this was 
increased up to 50ng.  
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The vast majority of the selected samples were successfully amplified using 
all 25 primer pairs. Those samples which failed to be amplified in the first round, were 
then re-amplified (with more template concentration) to fill in the gaps in the 
amplification profile of the tested cohort. A total number of 1406 amplicons were 
generated. All amplicons were then quantified using the QIAxcel automated 
electrophoresis (Qiagen, Hilden, Germany) and pooled. The pooled amplicons were 
then cleaned up using the Agencourt AMPure XP beads (Beckman Coulter, 
Pasadena, California, USA) to get rid of the extra primers, dNTPs and dsDNA 
fragments other than the target PCR product. The cleaned amplicons were then 
quantified by Qubit 2.0 fluorometer (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA), tagmented, barcoded and normalized by diluting the amplicon 
concentration down to about 0.2ng/µl to achieve a library concentration of 10 pM of 
pooled amplicons with 5% PhiX library. Pooled libraries were, then sequenced by 
MiSeq system using MiSeq Reagent kit v3 (600 cycles) (Illumina, San Diego, CA, 
USA).  
The raw data obtained from the MiSeq run were real time monitored, extracted 
and stored using the Basespace web based cloud on-site informatics tool (Illumina, 
San Diego, CA, USA). The run yielded 41,383,444 total reads, of which 92.7% 
passed filter. The sequencing reads were successfully scored for all samples. The 
lowest percentage of raw reads were observed in sample 29 (0.17% of the total 
reads) while the highest percentage of raw reads identified in sample 2 (4.6%) of the 
total reads as shown in Figure  3-12. The coverage depth achieved by this run was 
approximately 10,000 paired end reads per amplicon. 




Figure ‎3-12: The distribution of sequencing reads for all tested samples.X-axis refers to 
sample number and Y-axis refers to the percentage of reads scored for each sample compared to 
overall sequencing reads. 
Q30 is a fundamental quality metric for the MiSeq run as it reflects the 
probability that one base is called erroneously in each 1000 bases called. The MiSeq 
run achieved a Q30 value of 66.7% as shown in the Figure  3-13 
 
Figure ‎3-13: Q30 of the sequencing reads generated in MiSeq run.Green bars= number of 
bases with Q-score >30, Blue bars= number of bases with Q-score<30. Y-axis refers to the number 
of bases (in millions). X-axis refers to Q-score. 
Variant calling was performed using an in-house variant caller developed and 
run by Dr Mauro Santibanez Koref (Institute of Genetic Medicine, Newcastle 
University) called Concordant Overlapping Paired Reads Caller (COPReC) and the 
sequencing reads were quantified for each allele of a unique length in each marker 
individually. The data were exported in the form of text files that were processed 
using the R studio (R-Core-Team) to generate the spreadsheet format of the 
sequencing reads.  
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In the previous analysis conducted by Dr Lisa Redford (Newcastle University, 
UK), deletions of homopolymers were found far more abundant than insertions in 
MSI-H samples and data, therefore, were analysed based on the calculation of 
deletion frequency (Redford, 2016). Similarly, the data analysis of the current study 
was based on deletion frequency in addition to allelic bias. 
3.2.2.1. Calculation of deletion frequency for all the 25 short repeats across all 
samples 
Sequencing reads were called and reported for each marker across all 
samples separately. The sequencing reads were sorted in a way to recognise all 
alleles and genotypes. The genotypes were categorized as wildtype (the reference 
sequence in which no insertion or deletion was observed, which is, commonly, the 
most prevalent genotype), -1 (deletion of 1bp), +1 (insertion of 1bp) as shown in 
Figure  3-14. 
 
Figure ‎3-14: The organisation of sequencing reads. The leftmost column represents genotypes, 
the most prevalent is 0 genotype (Wildtype genotype), -1 and 1 refers to 1bp deletion and 1bp 
insertion genotypes respectively. The uppermost raw represents the called alleles for the adjacent 
SNP. NA refers to the reads that have skipped the homopolymer of interest (Horizontal) or the SNP 
(Vertical). 
All amplicons with an overall number of sequencing reads exceeding 100 
were included in the subsequent analysis. If the total number (for all observed alleles 
and variants) didn’t reach that threshold, then the marker was excluded from the 
baseline calculations. For purposes of normalisation, the number of reads for the 
deletion allele was compared to those of the most abundant genotype (wildtype) to 
determine the ratio (in the form of a percentage) between them as shown in 
Figure  3-15. This percentage was called “deletion frequency” and used as a main 
classifier in the subsequent analyses.  




Figure ‎3-15: The COPReC data format for a single amplicon in a single sample.  Numbers 
corresponding to (-2, -1, 0 and 1) refer to the sequencing reads registered for each variant length. The 
most abundant genotype is the 0 (wildtype). The next frequent genotype is the -1 (deletion of 1 bp). A 
and G represents both alleles for the adjacent SNP. NA refers to the sequencing reads that skip either 
the SNP (vertical NA) or the homopolymer (Horizontal NA). The reads are represented in the form of 
bar charts shown on the right side. 
 Deletion frequencies were then calculated for all markers both in MSI-H and 
MSS samples to generate deletion curves as shown in Figure  3-16. These deletion 
curves can provide estimates of sensitivity and specificity respectively. For purposes 
of comparisons, the reported phenotype was based on the MSI status provided by 
the original lab, which based on testing by the MSI Analysis System, Version1.2 
(Promega, Madison, WI, USA). According to this test, samples that show instability in 
≥ 2 of the 5 tested markers were called as MSI-H and those which didn’t show 
instability in any of the tested markers were called as MSS.  
Sensitivity and specificity curves were generated for each marker by plotting 
the deletion frequencies observed across all MSI-H and MSS samples respectively. 
The sensitivity curves were constructed in a way to show the proportion of MSI-H 
samples (in Y-axis) that have a deletion frequency equal to or above the value shown 
in the X-axis. The specificity curves, on the other hand, show the proportion of MSS 
samples (on the Y-axis) that have a deletion frequency equal to or above the value 
indicated in the X-axis (displayed in the form of 1-specificity). Based on these curves, 
it was possible to define threshold values of deletion frequency for each marker 
which most effectively separated MSI-H from MSS samples (maximising specificity 
relative to sensitivity) as potentially suitable cutoff values to be considered in 
potential assays (shown in Figure  3-16).   




Figure ‎3-16: Threshold curves of the marker LR24. The sensitivity curve represents the deletion 
frequencies in MSI-H samples and specificity curve represent deletion frequencies in MSS samples. 
The specificity was designed in the form of 1-specificity. The X-axis represents deletion frequencies 
observed of that marker across all samples. Y-axis refers to the proportion of samples. In this 
particular example, 62% of MSI-H samples show a deletion of ≥0.05, while none of the MSS samples 
have that value of deletion frequency. A deletion frequency of 0.05 (5%) therefore can be considered 
as a reasonable cutoff value for this marker. 
In the initial analysis, short repeats (7-9bp) showed a very low degree of 
variability, while longer repeats (10-12bp) were more variable both in the MSI-H and 
MSS samples. It was expected, therefore, that a relatively low threshold of deletion 
frequency could be used to assess the variability of the repeats in the current assay. 
The deletion curves of 7bp markers are shown in Figure  3-17. Three markers 
out of the 10 tested markers (LR51-7, IM43-7 and IM55-7) didn’t show any noticeable 
deletion both in MSS and MSI-H samples and a very low sensitivity was observed for 
another 2 markers (LR15-7 and LR8-7) with a sensitivity of 4.3% and 4.1% 
respectively at a deletion frequency of ≥5% (1/23 MSI-H samples for LR15-7 and 
1/24 for LR48-7). Four out of the above mentioned 5 markers (LR51-7, IM43-7, IM55-
7 and LR15-7) exhibited 100% specificity (no false positives) at deletion frequency of 
5%, while one (LR8-7) had a single false positive sample. However, the specificity of 
the marker LR8-7 only reached 100% at a deletion frequency of 10%, where the 
sensitivity was 4.1%.  




Figure ‎3-17: Sensitivity and specificity curves for the 7bp markers.X-axis represents deletion 
frequency observed in proportion of MSI-H cases (blue curves) and MSS cases (red curves). The 
specificity curve was constructed in the form of 1-Specifcity. At a deletion frequency of ≥5%, the 
marker LR49-7 shows the highest sensitivity and specificity. 
The remaining five 7bp markers exhibited 100% specificity (no false positives) 
at a deletion frequency of 5%, with sensitivity ranging between 10%-57%. The 
highest sensitivity at that deletion frequency (i.e. 5%) was achieved with the marker 
LR49-7, where 57% of MSI-H samples showed a ≥ 5% deletion in that marker, while 
none of the MSS cases show any degree of instability at or above 5%. For that 
marker (i.e. LR49-7), up to 17% of MSI-H samples, have had deletion frequencies up 
to 30% and a single sample (out of the 23 tested MSI-H cases) had a 51% deletion 
frequency.  
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In conclusion, at a deletion frequency of 5%, all the 7bp markers show a 
perfect specificity (= 100%) except a single marker, while sensitivity was relatively 
low. Thus, in order to have an informative panel, more than one marker would need 
to be included to improve the overall sensitivity. 
For the 8bp repeats, all of the 5 markers showed 100% specificity at and 
above 5% deletion frequency. At that deletion frequency, the marker IM41-8 had the 
lowest sensitivity (4.1%), while the marker LR20-8 had the highest sensitivity 
(47.8%). At the same deletion frequency (i.e. 5%), the other 3 markers (LR46-8, 
GM9-8 and IM59-8) have had a sensitivity ranging between 29.1%- 37.5% as shown 
in Figure  3-18. This gives a conclusion that these markers are very specific but less 
sensitive, thus again, many repeats would need to be included in a panel to improve 
sensitivity. 
 
Figure ‎3-18: Sensitivity and specificity of the 8bp markers. The X-axis represents deletion 
frequency observed in proportion of MSI-H cases (blue curves) and MSS cases (red curves). The 
specificity curve was constructed in the form of 1-Specifcity. The highest sensitivity and specificity at 
≥5% deletion frequency was observed in the marker LR20-8. 
 For the 9bp repeats, 6 markers (LR24-9, GM21-9, GM28-9, IM16-9, LR21-9 
and LR40-9) exhibited 100% specificity at a deletion frequency of 5% and a 
sensitivity ranging from 1%-71%, with the highest sensitivity (17 out of the 24 tested 
MSI-H samples) being observed in the marker IM16-9, and the lowest sensitivity in 
the marker GM21-9 (1%). At a deletion frequency of 10%, an additional 2 markers 
(GM11-9 and GM17-9) achieved 100% specificity while sensitivity was 58.3% and 
25% respectively. The remaining 2 markers (GM23-9 and LR10-9) have achieved 
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100% specificity at a deletion frequency of 15% and 20% respectively as shown in 
Figure  3-19. 
 
Figure ‎3-19: Sensitivity and specificity of the 9bp markers.The X-axis represents deletion 
frequency observed in proportion of MSI-H cases (blue curves) and MSS cases (red curves). The 
specificity curve is constructed in the form of 1-Specifcity. The highest sensitivity and specificity at 
≥5%, was observed in the marker IM16-9. 
Compared to other markers (i.e. 7 and 8bp markers), relatively higher deletion 
frequency is required to achieve a 100% specificity in the 9bp markers. However, 6 of 
the 9bp markers achieved 100% specificity at 5% deletion frequency.  
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All markers in all the 3 groups (7, 8 and 9bp) exhibited a high specificity but 
relatively low sensitivity at the same deletion frequency (e.g. 5%). This means, to 
improve the sensitivity, more than one marker from each group need to be included 
in a collated panel.  
The performance of all markers, then, analysed on a sample by sample basis. 
The above calculations were performed for all markers across all samples to 
compare the deletion profile for each marker in the MSS and MSI-H groups. Below in 
Figure  3-20, is a representation of the variant repeat frequencies for all markers in 2 
samples, one is MSI-H (S42= G42) and one is MSS (S19= G19). Nine markers (out 
of the 25 tested markers) showed a high proportion of variant reads (in the form of 
1bp deletions) in the MSI-H sample, while none of the 25 tested markers show any 
observable deletion in the MSS sample (see the legend of Figure  3-20 for details). 
 
Figure ‎3-20: Deletion frequencies (Y axis) of all the 25 markers in 2 samples, one is MSI-H 
(S42) and the other is MSS (S19).X-axis represents the nature of the observed genotype (0= 
Wildtype, -1= 1bp deletion, -2= 2bp deletion, 1= 1bp insertion). A clear degree of instability (1bp 
deletion) can be observed in 9 markers in the MSI-H sample (IM14-7, LR49-7, LR20-8, GM11-9, 
GM17-9, IM16-9, LR10-9, IM66-7 and IM67-7) (blue squares). None of the markers exhibit such a 
frequency of instability in the MSS sample. 
In the Figure  3-20, it was clear that 4 markers from the 7bp group and another 
4 from the 9bp group exhibited deletion frequency in the MSI-H sample far more that 
those observed in the MSS sample. An additional 8bp marker showed a 25% 
deletion frequency in the MSI-H sample compared to 1% in the MSS sample. This 
indicates that the inclusion of more than one marker from each group would add 
more to the informativeness of the panel. 
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Almost all markers showed variable frequencies of deletion, but deletion 
frequencies were higher in MSI-H than MSS samples as shown in Figure  3-21 as an 
example.  
 
Figure ‎3-21: The deletion frequencies for the marker LR24 across all samples. Deletion is 
more abundant in MSI-H than MSS samples. 
3.2.2.2. Optimisation of thresholds for calling instability of the short mononucleotide 
markers 
It was clear from deletion curves of individual markers that at certain deletion 
frequency, certain markers achieved 100% specificity while others are not (even 
within the same length group). In order to generate a unified scale for calling 
instability, I have tried to test different cutoff values for each group of markers.  
Based on the data extracted from threshold curves, 4 arbitrary threshold sets 
were tested. Each threshold set has been tested for each marker by examining 
deletion frequencies both in MSI-H and MSS samples.  
 For purposes of correct classification of samples, any marker shows a 
deletion frequency at or above the threshold was classified as “unstable”, while those 
with lower frequencies (below the threshold value) are classified as “stable”. False 
positive rate (FPR) and false negative rates (FNR) were calculated as explained in 
Chapter 2 section  2.10.6 
The first threshold set was based on using a very low deletion frequency 
(0.01) as a cutoff value for all markers (7, 8 and 9bp markers). Applying this low level 
of deletion frequency as arbitrary threshold resulted in a high false positive and false 
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negative rates (FPR, FNR) as shown in Table  3-3. Because the cutoff values were 
very low, all MSS samples have had a high number of unstable markers (ranging 
from 12 to 19 markers) as shown in Figure  3-22. This clearly indicates a very poor 
discriminatory power of the panel at those cutoff values.  
 Group Cutoff FPR FNR Sensitivity Specificity 
 
0.01 Threshold set 
7bp 0.01 0.25 0.59 41% 75% 
8bp 0.01 0.76 0.14 86% 24% 
9bp 0.01 0.84 0.11 89% 16% 
 
0.05 Threshold set 
7bp 0.05 0.00 0.82 18% 100% 
8bp 0.05 0.01 0.70 30% 99% 
9bp 0.05 0.05 0.52 48% 95% 
 
0.1 Threshold set 
7bp 0.1 0.00 0.88 12% 100% 
8bp 0.1 0.00 0.84 16% 100% 
9bp 0.1 0.01 0.65 35% 99% 
 
Final Threshold set 
7bp 0.05 0.00 0.82 18% 100% 
8bp 0.05 0.01 0.70 30% 99% 
9bp 0.1 0.01 0.65 35% 99% 
Table ‎3-3: Cutoff values and false calling rates in the 4 threshold sets.The highest FPR and 
FNR were observed in the 0.01 threshold set while, the lowest were in the final threshold set.  
To minimise both FNR and FPR, a second set of thresholds was tested using 
5% (0.05) as a cutoff value for all groups, this resulted in a significant decline in both 
FPR and FNR especially in the 7bp group of markers, but FNR in the 9bp persisted 
high as shown in Table  3-3. 
Applying these cutoff values resulted in a dramatic decrease in the number of 
unstable markers in the MSS samples and only 12 MSS samples (out of the 30 
tested MSS samples) have had ≥ 1 unstable marker as shown in Figure  3-22. 




Figure ‎3-22: Number of 7-9bp markers called as unstable in each sample using different 
threshold sets.  (A) 0.01 threshold set, (B) 0.05 threshold set, (C) 0.1 threshold set and (D) the final 
combined threshold set (0.05 and 0.1). The highest number of markers with deletion above the cutoff 
values was observed in the 0.01 threshold set, while the lowest in the 0.1 threshold set. In the 0.1 
threshold set, one MSI-H sample was miscalled as MSS. 
A third set of threshold values was applied using 10% (0.1) as a cutoff value 
for all groups of markers (7, 8 and 9bp repeats). Using this value as a threshold, FPR 
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has reduced to 0 in both 7 and 8bp markers and to 0.01 in the 9bp markers as shown 
in Table  3-3. Using 0.1 as a cutoff value has eliminated more unstable makers in the 
MSS group, and at that threshold value, only three MSS samples have had a single 
unstable marker. On the other hand, these relatively high cutoff values resulted in 
miscalling of a single MSI-H sample as stable as shown in Figure  3-22.  
As shown in the above threshold sets, empirical elevation of the cutoff values 
resulted in an obvious reduction in both FPR and FNR. The false positive rate is 
more important than false negative rate because of its subsequent clinical and 
biological impacts in the determination of a wrong MSI status. Therefore, the aim was 
to establish a cutoff value, high enough to eliminate all (or almost all) false positives. 
There is a substantial evidence that instability is proportional to the length of 
the repeat (Vilkki et al., 2002, Fazekas et al., 2010), suggesting it may be appropriate 
to generate length- specific threshold values and to investigate such a length specific 
threshold set using the same parameters. As long as using 0.05 (5%) as a cutoff 
value resulted in elimination of almost all FPR for the 7 and 8bp markers while the 
least FPR for the 9bp markers was achieved by the cutoff value of 0.1 (10%), a 
collated threshold set was designed using 0.05 as the cutoff value for the 7 and 8bp 
markers and 0.1 as the cutoff value for the 9bp markers. The application of this 
threshold set resulted in the least FPR and FNR for both groups of markers as shown 
in Table  3-3. 
 Then, sensitivity and specificity were calculated for the final threshold set 
(with the length specific cutoff values) as explained in Chapter 2 section  2.10.6. 
Applying these values in a single threshold set, and using a criterion of calling 
instability for those samples that have at least single marker with a deletion 
frequency above the length-specific threshold value, resulted in 100% sensitivity and 
83% specificity as shown in Table  3-4.  
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TP TN FP FN Sensitivity Specificity 
25 25 5 0 100% 83% 
Table ‎3-4: Outputs and performance metrics of the Final (0.05, 0.1) threshold set.TP= True 
positive, TN= True negative, FP= False positive and FN= False negative.  
The suboptimal specificity was due to 5 MSS samples were called unstable 
(false positives). Interestingly, all the 5 false positive samples had a single marker 
with a deletion frequency equal or more than the cutoff value designed for each 
group as shown in Figure  3-22. 
Microsatellite instability might affect any repetitive sequences in the human 
genome and there is evidence suggesting that all colorectal cancer cases could 
exhibit a low level of microsatellite instability when a large enough number of markers 
are tested (Laiho et al., 2002, Umar et al., 2004). Therefore, it is expected to find a 
low level of instability even in MSS samples. Based on that assumption and to 
eliminate the possibility of misclassification, it was possible to use a cutoff value of 
having at least 2 unstable markers for each sample to be called as MSI-H and those 
with none or less than 2 unstable markers are called MSS. Applying this rule has 
raised the specificity to 100%. 
All unstable markers showed higher degrees of instabilities in MSI-H than 
MSS cases, as shown in Figure  3-23.  
 
Figure ‎3-23: Deletion frequencies (Y-axis) of all markers (X-axis) in 2 different samples; 
one is MSI-H (blue) and the other is MSS (red). Thresholds are 0.05 in 7 and 8bp markers and 0.1 in 
9bp markers shown as horizontal red lines. Ten markers have a higher deletion frequency than the 
specified threshold in the MSI-H sample compared to MSS sample. 
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3.2.2.3. Assessment of the utility of allelic biased instability as an additional 
parameter for calling instability 
The other parameter against which all markers were stratified, is the allelic 
bias. All primers were designed to amplify a genomic segment that spans both the 
target homopolymer and an adjacent high frequency SNP. The amplicon was 
considered as heterozygous when the overall number of sequencing reads from the 
minor allele exceeds ≥10% of the overall reads for the other allele. However, in 
almost all heterozygous amplicons, minor alleles showed ≥40% sequencing reads 
compared to the other allele. Deletion frequencies were calculated for all alleles of 
each SNP to observe the difference between them. If that difference is significant, 
then deletion is said to be allelic biased and it is more likely to be a real instability 
rather than sequencing errors. To do this, the ratio between sequencing reads of 
deletion genotypes and wildtype reads for both alleles were calculated as shown and 
explained in the Figure  3-24 and its legend. 
 
Figure ‎3-24: Sequencing reads of the marker LR24 linked to a specific SNP in one of the 
MSI-H samples. The most abundant genotype is the 0 (wildtype). The next frequent genotype is the -
1 (deletion of 1 bp). The deletion is observed on both SNP alleles (A and G), but more frequent in 
allele A where deletion frequency of -1 allele is 13%. By applying the Fisher’s Exact test, deletion in 
allele A is shown to be significant (P value less than 0.05) compared to deletion in allele G. Because 
the instability is allelic biased and above the allotted cutoff value, this marker is therefore considered 
unstable in that particular sample.  
Fisher’s Exact test (of a 2x2 contingency table) was used to test the 
probability that a deletion has an allelic bias. The significance of instability is 
expressed as p value, with a p value less than 0.05 considered significant (as shown 
in Chapter 2 section  2.10.5).  
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3.2.2.4. Assigning an informative panel of 8 markers from within the 25 short markers 
Allelic bias was used as an extra tool to assess the instability of a marker and 
its existence increases the likelihood that a registered deletion reflects real instability 
rather than just a technical artefact. Instability was then called based on the fulfilment 
of both criteria, deletion frequency above the threshold which shows a significant 
allelic bias. Those markers that fulfil these 2 criteria were called as unstable markers 
and each sample was then called unstable if it has at least a single unstable marker 
(fulfilling both criteria). Deletion frequency and allelic bias were assessed for each 
marker individually as shown in Figure  3-25. 
 
Figure ‎3-25: The deletion frequency and allelic bias of the 25 markers. Markers are plotted 
on the X- axis and percentage of MSI-H samples on Y- axis. DF= Number of markers that show 
deletion frequency above threshold value, DF+AB= Number of markers that showed deletion 
frequency above threshold value in addition to allelic bias. Four markers did not show any deletion and 
an additional 6 markers did not show evidence of allelic bias. 
The sensitivity and specificity of the 25 marker panel were calculated by 
defining instability as having at least a single marker with a significant allelic bias and 
a deletion frequency above the specified threshold values. This panel has efficiently 
discriminated MSI-H from MSS samples. At a threshold of at least one marker with a 
deletion frequency above the length specific cutoff value in addition to a significant 
allelic bias in each MSI-H sample, the panel achieved 100% sensitivity and 97% 
specificity. The suboptimal specificity was attributable to the finding that one marker 
was unstable in one MSS sample (marker GM23). Out of the 25 markers used in the 
initial panel, 4 markers (LR51, IM43, IM55 and GM21) didn’t show observable 
instability both in MSI-H and MSS samples, indicating that these are less informative 
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and inclusion of such markers, therefore, is unlikely to add more information about 
the MSI status, therefore, they were excluded from the subsequent analysis. 
An additional 6 markers (IM19, IM67, LR15, LR8, IM41 and LR40) lack 
evidence of allelic bias throughout the cohort, thus these were also excluded from the 
panel. The remaining 15 markers (shown in Figure  3-26) were chosen for further 
analysis. Both sensitivity and specificity remained unaffected by this reduction in the 
number of markers (100% and 97%, respectively); indicating that within this cohort of 
samples, omitting these markers had no effect on the overall performance of the 
panel.  
 
Figure ‎3-26: The instability (shown in percentage) of the 15 markers in MSI-H samples.  
DF= Number of markers that show deletion frequency above threshold value, DF+AB= Number of 
markers that showed deletion frequency above threshold value in addition to allelic bias. LR49 is the 
most unstable marker as it showed allelic bias in 38% of the tested MSI-H samples and stable in all 
MSS samples. The marker GM23 (red rectangle) was unstable in 14% of MS-H samples and in a 
single MSS sample.  
 The overall aim of this part of the study was to find out the most informative 
markers that can efficiently distinguish the unstable tumours. Therefore, the number 
of markers has been reduced further to improve specificity and to have the minimal 
number of informative markers based on results from the tested cohort in this part of 
the study. The selection of the most informative markers was based on the following 
criteria: 
1) The selected marker should have instability in a high percentage of MSI-H 
samples with evidence of allelic bias. 
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2) The selected markers should be stable across all MSS samples 
(Specificity= 100%). 
3) Each MSI-H case should have at least one unstable marker with evidence 
of allelic bias. 
A nominated panel of 8 markers (from the 15markers) was then suggested as 
shown in Figure  3-27. By applying this 8 markers panel, all false positives were 
eliminated and the sensitivity and specificity were both 100% in the tested cohort.  
 
Figure ‎3-27: The instability (shown in percentage) of the final panel ,which composed of 8 
markers in MSI-H samples. DF= Number of markers that show deletion frequency above threshold 
value, DF+AB= Number of markers that showed deletion frequency above threshold value in addition 
to allelic bias. 
 Using this panel, each MSI-H sample within the cohort exhibited at least one 
unstable marker with additional evidence of allelic bias and none of the MSS samples 
showed any unstable marker, suggesting this panel may be useful in differentiation 
between MSS and MSI-H samples in the tested cohort. Interestingly, one 7bp marker 
(LR49) was unstable in up to 38% of the MSI-H samples (9 out of 24) and additional 
two 9bp markers (IM16 and GM11) were unstable in up to 42% (10 out of 24) of the 
MSI-H samples as shown in Figure  3-28. 




Figure ‎3-28: The 8 informative markers selected from the 25 tested markers.   A: The 
markers IDs are shown at the top and MSI-H sample numbers are grey highlighted on the leftmost 
column. Unstable markers in each sample are highlighted in pink. All samples have at least one 
unstable marker out of the 8 markers in this panel. B: The number of unstable markers and their 
length for each MSI-H sample. The most unstable group of markers is the 9bp group. 
The poly A/T homopolymers constituted the majority of the markers, both in 
the initial 25 marker panel (22 out of 25 markers) and the 8 marker panel (7 out of 8 
markers) as shown in Figure  3-29A. The 25 marker panel was composed of exactly 
the same number of 7bp and 9bp repeats (10 markers for each), while in the 8 
marker panel; most of the markers were 9bp repeats as shown in Figure  3-29B.  




Figure ‎3-29: A: Base composition of the homopolymers tested in this study. The poly A/T 
markers represent the main component both in the 25 marker panel (Panel 25) and the 8 marker 
panel (Panel 8). B: The length of the homopolymers used in the 25 marker panel (Panel 25) 
encompassed an equal number of 7 and 9bp repeats. In the 8 marker panel (Panel 8), half of the 
markers were 9bp repeats. 
3.3. Discussion 
The overall aim of this study was to develop a microsatellite panel, convenient 
enough to supersede the currently used test and able to fulfil the increasing demand 
for MSI testing. In this part of study, it was possible to assemble a highly informative 
panel of short homopolymers that can efficiently discriminate between MSI-H and 
MSS samples.  
The work presented in this Chapter showed that deletion of homopolymers is 
far more frequent than insertion, which is consistent with what was reported by others 
(Kunkel, 1990, Clarke et al., 2001, Redford, 2016). Therefore, deletion frequency has 
been used as the main classifier for calling instability. 
For all markers across all samples in the cohort, deletion frequency and allelic 
bias have been calculated and then different threshold sets were tested. A marker 
was said to be informative if it was unstable in MSI-H and stable in MSS samples, 
while a marker called as uninformative when it was stable in MSI-H and/or unstable 
in MSS samples. Different thresholds were tested and in the first instance, very low 
cutoff values (0.01) were set to examine the deletion profile of all markers. At that 
cutoff, all MSI-H and MSS samples showed a high number of markers exceeding that 
cutoff value, and some MSS samples have had up to 19 markers with deletion 
frequency above that cutoff value. That 0.01 threshold set resulted in a very high 
false positive rate (up to 0.82) and, therefore, it was inconvenient to be applied. The 
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raising of cutoff values was mandatory to get rid of the false positive results and 
therefore, a second set of cutoff values was used. A cutoff value of 0.05 was adopted 
for all markers (7, 8 and 9bp markers). With that set of threshold, both false positive 
and false negative rates (FPR and FNR) were dramatically decreased (down to 0.003 
in the 7bp markers). However, at that threshold set, 4 MSS samples showed 2 
markers with a deletion frequency above that cutoff value (i.e. 0.05). With that 
threshold set, it was possible to use the criteria of 3 markers or more with deletion 
above the threshold to differentiate all MSI-H from MSS samples. Another threshold 
set was tested, in which the cutoff value was raised to 0.1 for all markers (7, 8 and 
9bp markers). This resulted in a further decline in the FPR and FNR, but at the same 
time, resulted in misclassification of one MSI-H sample.  
The instability of a homopolymer was known to be increased proportionally 
with the repeat length (Sammalkorpi et al., 2007, Vilkki et al., 2002, Redford, 2016), 
therefore, it would be better to design cutoff values so as to be increased with the 
longer repeat length. The combined threshold set was designed to be 0.05 for both 
7bp and 8bp repeats and 0.1 for the 9bp repeats. With that set, all MSI-H samples 
have got at least 2 unstable markers. For an optimal MSI test, this set of threshold 
values was able to distinguish all MSI-H samples at a cutoff of having at least 2 
unstable markers, within this cohort.  
Consistent with other studies (Ward et al., 2001, Laiho et al., 2002, de la 
Chapelle and Hampel, 2010), there was no observable difference in the deletion 
frequency of all the tested markers between MSS and MSI-L samples. They, 
therefore, were considered as a single group (both called as MSS) for purposes of 
subsequent classification. 
Most of the significant allelic bias length alterations in the tested markers were 
observed in MSI-H samples; therefore, it can be used as an additional criterion for 
classification of CRC samples. The inclusion of this parameter adds more confidence 
that the alteration is likely a real instability rather than a technical artefact. However, 
this parameter is only applicable when the adjacent SNP is heterozygous. At a 
threshold of having at least one unstable marker which have evidence of allelic bias, 
all MSI-H samples were called correctly using the final (0.05, 0.1) threshold set, while 
a single MSS sample was called as unstable (100% sensitivity and 97% specificity). 
Only 15 markers showed allelic biased instability and out of them, 8 markers (from 
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those 15 markers) were found to be very informative in calling instability using both 
criteria (i.e. deletion frequency and allelic bias). At a threshold of having at least a 
single unstable marker, which shows evidence of allelic bias, the 8 markers panel 
was able to differentiate all MSI-H samples with a sensitivity and specificity of 100% 
for both.  
The inherent problem of DNA degradation and poor quality in FFPE samples 
represent one of the most eminent obstacles in the MSI testing. In this study, not all 
samples have successfully been amplified the 300bp primers and in order to check 
the possible reasons, the DNA quality has been checked and the parameter DV200 
was used for that purpose. DV200 refers to the percentage of DNA sized ≥ 200bp in 
the tested sample. The DV200 for those samples that successfully amplified the 
300bp amplicons was ranging between 15.6-44%, while it was 0-10% in those that 
failed to amplify 300bp amplicons. This strongly suggests that DNA quality is a 
fundamental factor in the success of this assay.  
Furthermore, a 100bp primer set was tested to assess the impact of DNA 
degradation on the successful amplification. Out of 36 samples that failed to amplify 
the 300bp amplicons, 42% (15/36 samples) were successfully amplified the 100bp 
amplicon. This suggests that a considerable proportion of failures in amplification 
was due to the FFPE induced- DNA degradation. This could represent a potential 
caveat in the MSI assay and it would be worthy, therefore, to try to redesign the 
primers to be smaller than those used in the current assay to increase the 
amplification success rate. 
The application of the final threshold set (0.05, 0.1) has resulted in the lowest 
FPR and FNR, and when allelic bias used as an additional classifying parameter, it 
resulted in the highest sensitivity and specificity. However, this threshold set and the 
allelic bias classification system need to be investigated on a larger independent 
cohort to find out the informativeness of such a set and conclude the optimal calling 
system. 
A concomitant study conducted by Dr Lisa Redford (Newcastle University, UK) 
was investigating the instability of longer markers (8-12bp) has concluded 9 markers 
as to be the most informative in that study. These 9 markers were sensitive and 
specific for the tested cohort, which was composed of 58 CRC samples (when 
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thresholds were set arbitrarily) (unpublished data). The informative markers from that 
study, were then collated with the 8 informative markers from my study to build up a 
joint informative panel composed of 8 short (7-9bp) and 9 long (8-12bp) markers. 
This panel will be extensively interrogated in next chapters to assess its accuracy in 
discrimination between MSI-H and MSS samples.   
3.4. Conclusions 
 In conclusion, it was possible to check the instability with evidence of allelic 
bias for most markers and 8 markers (from the initially tested 25 markers) were highly 
sensitive and specific (100% for both) using a cohort of 55 CRC samples. A joint 
panel can be generated by combining the informative markers from this study (eight 
7-9bp markers) and other informative markers from a parallel study (nine 8-12bp 
markers). It would be important to assess this combined panel (of the 17 markers) 
using an independent cohort. The threshold set proposed in this chapter also needs 
to be assessed in order to find out the most informative cutoff values that could be 
used for calling instability. 
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Chapter 4. Assessment of arbitrary threshold sets and 
determination of an optimal MSI scoring system 
4.1. Introduction and aims 
4.1.1. Introduction 
In the previous chapter, 25 short (7-9bp) markers were extensively analysed 
using a cohort of 55 CRCs and from them, a panel of 8 markers was found to be the 
most informative in terms of discrimination between MSI-H and MSS samples. In that 
part of the study, four threshold sets were tested and a final set of length specific 
cutoff values were chosen as the most informative threshold set based on the values 
of false positive and false negative rates. At a threshold of having at least a single 
unstable marker with allelic bias in each MSI-H sample in the tested cohort (i.e. 55 
CRCs), the 8 markers panel was able to differentiate between all MSI-H and MSS 
samples. An investigation of longer markers, performed by Dr Lisa Redford 
(Newcastle University, UK) identified cutoff values that enabled a panel of 9 longer 
(8-12bp) markers to discriminate between all MSI-H and MSS samples in the tested 
cohort which was composed of 58 CRC samples. In this chapter, the aim is to 
analyse these 17 markers (8 short and 9 long) against a larger cohort (composed of 
141 CRC cases) and assess different threshold sets to determine optimal threshold 
values that can be used to implement the target markers in an MSI assay. 
In 2012, TCGA published a seminal paper about the somatic alteration in CRC 
using the NGS platforms (Cancer Genome Atlas, 2012). In that paper, researchers 
used the exome data to assess the microsatellite instability. Since that time, several 
studies have tried to assess the MSI status using an NGS approach. In 2013, a novel 
method to assess microsatellite instability was proposed using RNA- seq data. In that 
study, RNA-seq data from 20 different cancer cell lines with known MSI status were 
analysed. The proportion of insertions in microsatellite loci over all insertions (named 
as PI) and the proportion of deletions in microsatellite loci over all deletions (named 
as PD) were calculated. PI/PD was referred to as MSI- seq index and used to assess 
the instability of each microsatellite locus. RNA- seq data from HapMap 
lymphoblastoid samples were used as a control as they were known to have no 
instability. A significant increase in the proportion of indels was observed in the MSI 
samples compared to those in HapMap samples, while there was no significant 
difference between MSS and the HapMap samples (Lu et al., 2013). 
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A new NGS based approach called mSING was proposed and assessed in 
2014 (Salipante et al., 2014). In that assay, NGS data from 324 different tumours 
(colorectal, endometrial, ovarian, breast and others) were curated to assess the 
instability in 15- 2957 mononucleotide markers. Variant allele frequency was 
calculated in the MSS group and each allele with reads exceeds 5% of the most 
abundant allele was tallied. The mean of the number of alleles for each marker was 
calculated to create a baseline reference value. The marker was said to be unstable 
if the variation exceeds (mean number of alleles + (3xSD) of the baseline reference). 
They called that approach as mSING (MSI by NGS) and they found it 96-100% 
sensitive and 97-100% specific in tested cohorts. 
In 2015, another study investigated the possibility of performing an MSI assay 
together with the inclusion of other relevant target genes panel in colorectal cancer 
(KRAS, NRAS and BRAF), using an NGS platform (Hempelmann et al., 2015). They 
assessed the microsatellite instability of 17 mononucleotide markers (15- 28bp in 
length) by using the mSING approach (mentioned above). The study concluded that 
the used panel of markers was 97.1% sensitive and 100% specific in detecting the 
microsatellite instability. 
Gan et al have used the MiSeq platform to assess the utility of both 
mononucleotides (3 markers 25-34bp in length) and dinucleotides (2 markers 40bp in 
length) in microsatellite instability (Gan et al., 2015). They calculated the most 
prevalent allele in both tumour and a corresponding normal sample; they called the 
marker as unstable if the deviation compared to normal is ≥2bp for mononucleotides 
and ≥ 4bp for the dinucleotide markers. Quantitative analysis of the MiSeq data from 
that study showed that the sensitivity and specificity of the mononucleotides were 
both 100%, while for dinucleotides, the sensitivity was 47- 59% and specificity was 
96- 100%. 
It is expected for such studies to evolve more over the next few years, as there 
is no consensus as to the optimal approach in terms of the number of markers that 
need to be included in the panel, the threshold for calling instability, use of control 
(normal) tissue  and other quality parameters (e.g. sequencing depth, Quality score 
and others).  




In the previous chapter, the study has nominated a panel of eight (7- 9bp) 
markers that were able to discriminate between MSI-H and MSS samples in terms of 
both deletion frequency and allelic bias. Concomitantly, a parallel study conducted by 
Dr Lisa Redford (Newcastle University, UK) selected a panel of nine (8-12bp) 
informative markers (able to discriminate MSI-H from MSS samples). To establish the 
overall sensitivity and specificity of the collated panel, these markers (8 from my 
study and 9 from the other study) were analysed using a larger cohort composed of 
141 CRCs, as summarized in the Figure  4-1. This chapter will outline the assessment 
of different threshold sets and determine the optimal MSI scoring system that can be 
used to implement the 17 markers as an MSI test. The overall aims are to: 
 Investigate a subset of 141 CRC samples with known MSI status using the 
joint panel of markers (17 markers). 
 Test several length- specific threshold sets and design a new MSI scoring 
system. 
 Investigate and evaluate the role of the allelic bias in calling instability. 
 Compare the threshold curves for all markers with their curves in the 
previous studies (that were done in chapter 3) to assess reproducibility 
across the 2 cohorts and detect any anomalies in deletion curves of 
markers. 




Figure ‎4-1: Illustration of the overall workflow in this study. The study has started by 
analysing the 120 variable markers from the whole genome study, and then the highly variable 66 
markers were split into short (7-9bp in length) and long (8-12bp in length) markers. Both groups of 
markers assessed independently and the markers that were able to differentiate MSI-H from MSS 
samples (17 markers) were gathered from both assays.  
4.2. Results 
4.2.1. Amplification and Sequencing of the new 17 marker panel 
In Chapter 3, 8 out of the 25 tested short (7-9bp) markers were found to be 
able to discriminate between MSI-H and MSS samples using a cohort composed of 
55 CRCs. At a threshold of a single unstable marker (based on the threshold set 
specified in Chapter 3) for each sample, the panel was able to detect all MSI-H 
samples in that cohort as clarified in Figure  4-2. Another parallel study (Redford, 
2016), concluded a panel of 9 mononucleotide markers (8-12bp in length) as the 
most informative using an independent cohort of 58 CRCs as shown in Figure  4-2. 
The results from both independent studies, substantially favours the feasibility of 
using short homopolymers in MSI testing.  
 
 




Figure ‎4-2: The informative mononucleotide markers from 2 independent studies. Long 
markers= 8-12bp mononucleotide markers, Short markers= 7-9bp mononucleotide markers. The 
names of the markers are shown at the top and MSI-H sample numbers are highlighted in yellow. 
Unstable markers (based on threshold sets specified in in each study) in each sample are highlighted 
in pink. The total number of unstable markers in each case is shown on the right pane (green column). 
The final panel is composed of 9 long markers on the left side and 8 short markers on the right side. 
All MSI-H samples from both cohorts have at least one unstable marker out of the 17 markers. 
The informative markers from both studies (8 short and 9 long mononucleotide 
markers= 17 markers) were collated together to be assessed using a large cohort of 
CRCs with mixed phenotypes. This assessment is to confirm the utility of these 
markers in detection of MSI and to establish a consensus threshold set can be used 
for the calling instability. 
As the ultimate aim is to develop a panel accurate enough to supersede the 
currently used one (Promega panel), it is fundamental to standardise the approach 
and extensively validate that panel prior to it being implemented in clinical 
laboratories. To assess the test, the collated panel (which is composed of 17 
markers), was analysed using a larger cohort of Spanish CRC samples with a mixed 
MSI phenotype (MSS and MSI-H). The Spanish batch of samples was initially 
composed of 201 samples and provided by the Genetics Service, Complejo 
Hospitalario de Navarra and the Oncogenetics and Hereditary Cancer Group, 
IDISNA (Biomedical Research Institute of Navarre, ESPANA). They were delivered in 
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the form of extracted DNA and have been quantified and MSI tested in the original 
lab. I was blinded to their MSI status during initial analysis for purposes of 
anonymization. Out of the 201 samples, 141 CRC samples (approximately composed 
of 50% MSI-H and 50% MSS samples) were selected for analysis to establish a 
standardised calling system for MSI classification.  
Primers were designed for the 17 markers of the collated panel. To streamline 
the assay, 2 main amendments were introduced in the primer designing: 
A) Generation of short amplicons 
In the previous part of the study, primers were designed to amplify ~300bp 
amplicons, as this was the recommended amplicon length by the Nextera library 
preparation protocol (Illumina, California, USA). The amplification of such a relatively 
long amplicons from FFPE DNA was associated with risk of failure, perhaps due to 
FFPE- induced DNA degradation, and thus likely to compromise the downstream 
analysis. 
In the current part of the study, the primers were designed to amplify smaller 
fragments (100-150bp). This delivers 2 main advantages: 
1) It will minimise the impact of FFPE associated- DNA degradation on our 
approach because such a small DNA fragment is more likely to be 
successfully amplified. 
2) In the downstream library preparation, it omits the need for the fragmentation 
step because PCR products are already relatively small. 
Furthermore, the skipping of fragmentation step (the enzymatic fragmentation 
in case of the Nextera library preparation) brings 2 additional advantages: 
1) It reduces the time and effort required for the library preparation and, thus, 
makes it more easy and straightforward. 
2) It obviates the use of Transposase (the enzyme used to fragment DNA) and 
thus, diminishes sequence errors induced by this step. 
B) Primer- Tag incorporation 
The second modification is the direct incorporation of the overhang tag 
sequences to the primers prior to amplification as shown in Figure  4-3. This direct 
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incorporation will make the process more user friendly, cutting the cost and time 
required for library preparation.   
 
Figure ‎4-3: Schematic representation of the primer designing and subsequent amplification 
and library preparation. The primers were designed by direct incorporation of overhang tag sequences 
to the primer in a single piece. This incorporation allows both sequences (primer and tag) to be 
incorporated into the target sequences by PCR. The tagged PCR amplicons are then barcoded (i7 and 
i5) by reduced cycle PCR to prepare the library. ROI= region of interest. 
As in the earlier analysis, these primers were designed using Primer 3 (Rozen 
and Skaletsky, 1999) and Primer BLAST, so that to amplify a genomic sequence that 
contains both a homopolymer and an adjacent high frequency SNP (shown in 
Table  4-1). 
For most primers, the SNPs were chosen to be situated no more than 30bp 
away from the homopolymer. Then, these primers were in- silico checked for 
theoretical amplifiability of a unique amplicon using the UCSC genome browser (Kent 
et al., 2002). All markers were derived from the initial 120 variable markers (which 
were initially retrieved from the whole genome analysis carried out at the beginning of 
the study as explained in Chapter 3), except 2. These 2 markers were chosen from 
the literature as they showed a high degree of instability. The 2 markers are 
DEPDC2-8G (Alhopuro et al., 2012) and AP003532-2-9 (Sammalkorpi et al., 2007) 
which were tested alongside the longer markers (8-12bp) (Redford, 2016). 
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  Amplicon Repeat 
Size 
SNP SNP alleles  MAF Repeat Position 
1 LR49-7 7 rs12903384 A/G G= 0.4898 Chr15:93619048 
2 IM66-C 7 rs4794136 C/T C= 0.3826 Chr17:48433967 
   rs141474571 C/G/T T= 0.0004  
3 DEPDC2-G 8 rs4610727 C/T C= 0.4762 Chr8:68926683 
4 LR20-8 8 rs217474 C/T G= 0.3175 Chr1:64029634 
   rs146973215 C/T C= 0.0110  
5 GM9-8 8 rs79878287 C/T C= 0.0006 Chr20:6836977 
6 GM11-9 9 rs347435  A/G G= 0.3522 Chr5:166099891 
7 LR24-9 9 rs192329538   A/G A= 0.0002 Chr1:153779429 
8 IM16-9 9 rs73367791  C/T T= 0.0639 Chr18:1108767 
9 GM17-9 9 rs666398  C/T T= 0.2718 Chr11:95551111 
10 AP003532-2-9 9 rs138081624 A/G G= 0.0002 Chr11:127625067 
11 GM7-11 11 rs2283006  A/G G= 0.3371 Chr7:93085748 
12 LR48-11 11 rs11105832 C/T T= 0.2270 Chr12:77988097 
13 LR11-11 11  rs13011054  A/C A= 0.4093 Chr2:217217871 
14 GM14-11 11 rs6804861  C/T T= 0.3758 Chr3:177328818 
15 IM49-12 12 rs7642389  C/G C= 0.2157 Chr3:56682066 
16 LR36-12 12 rs17550217 A/T A= 0.2654 Chr4:98999723 
17 LR44-12 12 rs7905388 C/T  T= 0.3237 Chr10:99898286 
   rs7905384 C/T  T= 0.3207  
Table ‎4-1: List of the 17 primers used in the MSI analysis.  For each primer, there is at least 
one adjacent high frequency SNP. MAF= the global minor allele frequency according to dbSNP build 
144. 
After trials of optimisations, three primer pairs (LR49-7, IM16-9 and GM14-11) 
failed to give a clear product. Therefore, I redesigned them and the amplification 
products were successfully obtained. The PCR products (2267 amplicons) were 
tested and quantified by the QIAxcel automated electrophoresis system (Qiagen, 
Hilden, Germany), then pooled at approximately equal concentrations and barcoded 
with unique indexes.  
As the amplicons were small in size (~150bp), the 16S metagenomics protocol 
was used in the library preparation. For barcoding, Herculase II Fusion DNA 
polymerase (Agilent Technologies, CA, USA) was used instead of the 2x HiFi Kappa 
enzyme (which is the recommended enzyme in both 16S metagenomics and Nextera 
protocols). This provide a couple of advantages as it is less costy and brings the 
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maximal proofreading function (error free replication for mononucleotide repeats 
≤13bp in length after 35 PCR cycles) (Fazekas et al., 2010) which, ultimately, is an 
optimal aim in our assay. Moreover, the number of PCR cycles used to incorporate 
the barcodes was fewer (10 cycles) compared to that in the Nextera protocol (12 
cycles). The barcoded products were then cleaned up by Agencourt AMPure XP 
beads (Beckman Coulter, Pasadena, California, USA), and diluted to achieve a 
library concentration of 4 pM. 
For the sequencing, MiSeq reagent v3 (600 cycles) (Illumina, California, USA) 
was used and a total reads of 11,862,294 were generated with an average depth of 
about 2900 paired end reads (per) per amplicon. The average depth was the highest 
for the marker LR24-9 (5096 per/ amplicon), while was the lowest for the marker 
LR36-12 (188 per/amplicon). A cluster density of a 510 k/mm2 was obtained and a Q- 
score above 30 (99.9% probability of a base being called correctly) was achieved in 
69.1% of the sequenced bases as shown in Figure  4-4 A. Towards the last 
sequencing cycles, the Q30 score started to drop as shown in Figure  4-4 B and that 
was expected as the sequencing reaches the last bases of amplicons. 
 
Figure ‎4-4: Q score distribution of MiSeq run (A) and the distribution of the sequencing reads 
with Q score >30 across the sequencing cycles (B). It is obvious that reads with a Q score >30 
diminish with the progress of sequencing cycles to be extremely low at the last cycles. 
The variant caller used in this assay was the same caller that was used in the 
previous analysis (COPReC variant caller). The amplicons with sequencing reads 
below 100 were excluded from baseline calculations in order to avoid reads that 
might be generated erroneously due to PCR duplicates.  
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Overall, 86% of samples (121/141) were successfully amplified, 85% of 
samples (120/141) were successfully sequenced and 80% (113/141) were 
sequenced to adequate depth (i.e. ≥100 per/ amplicon) for 15 markers or more as 
summarised in Table  4-2. 
 
No. of markers 
No. of cases 
Amplified Sequenced Sequenced‎to‎≥100‎per/‎amplicon 
17 78 73 33 
16 29 29 52 
15 14 18 28 
14 12 12 12 
13 4 4 10 
12 3 4 4 
11 1 1 2 
10 0 0 0 
Total 141 141 141 
Table ‎4-2: The number of samples that were successfully amplified, sequenced and 
called to adequate depth (≥100 reads). 86% of samples were amplified 15 markers and more, 
85% of samples were sequenced 15 markers and more, and 80% of samples were sequenced ≥ 100 
reads for 15 markers or more. 100 sequencing reads were used as an arbitrary cutoff value to avoid 
sequencing reads that originate from sequencing errors. per= paired end reads. 
4.2.2. Analysis of MiSeq data and calculation of deletion frequency  
 The COPReC data output were initially retrieved by R studio (R-Core-Team) 
to generate the spreadsheet format in order to be analysed. Deletion frequency and 
allelic bias were used as the main parameters for subsequent analysis. The deletion 
frequency for each variant genotype was calculated as before. 
Sequencing of homopolymers is likely to be accompanied by the generation of 
non-specific reads due to the inefficiency of PCR and sequencing chemistries to deal 
with these repetitive sequences. Therefore, it is important to find a tool by which we 
can differentiate between events which represent a real instability from sequencing 
errors. Allelic bias is the tool we have used for that purpose. Because each primer 
pair was designed to amplify a genomic region that contains both a homopolymer 
and an adjacent SNP, it should be possible to identify allele specific instability, which 
would be inconsistent with sequence error (as explained in Chapter 3). To increase 
the confidence that allelic bias reflects a real instability, Fisher’s Exact test was used 
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to calculate the significance of alterations (as explained in Chapter 2 section  2.10.5). 
With this approach, it is important to differentiate between instability with allele bias 
and polymorphism. For those markers where the vast majority of reads come from 
the wildtype for one allele and from a single variant (e.g. -1bp) of the other allele, 
such a marker is likely to be a polymorphic rather than an allelic biased. However, 
there is no clear role to be used in order to clearly differentiate between the 2 
situations and to be 100% sure, normal tissue needs to be tested. 
4.2.3. Assessment of different threshold sets to conclude the most informative 
cutoff values 
Cutoff values can be defined as a specific value of deletion frequency which 
can be used for classification of samples into MSI-H (have deletion frequency equal 
or more than that cutoff value) or MSS (have deletion frequency less than that cutoff 
value). Different thresholds (with length specific cutoff values) were applied to 
investigate how a change in cutoff values could influence the analysis outputs, with 
the ultimate aim to define the most informative threshold set. Thresholds were set to 
be length specific, i.e. markers that belong to each group (e.g. 7, 8, 9, 11 and 12bp) 
were interrogated using a specific threshold value. These thresholds were chosen 
based on my previous experiment and another study analysed 9-12bp 
mononucleotide markers (Redford, 2016). I have started with the threshold values 
that gave the best results (which showed the lowest false positive rate) from both 
previous analyses, then; cutoff values were increased gradually in each threshold 
set. For each threshold set, samples were classified into 3 main subgroups: 
1- Samples that have no any marker with a deletion frequency above the 
threshold value. These samples were deemed microsatellite stable. 
2- Samples that have at least one marker with a deletion frequency above the 
threshold. These samples were deemed unstable by deletion frequency 
(DF). 
3- Samples that have at least one marker with a deletion above the threshold 
that show allelic bias. These samples were deemed unstable by deletion 
frequency and allelic bias (AB). 
During the setting of thresholds, a single event was individually introduced for 
each set. Because the allelic bias was suggested to be a reliable evidence of 
     
92 
 
instability in the previous analysis, so it is likely that samples with both deletion 
frequency and allelic bias are genuinely unstable. Cutoff values, therefore, were 
altered in a way to eliminate those samples with deletion frequency only, on the 
assumption that the optimal threshold set will likely to be in those values. Therefore, 
prior to unlock the phenotype key, the difference between DF and AB groups was 
closely observed.  
 In all threshold sets, a specific threshold value was set to the Poly G/C 
markers and that value was relatively higher than their mates with corresponding 
length as this kind of repeats is known to have a higher mutation rate than A/T 
homopolymers (Boyer et al., 2002). 
The first threshold set was designed based on thresholds tested in previous 
experiments done by myself and Dr Lisa Redford (Newcastle University, UK). In the 
first 3 threshold sets, cutoff values for short markers (7-9bp) were changed, while 
those for longer markers (11 and 12bp) were kept constant. In the latter 3 threshold 
sets, on the other hand, cutoff values for longer markers were arbitrarily raised while 
those for short markers were kept constant as shown in Table  4-3. 
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Marker group 7bp 8bp 9bp PolyG/C 11bp 12bp  
Threshold 1 0.05 0.05 0.05 0.1 0.19 0.19  
Threshold 2 0.05 0.05 0.05 0.1 0.19 0.19 - GM14 
Threshold 3 0.05 0.05 0.08 0.1 0.19 0.19  
Threshold 4 0.05 0.05 0.08 0.1 0.19 0.25  
Threshold 5a 0.05 0.05 0.08 0.1 0.19 0.30 -GM14 
Threshold 5b 0.05 0.05 0.08 0.1 0.19 0.30 +GM14 
Threshold 6a 0.05 0.05 0.08 0.1 0.30 0.30 -GM14 
Threshold 6b 0.05 0.05 0.08 0.1 0.30 0.30 +GM14 
Table ‎4-3:  Cutoff values that used for threshold setting. For each threshold set, a single event 
is introduced compared to the preceding set (red coloured). In the first 3 threshold sets, cutoff values 
of short repeats (7-9bp) were changed, while for the latter 3 sets, cutoff values for long repeats (11 
and 12bp) were changed. The cutoff value for the Poly G/C group remained constant for all threshold 
sets.  
When these sets applied on the tested cohort, a relatively high number (101 
out of the tested 141 samples) showed instability in at least one marker out of the 17 
tested markers in threshold set 1, of them, 70 samples have at least one unstable 
marker with allelic bias as shown in Figure  4-5. Direct observation of the total number 
of samples in both groups (i.e. DF and AB subgroups), can clearly show the gradual 
reduction in the number of cases in the DF subgroup compared to samples in the AB 
subgroup. Conversely, the number in the AB subgroup showed the least variation 
with a total difference between T1 and T6 is 7 samples only. This observation is 
consistent with the assumption that AB is a more reliable event of instability 
compared to DF alone.  




Figure ‎4-5: The distribution of samples with and without deletion and allelic bias 
according to cutoff values in the 6 threshold sets. The variation in the number of samples in 
the DF subgroup is more prominent compared to that of the AB subgroup across threshold sets. 0= 
samples that have no unstable marker, ≥1= samples that have one or more unstable markers. 
Having set these thresholds, the phenotype was predicted for all samples. At 
that stage, the data became ready to be compared with the reported phenotype in 
order to elucidate the performance of the different threshold sets compared to a gold 
standard panel (which is the currently used MSI Analysis System, Version1.2: 
Promega, Madison, USA). I was then able to calculate Sensitivity and specificity (as 
explained in Chapter 2 section  2.10.6) 
The overall sensitivity and specificity were almost similar within the first three 
threshold sets. A notable difference was observed in the change of specificity 
between AB and DF subgroups for each threshold set with a higher specificity in the 
AB subgroup as shown in Table  4-4. On the other hand, the last 3 threshold sets (i.e. 
T4, T5 and T6) can clearly show a better overall performance (higher sensitivity and 
specificity) compared to the initial threshold sets (i.e. T1, T2 and T3), with the highest 
sensitivity and specificity were observed in T6 as shown in Table  4-4. 
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Threshold set  >1  0 Sensitivity Specificity 
Threshold 1 DF 101 40 96% 51% 
Threshold 1 AB 70 71 88% 82% 
Threshold 2 DF 97 44 96% 57% 
Threshold 2 AB 68 73 87% 90% 
Threshold 3 DF 97 44 96% 57% 
Threshold 3 AB 68 73 87% 90% 
Threshold 4 DF 79 62 96% 82% 
Threshold 4 AB 68 73 87% 90% 
Threshold 5a DF 75 66 91% 81% 
Threshold 5a AB 67 74 87% 91% 
Threshold 5b DF 78 63 93% 81% 
Threshold 5b AB 68 73 88% 90% 
Threshold 6a DF 72 69 94% 90% 
Threshold 6a AB 62 79 86% 96% 
Threshold 6b DF 73 68 94% 88% 
Threshold 6b AB 63 78 87% 96% 
Table ‎4-4: Analytical parameters of the 6 threshold sets. >1 refers to the number of samples 
that have a single unstable marker or more, 0 refer to the number of samples that have no unstable 
marker. 
The above results indicate that the increment of the cutoff values in the longer 
repeats (11 and 12bp repeats) was the main reason behind the improvement in the 
performance of the last threshold sets. This, also indirectly, indicate that most variant 
reads were came from the longer repeats and raising cutoff values for these markers 
was able to get rid of the majority of variant reads in the MSS samples.  
4.2.4. Assignment of a new scoring system for calling instability 
  The presence of AB in markers that have DF above the specified thresholds 
increase the likelihood that the observed deletion is real instability rather than just 
sequencing errors. To improve the classification of samples, whether stable or 
unstable in this panel, an arbitrary scoring system was suggested in which each 
marker with a deletion frequency above the specified threshold was given a score of 
1 and each marker with a deletion frequency above the threshold with evidence of 
allelic bias was given a score of 2 (because allelic bias represents an additional 
evidence of instability). According to that scoring system, an overall score of 3 was 
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set as a cutoff for a sample to be called as unstable. Setting the cutoff value to 3 was 
to avoid misclassifying MSS samples as MSI-H when there is a single marker with a 
deletion frequency above the threshold value in addition to allelic bias. Furthermore, 
it has been reported that all CRC cases have a certain degree of instability (Laiho et 
al., 2002), so setting the cutoff value to be 3 would be a safe decision to exclude 
those samples with such a baseline instability. This classification system was termed 
as the weighted scoring system and has been applied to T5 and 6 and the results 
were as shown in Table  4-5. The weighted MSI scoring system was named as 
threshold 7 (T7) which uses the same cutoff values specified in T6. When T7 was 
used, the highest sensitivity and specificity were achieved as shown in Table  4-5. 
 Sensitivity Specificity 
T7a 93% 99% 
T7b 93% 99% 
Table ‎4-5: Sensitivity and specificity of T7.  T7a and T7b refer to the inclusion and exclusion of 
the marker GM14-11 respectively. 
The sensitivity and specificity were both below 100% (93% and 99%, 
respectively) because there were 6 discordant samples. Five out of those 6 
discordant samples were miscalled as MSS (i.e. false negative) and a single sample 
miscalled as MSI-H (i.e. false positive). 
4.2.5. Stratification of the new MSI scoring system against MMR IHC status of 
the 141 CRC samples 
 The best results, in terms of concordance with reported phenotypes, were 
achieved by adoption of the weighted scoring system (as discussed above). To 
confirm the original classification, the Immunohistochemistry of the mismatch repair 
proteins (IHC MMR) status was requested from the original lab to investigate the 
consistency of IHC results with the predicted classification. 
 Almost all samples that have been picked up by our panel as MSI-H (65 
samples out of the 141 tested) showed loss of at least one MMR protein by IHC, as 
shown in Figure  4-6. Only one sample has been classified as MSI-H by our panel 
while was reported as MSS by the referring lab (i.e. false positive) and, interestingly, 
this sample was negative for both MLH1 and PMS2 proteins by IHC, raising the 
possibility that the sample has defective MMR genes and has been misclassified.  




Figure ‎4-6: The MSI score for all samples that were called as unstable by the weighted 
scoring system alongside their reported phenotype. Reported phenotype: Red colour indicates that 
a sample was reported as unstable and blue as stable. The corresponding MMR IHC results (MLH1, 
MSH2, MSH6 and PMS2) are shown for each sample, red colour indicates absent protein, blue 
indicates the presence of the protein and empty slots indicate no information is available. The single 
false positive case (S72) (marked as red bar) was negative for MLH1 and PMS2. 
Out of the 76 samples which have had an instability score less than 3, 5 
samples were classified as unstable by our panel but were originally reported as 
MSI-H (i.e. false negatives). As shown in Figure  4-7, three out of those 5 false 
negative samples had normal MMR IHC results, but were reported as MSI-H. 




Figure ‎4-7: The MSI score for all samples that were called as stable by the new scoring 
system alongside with their reported phenotype. Reported phenotype: Red colour indicates that a 
sample was reported as unstable and blue as stable. The corresponding MMR IHC results (MLH1, 
MSH2, MSH6 and PMS2) are shown for each case, red colour indicates absent protein, blue indicates 
the presence of the protein and empty slots indicate no available information. 3 out of the 5 samples 
that reported as MSI-H show normal MMR IHC staining. 
To definitively establish the status of those discordant cases (i.e. one false 
positive and 5 false negative samples), I re-tested them using the gold standard test 
(Promega panel). As these samples were referred from abroad, there were no 
matched normal DNA samples that are ideally required to perform the MSI test by the 
Promega panel. However, these samples were re-tested without matched normal 
and blindly interpreted by myself and checked by a qualified clinical scientist (Ottie 
O’Brien, Northern Genetics Service, Newcastle Upon Tyne Hospitals NHS 
Foundation Trust, UK). The results presented in Figure  4-8 show that the single false 
positive sample (S72) is unstable, so was misclassified. One sample out of the 5 
false negatives (S17) was found to be stable and another one was found to be MSI-L 
(S135) rather than MSI-H. The remaining 3 false negatives (S78, S91 and S97) were 
confirmed to be MSI-H. 




Figure ‎4-8: MSI results from fragment analysis of the equivocal cases.  Sample IDs are 
labelled in blue boxes and the markers IDs are shown in the top pane. The sample S72 is the false 
positive, while all the other samples were false negatives. There is no clear instability in the sample 
S17 (=MSS), while there are 3 unstable markers in samples S78 and S72 (=MSI-H), 2 unstable 
markers in samples S91 and S97 (=MSI-H), while a single unstable marker in the sample S135 (MSI-
L).  
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 With these updates, the final specificity and sensitivity became 100% and 
96%, respectively, as shown in Figure  4-9. Because there is no difference between 
T7a and T7b, this means that the inclusion or exclusion of the marker GM14-11 does 
not affect the performance when the new scoring system was applied in that 
particular set. 
 
Figure ‎4-9: The final sensitivity and specificity of the weighted MSI scoring system (T7) 
after the inclusion of updates. There is no difference between the two T7 values.   
 The suboptimal sensitivity was because 3 samples were still considered as 
false negatives, however, one sample (out of the three) has an IHC result that is 
consistent with our prediction and it would be worthy to test the matched normal 
tissue samples for these cases (if it became available) 
 To eliminate the possibility that sample mix up during MiSeq analysis has 
occurred, the 6 discordant samples were then re-tested using the mononucleotide 
panel in a new MiSeq run to have a look at their MSI score and compare it in both 
MiSeq runs. They were re-amplified, re-sequenced and analysed in the same way 
mentioned earlier. The only difference from the initial sequencing was the library 
concentration, where 10 pM concentration was used in the re-analysis run. The 
average depth for the re-analysis was 4499 per/amplicon (higher than the initial 
analysis which was 2900 per/amplicon). The deletion frequencies were calculated for 
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in both runs as shown in Figure  4-10. These results confirm the initial prediction of 
the discordant cases and give an additional evidence of repeatability of the test. 
 
Figure ‎4-10: Deletion frequencies of all the 17 markers in the 6 equivocal samples in 2 
MiSeq runs. X-axis represents the 17 markers and Y-axis represents deletion frequency. The 
deletion frequencies of the first MiSeq run referred to as (Initial) and presented in red bars, the 
frequencies of the second MiSeq run referred to as (Re-analysis) and presented in blue bars. 
Approximately, deletions are close between the 2 runs, keeping the calling of the sample S72 as MSI-
H while all other 5 samples are MSS. 
4.2.6. Comparison of deletion curves for all markers with those of the previous 
cohorts  
Deletion curves (or threshold curves) were generated for all markers by 
plotting the frequency of variant reads on the X- axis and the proportion of samples 
that have that value of deletion frequency on the Y- axis for both MSI-H and MSS 
samples. Threshold curves for the MSS samples were constructed in the form of 1- 
percentage of MSS samples. Threshold curves in MSI-H samples represent 
sensitivity and those of MSS samples represent specificity for a specific marker. 
 Deletion frequencies for each marker have been plotted across all MSI-H and 
MSS samples to examine the distribution of deletions. Furthermore, these values 
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were compared to those obtained from the previous analysis (done at 2014 using the 
Newcastle cohort). For purposes of comparison, the 2014 cohort was named as the 
Newcastle cohort (N) and the 2015 cohort was named as the Spanish cohort (S). To 
investigate the consistency in the behaviour of markers across different cohorts, P 
values were calculated (as detailed in Materials and Methods) to conclude the 
significance of the difference in sensitivities and specificities in the different cohorts 








N S p value N S p value 
7bp group 
LR49-7 0.05 57% 44% 0.6760 100% 98% 1.00 
8bp group 
LR20-8 0.05 44% 32% 0.3694 99% 98% 0.5439 
GM9-8 0.05 29% 24% 0.6343 100% 99% 1.00 
G/C group 
IM66-C 0.10 29% 22% 1.00 100% 99% 1.00 
DEPDC2-G 0.10 17% 39% 0.2122 100% 100% 1.00 
9bp group 
GM11-9 0.10* 54% 39% 0.4057 100% 97% 1.00 
LR24-9 0.10* 42% 28% 0.4776 100% 100% 1.00 
IM16-9 0.10* 50% 57% 1.00 100% 95% 0.5480 
GM17-9 0.10* 27% 20% 0.6141 100% 99% 1.00 
AP-9 0.10* 32% 21% 0.4522 100% 97% 1.00 
11bp group 
GM7-11 0.30 57% 73% 0.5918 100% 97% 1.00 
LR48-11 0.30 35% 51% 0.4107 100% 100% 1.00 
LR11-11 0.30 20% 19% 1.00 100% 100% 1.00 
GM14-11 0.30 25% 75% 0.0228 100% 89% 0.0930 
12bp group 
LR44-12 0.30 64% 77% 0.7265 100% 99% 1.00 
LR36-12 0.30 50% 86% 0.1891 100% 92% 0.2199 
IM49-12 0.30 39% 57% 0.4339 100% 100% 1.00 
Table ‎4-6: Sensitivity and specificity of all markers in the 2 tested cohorts (N= Newcastle 
and S= Spanish) at the cutoff values specified in T7. P values <0.05 were highlighted in dark 
red. Cutoff values of the 9bp group markers were shown in 0.10 while it is 0.08 in the T7 set (marked 
with asterisks). Among the 17 markers, only the marker GM14-11 showed a significant difference 
between the 2 tested cohorts. 
By comparing LR49-7 threshold curve in both Spanish and Newcastle cohorts, 
approximately similar curves can be observed as shown in Figure  4-11. At a deletion 
frequency of 5%, the specificity was 100% and 98% in Newcastle and Spanish 
cohorts, respectively, and no significant difference was observed in both sensitivity 
and specificity as shown in Table  4-6. 
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For the 8bp group of markers, a threshold value of 10% performs better in the 
Newcastle cohort as both markers achieved a specificity of 100% at that threshold 
and a sensitivity of 34% and 21% for LR20-8 and GM9-8 respectively as shown in 
Figure  4-11. The comparison between threshold curves for both 8bp markers (LR20-
8 and GM9-8) with their curves on the Newcastle cohort show a high degree of 
consistency between deletion profiles (p values for both sensitivity and specificity 
between the 2 different cohorts were >0.05). 
In the Newcastle cohort, specificity for both polyG/C markers was 100% at a 
deletion frequency of 10% and sensitivity for the marker IM66-C was 22% and 29% 
in the Spanish and Newcastle cohorts, respectively as shown in Figure  4-11. 
Sensitivity for DEPDC2-G was higher in the Spanish than that in the Newcastle 





Figure ‎4-11: Threshold curves of the 7bp, 8bp and Poly G/C markers in both Newcastle 
and Spanish cohorts. Deletion frequency in the X-axis across the MSI-H samples (blue and red 
lines) and for MSS samples (purple and green lines). S= Spanish and N= Newcastle cohorts. For MSS 
samples, 1-proportion of cases was used. There is a clear consistency (no significant difference) in the 
behaviours of markers across the 2 cohorts. 
Comparison of the performance of the 9bp markers in both Spanish and 
Newcastle cohorts, show that all markers notably have a 100% specificity at a 
threshold of 10% deletion frequency in the Newcastle cohort, while it was ranging 




Figure ‎4-12: Threshold curves of the 9bp markers in both Newcastle and Spanish 
cohorts. Deletion frequency in the X-axis across the MSI-H samples (blue and red lines) and for MSS 
samples (purple and green lines). S= Spanish and N= Newcastle cohorts. For MSS samples, 1-
proportion of cases was used. S= Spanish and N= Newcastle cohorts.  
In the Spanish cohort, none of the 11bp markers showed a 100% specificity at 
a threshold value of 10% deletion, therefore, the threshold designed so to be at least 
0.19 (i.e. 19%). This was the threshold value used in the previous assay (Redford, 
2016). At that threshold value (i.e. 0.19), only the marker LR48-11 showed a 100% 
specificity while specificity for other markers was ranging between 72- 99% with the 
least specificity was observed in the marker GM14-11 as shown in Figure  4-13. The 
other threshold values used in T7 is 0.30 (30%) and at that value, additional marker 
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(LR11-11) approached 100% specificity, while even with this relatively high threshold, 
specificity for the marker GM14-11 did not reach 90%. The marker GM14-11 showed 
sensitivity of 75% and specificity of 89% at a deletion frequency of 30%. 
When deletion profiles for the 11bp markers were compared against those of 
the Newcastle cohort, at a threshold value of 0.30, all markers (GM7-11, LR48-11, 
LR11-11 and GM14-11) showed a specificity of 100% with the highest sensitivity 
amongst them was for the marker GM7-11 where it reached to 57% at that deletion 
frequency in the Newcastle cohort. Interestingly, the deletion curve for the marker 
GM14-11 was significantly different (p value <0.05) between the 2 tested cohorts as 
shown in Figure  4-13 and Table  4-6. 
To investigate the possible reason for that significant change in the deletion 
curve between the 2 tested cohorts, I have retrospectively checked the sequence 
nature of the GM14-11 amplicon and found that there is a SNP (with a minor allele 
frequency of 0.06) within the primer binding site. Another SNP is located immediately 
adjacent to the homopolymer but this is unlikely to be the reason as this SNP was 
also included in the amplicons of the previous run. Another possible reason for this 
inter-cohort variability is the ethnic difference between the backgrounds of the 2 
cohorts. However, other factors like DNA quality could be contributory factors for this 
anomalous behaviour of the marker GM14-11. 
For 12bp markers in the Spanish cohort, 0.19, 0.25 and 0.30 values were set 
as cutoff thresholds. Both markers LR44-12 and IM49-12 performed well at a 
threshold of 0.30 with a specificity of 100% and 99% for both, respectively, and a 
sensitivity of 77% and 57% respectively as shown in Figure  4-13. The marker LR36-
12 showed a sensitivity of 86% and specificity of 92%. Interestingly, about half of the 
samples of the Spanish cohort had sequencing reads below 100 per/amplicon (which 
is the cutoff number of reads we used to assess instability) and the average number 
of sequencing reads (for those which achieved >100 per/amplicon) was relatively low 
(188 per/ amplicon) as mentioned in section  4.2.1. 
By comparing deletion frequencies with those of the Newcastle cohort, there 
was a high consistency for the marker IM49-12 where both sensitivity and specificity 
curves looks almost similar as shown in Figure  4-13. For both LR44-12 and LR36-12 
markers, there is a notable difference between deletion curves in the different cohorts 
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with the maximal difference was observed in the marker LR36-12. This is most likely 





Figure ‎4-13: Threshold curves of the 11bp and 12bp markers in both Newcastle and 
Spanish cohorts. Deletion frequency in the X-axis across the MSI-H samples (blue and red lines) 
and for MSS samples (purple and green lines). S= Spanish and N= Newcastle cohorts. For MSS 
samples, 1-proportion of cases was used. In the 11bp group, the marker GM14-11 showed a notable 
difference between the 2 cohorts. In the 12bp group, the marker LR36-12 showed difference in both 
sensitivity and specificity between the 2 cohorts. 
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4.2.7. Assessment of DNA fragmentation of a selected subset of Spanish 
samples 
As explained in the previous section, the marker GM14-11 showed the lowest 
specificity (due to 4 MSS samples exhibited deletion frequency more than 30% for 
that particular marker). To check for possible reasons behind such anomalous 
results, these 4 samples were selected for a further investigation of DNA integrity and 
compared with another group of concordant samples (MSS and MSI-H samples). In 
addition, the 3 false negative samples that caused the overall sensitivity to be 96%, 
and a fresh tissue sample, were tested. Results are shown in Figure  4-14. For that 
purpose, the percentage of DNA that have a size of <100bp (named as DV100) was 
calculated to be used as an indicator of DNA fragmentation.  
 
Figure ‎4-14: The DNA integrity test for a subset of Spanish samples.  Samples are plotted in 
the X-axis and the percentage of DNA in the Y-axis. 3 groups of samples were tested, the 4 MSS 
samples that showed deletion frequency >30% for the marker GM14-11, 7 concordant samples (MSS 
and MSI-H) and the 3 discordant false negative samples compared to a fresh normal tissue sample. 
The results of that assay showed that 17% of the tested DNA from the fresh 
tissue sample was <100bp in size and all samples in the first group (the 4 MSS 
samples with a deletion frequency of >30% in the marker GM14-11) had DV100 
<17% of the tested DNA sample. On the other hand, 3 from concordant and 1 from 
discordant groups showed DV100>17%. These results indicate that there is no clear 





It has been shown that threshold sets can be set such that an accurate 
discrimination between MSI-H and MSS samples can be obtained when applied to 
the 17 marker panel. In the work outlined in this Chapter, this panel was assessed 
using a large cohort composed of 141 CRCs with mixed phenotypes. Deletion 
frequency and allelic bias were used as parameters for the classification process and 
different thresholds were tested to find out the optimal cutoff values. For purposes of 
assessment, the initial analysis was done while I was blind to the MSI status of all 
samples in the tested cohort, therefore, thresholds were increased arbitrarily and the 
samples were categorized based on whether instability exceeds the length-specific 
threshold or not. In first 3 threshold sets (T1, T2 and T3), the cutoff values of short 
markers were changed, while for the other sets (T4, T5 and T6), the cutoff values for 
longer markers (11 and 12bp) were changed and those for short markers were kept 
constant. 
Based on the assumption that allelic bias is a more reliable sign of instability 
than deletion frequency alone, the difference in the number of samples that have one 
or more marker with a deletion above the specified threshold and the number of 
samples that have one or more of the markers that show deletion frequency and 
allelic bias was closely observed. The number of samples that showed one or more 
deletion- only marker (DF subgroup) was significantly more than AB subgroup for the 
first group of threshold sets (T1, T2 and T3). When threshold values increased for the 
longer repeats, DF and AB numbers started to approximate to each other and the 
least difference was achieved in T5 where it became 8 samples only (this means 
those 8 samples have shown a deletion above the threshold in at least one marker 
but none of these markers show allelic bias). The very consistent and slightly 
changing values in the AB subgroup across the different threshold sets indicate that 
the existence of AB is a more confident sign of instability (compared to DF only) as it 
has been marginally changed with higher threshold values (from T3 upwards).   
When the reported phenotype was unlocked, I became able to test the quality 
of the classification. Sensitivity and specificity for the first 3 threshold sets were low 
compared to those of T4, 5 and 6. This indicated that with increasing threshold 
values for the longer homopolymers, most of the faulty results were discarded. This 
also suggests that the PCR induced errors are far more associated with the longer 
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homopolymers (11bp and 12bp) compared to short homopolymers (7,8 and 9bp), 
which is consistent with what was stated by others (Fazekas et al., 2010, Redford, 
2016). These results are also consistent with other studies where they found that the 
longer the repeat, the higher is the degree of length variation (Vilkki et al., 2002, 
Sammalkorpi et al., 2007, Clarke et al., 2001). 
It was obvious from the analysis of threshold sets that the measuring of the 
allelic bias (AB) was more informative as it changed less with different cutoff values, 
and had better sensitivities and specificities than their corresponding DF subgroup. 
This indicates that allelic bias is likely to be a reliable parameter that can be collated 
in the analysis of our panel. Therefore, we sought combining both deletion frequency 
and the allelic bias in the scoring would strengthen the conclusion. However, it was 
evident that low level of microsatellite instability could be found in all CRCs (Laiho et 
al., 2002), so it was important to create a cautious threshold set in order to avoid 
misclassification. For that purpose, a weighted scoring system (called as T7) was 
adopted in which the marker that shows a deletion above the length-specific 
threshold was given a score of 1 and the marker which shows deletion and allelic 
bias was given a score of 2. According to T7, samples that have an overall score of 
equal or more than 3 were called as MSI-H and those with a score below 3 were 
called as MSS. With the new scoring, a cutoff value of 3 seems more cautious than 
being 2 only (where a single marker with deletion and allelic bias could achieve that 
score), as there must be at least 2 or 3 unstable markers for a sample to be called as 
unstable. Applying that scoring scheme has clearly improved the specificity (100%) 
while 3 MSI-H samples were miscalled as MSS in our panel (false negatives) giving 
rise to 96% sensitivity.  
Further interrogation of the MMR IHC status of all samples, showed that the 
concordance rate of MSI scoring system was higher (=95%) than that of the reported 
MSI phenotype (=93.6%). One sample (out of the 3 false negative cases) has had 
normal IHC results, consistent with the possibility of being stable rather than MSI-H 
(as they were reported). All the equivocal samples were retested in an independent 
MiSeq run, and all of them yielded the same predicted phenotype. These results 
confirm the initial prediction and it might be worthy to test matched normal tissue for 
them (if it became available) in order to be 100% sure about the correct phenotype. 
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Furthermore, gaining the same prediction in 2 separate MiSeq runs give an additional 
evidence of the repeatability and reproducibility of our assay. 
A single sample was called as polymorphic for a single marker (sample 132, 
marker DEPDC2-G), and this polymorphism was not found in other samples for the 
same marker. However, testing of a matched normal tissue (if it became available in 
future) is recommended for such a case to confirm the polymorphism. 
The deletion curves were generated for all markers across MSI-H and MSS 
samples to examine the sensitivity and specificity respectively. Furthermore, deletion 
curves of all markers were compared to their curves in the Newcastle cohort. There 
was an overall consistency (no significant changes) in the marker behaviours in both 
Spanish and Newcastle cohorts. The only noticeable exception was the marker 
GM14-11. The sensitivity and specificity of the marker GM14-11 in the Spanish 
cohort were 75% and 89%, respectively. This profile is different (based on both 
sensitivity and specificity) from what was observed in the Newcastle cohort, with a 
significant difference (p value <0.05) between sensitivities in the 2 tested cohorts. In 
addition, 4 MSS samples showed deletion frequency >30%. To further investigate the 
reason behind that difference, the amplicon sequence has been checked and a SNP 
(with 0.06 MAF) was found in the primer annealing site. DNA integrity has been 
tested for a selected subset of samples and showed that there is no clear impact of 
the DNA fragment size on the subsequent analysis in these samples. The marker 
LR36-12, showed a difference in both sensitivity and specificity between the 2 tested 
cohorts. However, the sequencing read depth for that marker was relatively low 
compared to the overall depth (average depth of the LR36-12 amplicons was 188 
per/amplicon compared to the 2900 per/amplicon coverage for the overall MiSeq 
run). In the re-analysis done for the 6 discordant samples, the overall average depth 
was higher than that in the initial analysis (= 4499 per/amplicon). The average depth 
for the marker LR36-12 in the re-analysis was higher (617 per/amplicon) than that in 
the initial analysis. This improvement in the coverage is likely to be due to the use of 
relatively higher library concentration (10 pM in the re-analysis run compared to 4 pM 
in the initial analysis run) as explained in section  4.2.5.  
In this Chapter, 141 CRC samples were used to test the 17 marker panel. All 
of these samples were extracted from FFPE blocks and provided in the form of 
extracted DNA. Although there were some samples that have failed to amplify certain 
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amplicons, I successfully amplified at least 15 markers in 86% of samples. This is 
likely to be due to the designation of primers so that to amplify small sized amplicons 
(100-150bp). 
4.4. Conclusions 
 It was possible for the combined panel to discriminate successfully between 
MSS and MSI-H samples after adjusting the threshold sets. Different threshold sets 
were tested and a weighted MSI scoring system was assessed. The weighted MSI 
scoring system yielded the highest sensitivity and specificity. Moreover, the 
modifications we made in the library preparation protocol and primer designing were 
shown to be working, adding more privileges to the overall approach. This suggests 
that our panel can be used efficiently in the routine diagnostic work for MSI testing. 
However, further validation would enforce and consolidate the hypothesis of the 
panel’s employability in the clinical practice. 
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Chapter 5. Analytical validation of the weighted MSI score using an 
independent cohort of CRCs 
5.1. Introduction and aims 
5.1.1. Introduction 
 Prior to being implemented in the clinical laboratories, NGS- based genetic 
tests need to be extensively validated to ensure they perform efficiently in solving the 
target problem (discrimination between MSI-H and MSS in case of my test). Because 
of its recent and fast development, NGS approaches require worldwide standardised 
quality control guidelines. However, in 2013, the American College of Medical 
Genetics published the first practice guidelines for clinical laboratories adopting NGS 
approach in their routine work (Rehm et al., 2013). Recently, the Association of 
Clinical Genetics Sciences (ACGS) has approved practice guidelines for target NGS 
guidelines (Deans et al., 2015). Although both of these guidelines are relevant to 
mutation detection rather than MSI analysis and because there is no consensus 
guidelines to NGS- based MSI assay, these guidelines could be used to guide the 
quality requirements for the current assay as our assay represents an example of the 
targeted NGS assay.  
5.1.1.1. Validation of the technical steps involved in the NGS test workflow 
In the validation, all technical levels that are involved in the sequencing 
process should be evaluated, these include: 
- Clinical cases: The clinical criteria of sample selection need to be 
carefully optimised and it is essential to use the same kind of samples 
that will be utilised in practice when the test is implemented.  
- Sample processing: The preservation, transportation, macrodissection 
of tissue blocks, DNA extraction and storage of extracted DNA, all 
these steps need to be valid and follow careful instructions. 
- Targeting technique: There are 2 main approaches currently available 
for targeting the region of interest (ROI),  these are:  
1) PCR based techniques: In this approach, sequence specific 
oligonucleotide primers that flank the region of interest were utilised 
to amplify the ROI (also known as amplicon targeted NGS). 
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2) PCR-free protocols: in which, the target DNA directly subjected to 
library preparation and sequencing, thus cutting the cost and time 
and obliterate the PCR induced sequence artefacts. Hybridisation 
based assays is an outstanding example of the PCR free 
approaches. 
- Library preparation: it has been recommended that all steps of the 
library preparation need to be carefully monitored, including pooling, 
clean up, barcoding and normalisation. 
- Sequencing: it is essential to choose the sequencing platform that fits 
the purposes for which the test has been developed. 
- Data analysis: during data analysis, all run metrics need to be 
interrogated and registered. These include quality score, cluster 
density, coverage depth and variant calling. 
5.1.1.2. Assessment of reproducibility  
 It is recommended to achieve a reproducible test that fit with the clinical 
laboratory's requirements. It is recommended to test the NGS based assay (NGS 
based MSI assay in case of the current study) in at least 3 independent sequencing 
runs and then to document the concordance rate of results among cohorts (Rehm et 
al., 2013). 
5.1.1.3. Calculation of sensitivity and specificity  
One of the essential requirements for the NGS based test is to check the 
sensitivity and specificity of the target test. Sensitivity can be established by 
comparing the results obtained from the new test with results from a gold standard 
test. Analytical sensitivity is defined as the proportion of cases that tested positive by 
the assay and reported as positives by the gold standard assay (i.e. true positive) 
(Rehm et al., 2013), whereas analytical specificity is defined as the proportion of 
cases that were predicted as negative by the assay test and reported as negatives by 
the gold standard assay (i.e. true negative). Determination of the optimal sensitivity 
depends on the downstream application, for instance, for an ideal targeted NGS test 
designed for mutation detection, an error rate of a heterozygous/ homozygous 
mutation is recommended to be ≤ 5% (with 95% confidence) (Mattocks et al., 2010, 
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Deans et al., 2015). As our assay is still under development and there is no 
recommended sensitivity and specificity for such an assay, the aim is to achieve the 
highest concordance rate with the gold standard test during validation. 
5.1.1.4. Establishing an optimal read depth (Coverage)  
 Read depth and coverage depth are used interchangeably in the literature, 
but they refer to the same definition. Coverage (read depth) is the number of times to 
which a base has been sequenced in a sequencing reaction. Read depth varies 
depending on the sequencing chemistry, sequencing approach, quality of the 
template DNA and other factors. The larger the read depth, the bigger the confidence 
the base is called correctly. It is essential to assess the read depth of all amplicons in 
the next generation sequencing run in addition to the minimum depth. Determination 
of the minimum read depth should be established during the validation assay and 
should meet the required criteria for the specified aim for instance, the coverage 
depth was recommended to be high in cancer samples in order to make it possible to 
detect those variants with low prevalence (Deans et al., 2015).  
Based on this, the NGS based assay need to be validated to ensure the ability 
of the test to solve the target problem for which it has been designed. In the previous 
2 chapters, the microsatellite panel of short homopolymers (which was composed of 
17 markers) was tested across 2 different cohorts. The assessment of instability was 
done by testing different threshold sets and the final MSI scoring system showed the 
highest sensitivity and specificity.   
In this chapter, the weighted MSI scoring system will be validated using a new 
independent cohort to consolidate the initial findings and further check the overall 
performance of the assay as a requirement for validation. 
5.1.2. Aims 
 In the previous chapter, the short mononucleotide panel (which is composed 
of 17 short mononucleotide markers) was assessed across a large cohort 
represented by 141 CRC samples, which was composed of 68 MSI-H and 73 MSS 
samples. The tested approach showed a high sensitivity and specificity (96% and 
100%, respectively) in that part of the study using the weighted MSI scoring system. 
To further validate the developed panel and the weighted MSI scoring system, a new 
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cohort of 100 CRC samples was used. These 100 CRCs were obtained from 
Department of Molecular Pathology, University of Edinburgh, UK. This chapter will 
outline the assessment and validation of the weighted MSI scoring system using this 
cohort. The overall aims of the work presented in this chapter are to: 
 Assess a cohort of 100 previously analysed CRCs, blinded to MSI status using 
the optimal threshold set defined previously (weighted MSI scoring system). 
 Assess the role of allelic bias as an additional parameter can be used in MSI 
calling, by assessing the sensitivity and specificity of allelic bias subgroups in 
each threshold set. 
 Compare threshold curves of each individual marker with those from different 
cohorts (that were done in chapter 3 and 4) to compare their behaviour in 
different cohorts and detect if there is anomaly for each marker individually. 
 Assess the quality metrics (Depth, quality score, cluster density and others) 
and provide bases for suggested values in an ideal MiSeq run. 
5.2. Results 
5.2.1. Amplification and sequencing of the short mononucleotide panel using a 
cohort of 100 CRC samples 
 For purposes of validation, a new independent cohort of 100 CRCs of a 
mixed MSI phenotype referred from Edinburgh (Dr Mark Arends, Department of 
Molecular Pathology, University of Edinburgh, UK). These cases were extracted, 
quantified and MSI tested in the original laboratory, and therefore, they were 
provided in the form of an extracted DNA. As a prerequisite for the validation, I have 
analysed the cohort blindly (without knowing their MSI status). 
All samples were amplified using the 17 short mononucleotide markers panel. 
The primers were the same as those used in chapter 4. PCR amplifications were 
performed using the Herculase II Fusion DNA Polymerase (Agilent Technologies, CA, 
USA) in 35 PCR cycles. Out of those 100 samples, 70 were amplified using the 17 
marker panel and a total of 1167 amplicons were generated. The library 
concentration used in the current MiSeq run was 10 pM. 
 Out of the 70 samples, 20 samples were included in the previous MiSeq run 
alongside with the Spanish cohort. The remaining 50 Edinburgh samples were 
 119 
 
analysed in a separate run. The cluster density was 1450 k/mm2 and the Q30 of the 
MiSeq run was 55.5% as shown in Figure  5-1. 
 
Figure ‎5-1: Q score (on the left) and cluster density (on the right) of the MiSeq run.  The 
green box in cluster density graph is near to the blue box indicates that most of the reads passed filter.
 The data outputs of the MiSeq run were generated in the form of FASTQ files 
which were analysed as explained in Chapter 2. Although all DNA samples were 
extracted from FFPE tissue curls, the vast majority of the 70 samples (99%) was 
successfully amplified, sequenced and called to adequate depth (i.e. ≥ 100 paired 
end read/ amplicon) for at least 15 markers of the tested 17 markers as shown in 
Table  5-1. Notably, a single sample was called for only 4 markers to ≥100 per/ 
amplicon. This sample was excluded from the downstream analysis. So the overall 
number of samples that were included in the downstream analysis was 69 samples. 
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No. of markers No. of cases 
 Amplified Sequenced Called‎≥100‎per/amplicon 
17 55 34 34 
16 8 30 29 
15 6 5 6 
14 1 0 0 
13 0 0 0 
12 0 0 0 
11 0 1 0 
10 0 0 0 
9 0 0 0 
8 0 0 0 
7 0 0 0 
6 0 0 0 
5 0 0 0 
4 0 0 1 
3 0 0 0 
Total 70 70 70 
Table ‎5-1: Number of amplicons that were amplified, sequenced and called to adequate 
depth (i.e. ≥100 reads) in Edinburgh cohort. The majority of samples amplified and sequenced ≥ 
15 markers. per= paired end reads. 
5.2.2. Analysis of the sequencing data and assessment of the weighted MSI 
scoring system (Threshold 7) 
As explained in previous chapters, the COPReC data were generated to allow 
recognition of sequencing reads that generated from both SNP alleles. The two main 
parameters used in the subsequent analysis were deletion frequency and allelic bias. 
Allelic bias was calculated for heterozygous amplicons by Fisher’s Exact test to 
assess its significance. The initial analysis was done while I was unaware of the MSI 
status of the tested samples. After the assessment of threshold sets, the phenotype 
key was unlocked in order to make a direct comparison between the predicted 
phenotype (by our panel) and the reported phenotypes (which is provided by the 
original lab) and calculate the sensitivity, specificity as explained in Chapter 2 
section  2.10.6. 
 As done in Chapter 4, the weighted MSI scoring system (threshold 7) was 
designed by merging both deletion frequency (DF) and allelic bias (AB) features for 
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all markers in each sample. The score was calculated by giving a score of 1 for each 
marker with only deletion frequency more than cutoff values and a score of 2 for each 
marker with DF+AB. Those samples with an overall score of ≥3 were called as MSI-H 
and those with a score of <3 were called as MSS. Applying this scoring resulted in 36 
samples to be called as MSI-H and 33 as MSS as shown in Figure  5-2. 
 
Figure ‎5-2: The distribution of samples, according to cutoff values in T7,where the new MSI 
score was used. Samples that showed an overall score of ≥3 are represented in red bar and those 
with a score less than 3 are presented as blue bar. 
 In this MSI scoring, the sensitivity and specificity were both approached 
100% indicating a high efficiency in discrimination between MSI and MSS samples. 
By applying T7 across the tested cohort, all MSI-H samples have had a score more 
than 3 while all MSS samples have got an overall score of less than 3 as shown in 
Figure  5-3. These results consolidate the initial assessment of this system that done 
















Figure ‎5-3: The overall MSI score for all tested Edinburgh samples (69 samples). Y axis 
represents the overall score. All MSI-H samples have got a score above 3 compared to MSS samples 
which have not. 
Then, I tested the same threshold sets that were proposed and assessed in 
Chapter 4 with their cutoff values shown in Table  5-2. This assessment was to 
observe the performance of these different cutoff values in this particular cohort. 
Threshold set 7bp 8bp 9bp PolyG/C 11bp 12bp   GM14 
Threshold 1 0.05 0.05 0.05 0.1 0.19 0.19  
Threshold 2 0.05 0.05 0.05 0.1 0.19 0.19 - GM14 
Threshold 3 0.05 0.05 0.08 0.1 0.19 0.19 - GM14 
Threshold 4 0.05 0.05 0.08 0.1 0.19 0.25 - GM14 
Threshold 5a 0.05 0.05 0.08 0.1 0.19 0.30 - GM14 
Threshold 5b 0.05 0.05 0.08 0.1 0.19 0.30 +GM14 
Threshold 6a 0.05 0.05 0.08 0.1 0.30 0.30 -GM14 
Threshold 6b 0.05 0.05 0.08 0.1 0.30 0.30 +GM14 
Table ‎5-2: Threshold sets and their cutoff values. In each set, a single new event was 
introduced (red coloured) compared to the preceding threshold set.  
When these threshold sets were applied, the number of samples that were 
called as unstable, especially in the DF subgroup was relatively higher in the initial 
threshold sets (T1- T3) compared to higher threshold sets (T4- T6), with the lowest 
number of samples observed in the T6 threshold set. As noted in Chapter 4, the 
specificity of the DF subgroup in the first 3 threshold sets (i.e. T1-T3) was generally 
low, with the lowest specificity (= 59%) observed in T1 DF set. The sensitivity was 
100% for all threshold sets (DF subsets), as shown in Table  5-3. 
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The specificity was higher in the AB subgroup compared to the DF subgroup 
across all threshold sets. This likely justifies the inclusion of the allelic bias as an 
additional parameter to call instability compared to deletion only. 
Threshold set ≥1 0 Sensitivity Specificity 
T1.DF 50 19 100% 59% 
T1.AB 33 36 92% 97% 
T2.DF 49 20 100% 62% 
T2.AB 33 36 97% 97% 
T3.DF 49 20 100% 62% 
T3.AB 33 36 92% 97% 
T4.DF 41 28 100% 85% 
T4.AB 33 36 92% 100% 
T5a.DF 41 28 100% 85% 
T5a.AB 33 36 92% 97% 
T5b.DF 43 26 100% 79% 
T5b.AB 33 36 89% 97% 
T6a.DF 40 29 100% 88% 
T6a.AB 32 37 89% 97% 
T6b.DF 40 29 100% 88% 
T6b.AB 32 37 89% 97% 
Table ‎5-3: The sensitivity, specificity for all threshold sets in both DF and AB subgroups. 
DF, deletion frequency subgroup and AB= allelic bias subgroup. 
5.2.3. Comparison of threshold curves for all markers in the 3 independent 
cohorts 
 As done before, deletion frequencies for each marker were plotted across all 
MSS (specificity) and MSI-H (sensitivity) samples to construct the deletion curve (or 
threshold curve). Furthermore, deletion curves for each marker were compared to 
those curves from previous cohorts (Newcastle and Spanish) to investigate the 
difference between the values in different cohorts at a specific deletion frequency as 
shown in Table  4-5. The significance of difference (p value) between sensitivities and 
specificities across the different cohorts were calculated as explained in Chapter 2, 
section  2.10.6, with p values <0.05 considered as significant. Threshold curves for 









Cutoff value Sensitivity p value (Sensitivity) Specificity p value (Specificity) 
E N S E vs N E vs S E N S E vs N E vs S 
LR49-7 0.05 56% 57% 44% 1.00 0.5796 100% 100% 98% 1.00 1.00 
LR20-8 0.05 36% 44% 32% 0.6267 0.8385 97% 99% 98% 1.00 1.00 
GM9-8 0.05 26% 29% 24% 1.00 1.00 100% 100% 99% 1.00 1.00 
IM66-C 0.10 75% 29% 22% 0.0690 0.0070 100% 100% 99% 1.00 1.00 
DEPDC2-G 0.10 30% 17% 39% 0.5497 0.6874 100% 100% 100% 1.00 1.00 
GM11-9 0.10* 58% 54% 39% 1.00 0.2834 100% 100% 97% 1.00 1.00 
LR24-9 0.10* 60% 42% 28% 0.4975 0.0560 100% 100% 100% 1.00 1.00 
IM16-9 0.10* 56% 50% 57% 0.4837 1.00 100% 100% 95% 1.00 0.5480 
GM17-9 0.10* 46% 27% 20% 0.3105 0.0560 100% 100% 99% 1.00 1.00 
AP-9 0.10* 36% 32% 21% 1.00 0.2642 97% 100% 97% 1.00 1.00 
GM7-11 0.30 94% 57% 73% 0.2462 0.4505 100% 100% 97% 1.00 1.00 
LR48-11 0.30 83% 35% 51% 0.0574 0.1458 100% 100% 100% 1.00 1.00 
LR11-11 0.30 64% 20% 19% 0.0521 0.0030 97% 100% 100% 1.00 1.00 
GM14-11 0.30 82% 25% 75% 0.0158 0.8691 100% 100% 89% 1.00 0.093 
LR44-12 0.30 92% 64% 77% 0.4441 0.6499 100% 100% 99% 1.00 1.00 
LR36-12 0.30 88% 50% 86% 0.2267 1.00 100% 100% 92% 1.00 0.2123 
IM49-12 0.30 78% 39% 57% 0.1442 0.3398 100% 100% 100% 1.00 1.00 
Table ‎5-4: Sensitivity and specificity of all markers in the 3 cohorts (E= Edinburgh, N= Newcastle and S= Spanish cohorts) at the cutoff values 
specified in T7.P values <0.05 were highlighted in dark red boxes. Cutoff values of the 9bp group markers were shown as 0.10 while it was 0.08 in the T7 set 
(marked with asterisks). Among the 17 markers, 3 markers (IM66-C, LR11-11 and GM14-11) showed significant difference in sensitivity among cohorts.  
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 By comparing the deletion profile of the marker LR49-7 with those in other 
cohorts (i.e. Newcastle and Spanish), the specificity was 100% for both Newcastle 
and Edinburgh cohorts at a deletion frequency of 5%, while it was 98% in the 
Spanish cohort. The sensitivity, on the other hand, was approximately the same for 
both Newcastle and Edinburgh cohorts (56% and 57%, respectively), while it was 
44% for the Spanish cohort at the same deletion frequency as shown in Figure  5-4. 
However, there was no significant difference in both sensitivity and specificity 
between the 3 tested cohorts as shown in Table  4-5. 
  By comparing deletion profiles of the 8bp markers in the 3 different cohorts, 
the marker GM9-8 showed 100% specificity at the deletion frequency of 5% for both 
Newcastle and Edinburgh cohorts and 99% in the Spanish cohort. The sensitivity 
was ranging between 24-29%, with the lowest was observed in the Spanish cohort at 
5% deletion frequency. There was no significant difference, neither in sensitivity nor 
in specificity across the 3 tested cohorts. 
For the marker LR20-8, at the same deletion frequency (i.e. 5%), the 
specificity was ranging between 97% (in the Edinburgh cohort) to 99% (in the 
Newcastle cohort) and sensitivity was ranging between 32% (in the Spanish cohort) 
and 44% (in the Newcastle cohort) as shown in Figure  5-4. 100% specificity for the 
marker LR20-8 was achieved at a deletion frequency of 10% (in Newcastle), 20% (in 
Spanish cohort) and 40% in the Edinburgh cohort.  
Comparison of deletion profiles for both Poly G/C markers across the different 
cohorts shows that, for the marker DEPDC2-G, the specificity was 100% at a deletion 
frequency of 10% for all cohorts. The least sensitivity (17%) was observed in the 
Newcastle cohort while the highest (39%) was observed in the Spanish cohort at the 
same deletion frequency. 
For the marker IM66-C, the specificity at a deletion frequency of 10% in both 
Newcastle and Edinburgh cohorts was 100% while it was 99% in the Spanish cohort. 
At the same deletion frequency, the highest sensitivity (75%) was observed in the 
Edinburgh cohort while the lowest (22%) was observed in the Spanish cohort as 
shown in Figure  5-4. Interestingly, there was a significant difference in sensitivity 
between Edinburgh and Spanish cohorts at deletion frequency of 10% as shown in 




Figure ‎5-4: The deletion curve of the 7bp, 8bp and poly G/C markers in both MSS and 
MSI-H samples in the 3 independent cohorts (Newcastle, Spanish and Edinburgh). Y- axis refers 
to the proportion of samples, X- axis refers to the deletion frequency. Deletion curves of MSS group 
were plotted in 1- of MSS cases. E= Edinburgh, S=Spanish and N= Newcastle cohorts. 
 By comparing the deletion profile of the 9bp markers across the different 
cohorts, the marker LR24-9 was the only marker that showed 100% specificity across 
all cohorts at a 10% deletion frequency. At the same deletion frequency, 3 other 
markers (GM11-9, IM16-9 and GM17-9) have shown 100% specificity both in 
Newcastle and Edinburgh cohorts, but not in the Spanish cohort. The marker 
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AP0035322-9, have shown a 100% specificity at 10% deletion frequency only in the 
Newcastle cohort as shown in Figure  5-5 and there was no significant difference 
neither in sensitivity nor in specificity across all cohorts at deletion frequency of 10% 




Figure ‎5-5: The deletion curve of the 9bp markers in both MSS and MSI-H samples in 3 
independent cohorts (Newcastle, Spanish and Edinburgh). Y-axis refers to the proportion of cases; 
X- axis refers to the deletion frequency. Deletion curves of MSS group were plotted in 1- of MSS 
cases. E= Edinburgh, S=Spanish and N= Newcastle cohorts. 
 By comparing the deletion profiles of the 11bp markers across the different 
cohorts, a consistency in the specificity was observed in the marker LR48-11 at 30% 
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deletion frequency (100% specificity in all cohorts), while a mild difference was 
observed in the specificity curves of the markers LR11-11 (specificity was 99% in the 
Edinburgh cohort). For both markers (i.e. LR48-11 and LR11-11), the sensitivity at 
30% deletion frequency was higher in the Edinburgh cohort (83% and 64%, 
respectively). For the marker LR11-11, there was a significant difference between 
sensitivities in Edinburgh and Spanish cohorts at a deletion frequency of 30% as 
shown in Table  4-5. 
For the marker GM7-11, the specificity was the same for both Newcastle and 
Edinburgh at 30% deletion frequency (100% for both), while it was 97.2% in the 
Spanish cohort at the same deletion frequency. However, the specificity for the 
marker GM7-11 approached 100% at 60% deletion frequency. There was no 
significant difference among various cohorts, neither in sensitivity nor in specificity as 
shown in Table  4-5. 
  At 30% deletion frequency, the specificity of the marker GM14-11 was 100% 
for both Newcastle and Edinburgh cohorts, while it was 89% at the same deletion 
frequency in the Spanish cohort. At the same deletion frequency (30%), sensitivity 
was 82%, 75% and 25% in the Edinburgh, Spanish and Newcastle respectively. In 
the Spanish cohort, the specificity persisted suboptimal until 70% deletion frequency 
as shown in Figure  5-6. There was a significant difference in sensitivity between 
Edinburgh and Newcastle cohorts as shown in Table  4-5. 
 By comparing the deletion profiles of the 12bp markers in the different 
cohorts, there was a clear consistency (no significant difference) in the deletion 
profiles of the marker IM49-12 across the three cohorts, where the specificity was 
100% at 30% deletion frequency for all cohorts and the sensitivity was ranging 
between 39- 78%. 
For the marker LR44-12, specificity was 100% in both Newcastle and 
Edinburgh cohorts while it was 99% in the Spanish cohort at 30% deletion frequency. 
The sensitivity was ranging between 64- 92% in the three cohorts. 
 Interestingly, the marker LR36-12 showed a difference in the specificity curve 
between Spanish and Edinburgh cohorts at 0.30% deletion frequency as shown in 
Figure  5-6 and Table  4-5. Notably, the LR36-12 amplicon was sequenced to a 
relatively low depth (average depth was 188 paired end reads per amplicon) in that 
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cohort as mentioned in Chapter 4, section  4.2.1. This might be the underlying reason 
behind this alteration in the deletion curve among cohorts.  
 
Figure ‎5-6: The deletion curve of the 11 and 12bp markers in both MSS and MSI-H 
samples in 3 independent cohorts  (Newcastle, Spanish and Edinburgh). Y-axis refers to the 
proportion of cases; X- axis refers to the deletion frequency. Deletion curves of MSS group were 
plotted in 1- of MSS cases. The most obvious differences are observed in markers GM14-11 and 
LR36. E= Edinburgh, S=Spanish and N= Newcastle cohorts. 
 In conclusion, there was a clear consistency in the deletion curves of almost 
all markers in the Newcastle and Edinburgh cohorts. However, in the Spanish cohort, 
the most prominent variation was observed in the marker GM14-11, where it showed 
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the lowest specificity at 30% deletion frequency. Therefore, a further assessment of 
this marker would be useful to find out the possible reason underpin that variation. 
5.2.4. Assessment of the inter-cohort inconsistency of marker GM14-11 
deletion 
5.2.4.1. Investigating the nature of the nucleotide sequence of the marker GM14-11 
 As shown in chapter 4, the marker GM14-11 showed the lowest specificity 
amongst other markers in the Spanish cohort. In this chapter, a comparison of the 
deletion curves of the marker GM14-11 across the 3 different cohorts showed that 
there is a significant difference between deletion curves in Edinburgh and Newcastle 
cohorts. Furthermore, the marker GM14-11 showed the lowest specificity in the 
Spanish cohort at 30% deletion frequency as explained in Table  5-4. To check for the 
possible reasons behind the different behaviour of that marker, the primer set was 
tested by the in silico PCR tool in UCSC genome browser. There were 3 noteworthy 
findings that might contribute to the variation of the marker, these are: 
1) There was a SNP at the primer annealing site (rs539119173); however, that 
SNP has a very low minor allele frequency (0.06%). 
2) There is a high MAF frequency SNP immediately adjacent to the target 
homopolymer (rs6804861) with a minor allele frequency of 0.37.  
3) By direct observation of the nucleotide sequence of the GM14-11 amplicon, 
another shorter homopolymer (8bp (A) homopolymer) was found in the close 
vicinity of the target 11bp (A) homopolymer. This might generate an 
interrupted microsatellite tract, giving rise to compound instability. However, 
this is unlikely to be the reason, as the whole amplicon was included in the 
other cohorts. 
In order to check the origin of the variant reads, BAM files of the GM14-11 
amplicons for a selected group of MSI-H and MSS samples from the Spanish cohort 
were visualised by the Integrative Genome Viewer (IGV) (Robinson et al., 2011). The 
selected samples were composed of 4 MSI-H and 4 MSS samples, all of them 
showed a high deletion frequency of the marker GM14-11. For the MSI-H samples, 
re-alignment showed that all deletions were observed in the target homopolymer and 




Figure ‎5-7: The alignment of the sequencing reads of the marker GM14-11 in 4 MSI-H 
samples. The target (A) homopolymer is red squared and marked by the red arrow, another adjacent 
poly A homopolymer can be observed few bases away from the target homopolymer (red rectangle). 
Obviously, all deletions were registered for the target homopolymer.  
 For the MSS group, none of the examined 4 MSS samples showed any 
deletion in the adjacent homopolymer as shown in Figure  5-8, indicating that all 





Figure ‎5-8: The alignment of the sequencing reads of the marker GM14-11 in 4 MSS 
samples. The target (A) homopolymer is red squared and marked by the red arrow, another adjacent 
poly A homopolymer can be observed few bases away from the target homopolymer (red rectangle). 
All deletions were registered for the target homopolymer.  
Given the possible variability in the microsatellite tracts, the possibility of 
marker being a polymorphic cannot be excluded taking in account that the kind of 
populations is a major difference among the tested cohorts. However, to confirm that, 
matched normal tissue samples need to be tested. 
5.2.4.2. Re-amplification of the marker GM14-11 using samples from Newcastle and 
Spanish cohorts 
To examine the performance of the marker across different cohorts, GM14-11 
was tested against a selected subset composed of 8 Spanish samples (7MSS and 1 
MSI-H), and 16 Newcastle (8 MSS and 8 MSI-H) samples. All these samples were 
previously tested with the marker GM14-11, so a comparison between deletion 
frequencies from all samples would be possible. The new analysis was done using a 
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library concentration of 10 pM, which is different from both of the previous MiSeq 
runs (8 pM and 4 pM concentration in Newcastle and Spanish Miseq runs 
respectively). The 16 samples from the Newcastle cohort were tested previously for 
the marker GM14-11 using the long amplicon primers. This represented an additional 
testing of repeatability of the tests and the reproducibility of the results. Furthermore, 
this can be used to compare the results from the 2 different sets of primers that target 
the same homopolymer (300bp primers were used in Newcastle cohort, while 
~150bp primers were used in the Spanish cohort). The deletion frequencies in the re-
analysis test were broadly consistent with the initial results (reported from previous 
testing) as shown in Figure  5-9 with an average DF proportion (= DF re-analysis/ DF 
initial) = 1.1. 
 
Figure ‎5-9: Deletion frequencies of the marker GM14-11 in 24 samples from 2 different 
cohorts. Re-analysis= refers to the deletion frequency from the repeated (re-amplification) analysis, 
Initial= the deletion frequency in the initial analysis. The frequencies are generally consistent except 
for 2 samples, S74 and S79. 
Two notable exceptions can be observed in samples S74 and S79, where 
there is a notable difference in the deletion frequencies between the initial and the re-
analysis deletion frequency (DF proportion= 0.2 for each). Notably, this alteration 
changed the prediction for both samples, as they both showed deletion frequency 
>30% in the initial analysis (which is the cutoff value used for that particular marker). 
In both S74 and S79, the overall number of sequencing reads in the initial analysis 
was significantly lower than that in the re-analysis (initial reads/ Re-analysis reads = 
509/36487 and 253/37874 for both amplicons respectively), this might be the reason 
behind this alteration in deletion frequency proportion between the 2 analyses in 
these 2 particular samples. Interestingly, the predicted phenotype from the re-
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analysis assay is consistent with the reported phenotype for both samples (S74 and 
S79), and thus, resolved the ambiguity in both samples.  
5.3. Discussion 
5.3.1. Validation of the MSI scoring system 
In chapter 4, a panel of 17 mononucleotide markers was assessed using a 
large group of samples and different threshold sets were tested, and finally a 
weighted MSI score was proposed. In this chapter, an independent cohort was used 
to assess the weighted MSI score or T7, where an additional score was added to 
those markers that have instability with evidence of allelic bias. According to that 
score, samples with an overall score of ≥3 are called MSI-H and those with an overall 
score of less than 3 are called MSS. With that MSI score, 36 samples were called as 
MSI-H and 33 are MSS in the Edinburgh cohort with an overall sensitivity and 
specificity of 100%. This strongly consolidates the initial results and paves the way to 
use this MSI score as a main classifying system for the short mononucleotide panel. 
The different threshold sets proposed and tested in Chapter 4 (T1-T6), were 
assessed in this Chapter as well. In the 3 earlier threshold sets (T1-T3), where 
relatively low cutoff values were used, a relatively high number of samples were 
called as MSI-H especially in the DF subgroup. In the latter 3 threshold sets (i.e. T4-
T6), the number of samples that were called as MSI-H was considerably lower in the 
DF subgroup. Both sensitivity and specificity were higher towards the higher 
threshold sets, a finding that is consistent with that from the previous chapter. This 
indicates that most variant reads in longer homopolymers in the MSS group of 
samples were discarded by elevating cutoff values in T4-T6. 
5.3.2. Fulfilment of the recommended requirements for validation of targeted 
NGS assay 
5.3.2.1. Clinical samples 
To fulfil the requirements of validation, all the samples tested here (and even 
the previous cohorts) were FFPE tissue samples (which are the same kind of 
samples that would be tested in practice when the test is implemented in diagnostic 
lab). However, sample storage, transportation and processing should also be 
assessed. As most of the samples (both Spanish and Edinburgh samples) were 
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referred from different places, the assessment of these factors was beyond our 
capability. 
5.3.2.2. Sensitivity and specificity 
It was possible for our test to achieve a high sensitivity, and with the weighted 
MSI scoring system, both sensitivity and specificity approached 100% in the tested 
cohort. This provides subjective evidence that this test performs perfectly in our 
laboratory. 
5.3.2.3. Assessment of the test using multiple cohorts 
The 17 marker panel was assessed across 3 independent cohorts, 2 of them 
(Spanish and Edinburgh cohorts) were assessed blindly.  
5.3.2.4. Optimising library preparation and quality metrics 
In the previous experiment done in Chapter 4 (Spanish cohort), a 4 pM library 
concentration was used as this is the recommended concentration in the 16S 
metagenomics protocol. However, that concentration resulted in a relatively low 
cluster density and consequently, a relatively low coverage depth (~2900 
per/amplicon) as explained in Chapter 4. I, therefore, thought to increase the 
concentration to 10 pM in the MiSeq run of the Edinburgh cohort. This resulted in a 
much higher cluster density (1450 k/mm2) and higher coverage (~5500 per/ 
amplicon). However, the improvement in the cluster density, and hence in the 
coverage, was associated with a drop in the Q30 score to 55.5% compared to 69.1% 
in the Spanish cohort MiSeq run. An interesting contributory factor to the overall 
performance of the run is the overall number of amplicons being analysed. These 
values could be used as a basis to conclude the final recommended workflow, and it 
would be worthy to try 8 pM library concentration aiming to optimal Q30 score and 
average depth.  
5.3.3. Assessment of the run performance 
Although the used primers were targeting small amplicons (~150bp), not all 
samples investigated in this part of the study were successfully amplified (70 
amplified vs 30 failed). The failure of some samples to be amplified is possibly due to 
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severe FFPE-induced fragmentation. However, other factors like storage of samples, 
transportation of samples and the existence of PCR inhibitors could be possible 
reasons. Generally, 70% of samples included in this cohort were successfully 
amplified, of them, 99% of samples have amplified 15 markers or more as explained 
in Table  5-1. 
5.3.3.1. Inter-cohort assessment of deletion curves 
Comparison of deletion profiles of all the 17 markers across the 3 independent 
cohorts was important to compare the behaviour of individual markers, and the 
overall panel as well, in different cohorts. Only four out of the 17 tested markers 
(DEPDC2-G/C, LR24-9, LR48-11 and IM49-12) showed a clear consistency in the 
specificity across the 3 different cohorts (all of them showed 100% specificity across 
all the 3 tested cohorts). The marker GM14-11 showed the lowest specificity in the 
Spanish cohort (89% specificity at 30% deletion frequency) while it showed 100% 
specificity in both Newcastle and Edinburgh cohorts. This observable difference likely 
indicates that there is a cohort- specific reason. Assessment of the performance of 
marker GM14-11by retesting samples from different cohorts, has allowed a direct 
comparison of the deletion profile. In that assessment, 8 samples from the Spanish 
cohort and 16 from the Newcastle cohort were re-amplified and sequenced. The 
results showed a clear consistency of the deletion profile with the exception of 2 
samples. However, both of these 2 samples were sequenced to significantly lower 
coverage in the initial investigation compared to the latest re-analysis. This might 
increase the possibility that the variability in the marker GM14-11 in the Spanish 
samples is likely to be restricted to that cohort. A possible explanation, is the 
difference in the ethnic background of that cohort (Spanish cohort) compared to both 
other UK cohorts (Newcastle and Edinburgh cohorts), as this might affect the MAF of 
the SNP in the primer annealing site (rs539119173). Furthermore, the number of 
samples in each cohort could be an additional reason for that inter-cohort variability. 
The number of samples in the Spanish cohort is more than the combined number of 
samples for both Newcastle and Edinburgh cohorts.  
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5.3.3.2. Assessment of allelic bias as an additional parameter for calling instability 
 During the assessment of the performance of the 6 threshold sets, it was 
evident that both sensitivity and specificity of the AB subgroup were higher than the 
corresponding DF subgroup for the same threshold set. The weighted MSI scoring 
system (T7) was constructed by collating both features of DF and AB together. The 
application of the MSI scoring system resulted in optimal sensitivity and specificity as 
explained above. This strongly suggests that using both parameters rather than 
deletion frequency alone would enforce the pickup rate of the proposed MSI panel. 
Interestingly, the number of samples that was called as MSI-H in the AB subgroup 
was the same across almost all threshold sets. This indicates that markers, which 
show evidence of allelic bias in this cohort, have had a high deletion frequency 
relative to their specified cutoff values. 
However, the detection of allelic bias is limited to heterozygous amplicons 
only. In this cohort, it was not possible to assess the allelic bias in some samples, 
and out of the 36 samples that have a score of ≥3 (i.e. called as MSI-H), 3 samples 
were lacking evidence of allelic bias. These samples were E31 (MSI score=6), E46 
(MSI score= 8) and E91 (MSI score= 11). In this particular cohort, this provides 
substantial evidence that the adoption of the MSI scoring system can eliminate the 
possibility of miscalling a sample that lacks an evidence of allelic bias.   
5.4. Conclusions 
 The weighted MSI scoring system performed very well in discrimination 
between MSI-H and MSS samples in a cohort composed of 69 CRC samples. This 
system was able to raise both sensitivity and specificity of the test to 100% in this 
cohort. The role of allelic bias has been assessed and AB subgroup performed better 
in terms of sensitivity and specificity than their mate DF subgroups. This suggests 
that the existence of allelic bias adds more confidence to phenotype calling. It was 
possible to assess the quality metrics of the MiSeq run in this cohort and a better 
quality score and coverage were achieved compared to the previous run. The 
extensive validation done in this chapter provides an evidence of employability of the 
proposed 17 marker panel and the weighted MSI scoring system in MSI detection. 
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Chapter 6. Analysis of clonal characteristics of MSI-H CRC using 
short mononucleotide markers 
6.1. Introduction and aim 
6.1.1. Introduction 
 Cancer is a heterogeneous disease that results from uncontrolled cell 
division. Although it is heterogeneous, all cancers share common features 
collectively known as hallmarks of cancer (Hanahan and Weinberg, 2011). During 
evolution of cancer, cells acquire many genetic and epigenetic changes that give 
them the ability to divide out of control. The cancer- associated genetic changes can 
affect specific genomic sequences and/ or can be a stochastic process affecting any 
sequences. Different groups of genes can be considered as targets during 
carcinogenesis (which is the process of cancer development). Genetic mutations that 
affect a specific gene or group of genes and impose a positive selective advantage of 
the affected cells are called driver mutations. On the other hand, mutations that could 
randomly affect any gene or intergenic sequences and have no growth advantage 
are considered as passenger mutations (Stratton et al., 2009). The spatial distribution 
of the cancer associated mutations is not homogenous, thus it might happen in 
specific cells (and hence in subsequent clones) and not in others within the same 
tumour. The existence of specific mutations in specific cells could possibly add more 
features or make the bearing cells lack specific features. Because of the 
heterogeneous distribution of the genetic mutations, tumours are said to be 
genetically heterogeneous. From the molecular perspective, tumour heterogeneity (or 
genetic heterogeneity) can be classified into 4 subgroups: 
1) Intratumoral heterogeneity: This refers to the variable genetic changes in 
different cells within the same tumour mass. Despite this notable variation, all 
cancer cells still share the most common somatic mutations (these mutations 
are called “trunk” mutations) while the majority of differences are “branch” or 
even “leaves or private” mutations that confer the intratumor heterogeneity. 
This variability provides the bases for the consequent intermetastatic variability 
(Vogelstein et al., 2013). 
2) Intermetastatic heterogeneity: This kind of heterogeneity refers to the 
genetic variability in different metastases of the same tumour within the same 
patient. This kind of heterogeneity originates from the preceding intratumour 
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heterogeneity. The existence of this kind of heterogeneity gives rise to variable 
response to chemotherapy and, thus, eradication of a single clone will be 
unlikely to improve the long-term survival (Yachida et al., 2010). This kind of 
heterogeneity depends largely on the high number of passenger mutations, 
however all metastasis still share “positively selected” mutations from the main 
tumour mass. 
3) Intrametastatic heterogeneity: When metastases grow from different clones 
and due to the acquisition of further mutations during development, cancer 
cells become more heterogeneous giving rise to possible resistance to 
anticancer therapy. Cancer recurrence after surgery or therapy might partly be 
explained by this phenomenon. It has been shown that at the time of 
diagnosis, about thousands of cells from each metastatic lesion are resistant 
to any anticancer drug. Thus, by using a single–agent regimen, the recurrence 
of cancer is just a matter of time. To overcome this issue, multidrug regimens 
are employed in the clinical practice (Komarova and Wodarz, 2005). 
4) Interpatient heterogeneity: This kind of heterogeneity could be the 
underlying reason for the medical observation stating that; there are no 2 
cancer patients have identical clinical course. This might be due to the 
variation in somatic mutations among patients. Different somatic mutations, 
even within the same gene, might have different consequences (Vogelstein et 
al., 2013) 
The existence of different genetic mutations in different cells and clones 
resulted in intratumour variation in tumour characteristics and their response to 
therapy (Linnekamp et al., 2015, Hardiman et al., 2016). Moreover, intratumour 
heterogeneity (ITH) was suggested to have a role in prognosis and management of 
colorectal adenocarcinoma (Baisse et al., 2001). Thus, assessing ITH has clinical 
benefits. In addition, assessment of ITH helps to illuminate the evolution history of 
the different clones within the same tumour (Naxerova et al., 2014).  
X-chromosome inactivation (also called Lyonisation) refers to the process of 
inactivation of a single X chromosome during embryonic life in the female fetus, 
leaving a single active X chromosome (Lyon, 1961). This phenomenon has been 
used to assess the clonal characteristics in cancer. Tumour cells that do not carry the 
same X chromosome inactivated cannot be clonal. However, this approach does not 
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give more information about the other genetic changes that are existed in tumour 
clones (Wang et al., 2009). Alternatively, a genome and exome wide approaches 
using multiple specimens from the same tumour would be an ideal way to assess the 
ITH. Such an approach has many limitations, as currently, only the large genomic 
centers are capable of adopting this approach. Furthermore, an exome-wide 
approach would limit the search to the coding sequences and thus focusing mainly 
on the driver mutations (Naxerova et al., 2014). 
The proliferation of cancer cells is associated with increased DNA replication. 
DNA replication is usually accompanied by the generation of errors (up to 10,000 
errors per cell per day) due to the inefficiency of the enzymatic machinery (Loeb, 
2011). When mismatch repair (MMR) genes mutate, the mutation rate of the 
vulnerable sites (i.e. microsatellites) increases from 100-1000 folds (Bhattacharya et 
al., 1994, Shibata et al., 1994). These errors will accumulate with subsequent cell 
proliferation. Ideally, the time from the recent common ancestor cell can be 
documented by examining the microsatellite events in target tumour samples 
(Shibata et al., 1996). Both deletions and insertions of microsatellites could result in 
the generation of new alleles with different lengths that can be used to discriminate 
between different cells (and hence, the subsequent different clones) within the same 
tumour. It has been suggested that recently developed clones are likely to have 
similar alleles in adjacent cells, while the older clones are likely to show higher allelic 
diversity owing to the accumulations of more microsatellite mutational events 
(Shibata et al., 1996). Moreover, microsatellite mutations common to all specimens 
from a particular tumour were suggested to represent an early event during 
tumourigenesis.(Nagel et al., 1995). 
As microsatellites mutate after MMR loss and as they represent a neutral 
markers (passenger mutations), it is possible to use microsatellites on a genome 
wide approach to investigate the clonal characteristics of MSI-H tumours. It has been 
suggested that one of the initial microsatellite changes which happen following the 
loss of MMR genes is the mononucleotide alteration (Ionov et al., 1993, Blake et al., 
2001). Furthermore, the mutation frequency of polyguanine mononucleotides in 
mammals was estimated to be as high as 10-4 per cell per generation in both MMR 
deficient and proficient cells. Mutation rates of polyG repeats were found to be higher 
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than poly A repeats in both MMR proficient and deficient tumours (10-25 folds and 7-
15 folds respectively) (Boyer et al., 2002). 
Microsatellite (and minisatellite) markers were used to assess the intratumour 
heterogeneity using 20 different gastrointestinal tumours (includes 13 CRC tumours) 
(Nagel et al., 1995). It was concluded from that study that microsatellite mutations 
can be used to assess the clonal history of tumours irrespective to patient’s sex and 
type of tumour being tested. Tsao et al (2000), has quantatively analysed 
microsatellite changes (dinucleotide markers) in 13 MMR deficient CRCs and found 
that each tumour has a unique history since MMR loss. In 2004, dinucleotide 
microsatellite markers were used to assess the lineage relationship in different 
stages of cutaneous T-cell lymphoma. In that study, the microsatellite allelic profiles 
from multiple confined tumour lesions (Mycosis Fungoides) were compared to those 
from a benign condition (Lichen Planus). It was possible, from that study, to construct 
a lineage tree between different tumour lesions including those from early stages of 
the disease (Rübben et al., 2004). 
Poly G microsatellite markers were used to assess the cell fate in cultured 
mouse cells. Taking the advantage of change in length of polyguanine tracts after 
mitosis, it was possible to trace the phylogenetic tree of the cultured mouse cells 
(Salipante and Horwitz, 2006). Furthermore, alterations in polyG repeat length were 
found to be more abundant when there is associated neoplasia as opposed to 
ulcerative colitis with no neoplasia (Salk et al., 2009). In a study conducted at 2014, 
20 polyG markers were used to assess the intratumour heterogeneity between 
spatially different samples of different cancers including colorectal cancers. It was 
possible with that approach to construct the phylogenetic tree for the tumours 
involved in that study. This provided evidence of utility of mononucleotide markers to 
assess ITH and lineage relationship (Naxerova et al., 2014). However, these studies 
used the conventional fragment analysis approach to assess the allele length 
alterations. Quite recently, a panel of 20 short (8-14bp in length) mononucleotide 
markers was used to assess the clonal characteristics of 3 MSI-H CRCs using a next 
generation sequencing approach (Redford, 2016). In that panel, 8 markers were 
included in the 17 marker panel that was developed and validated in the previous 
Chapters. It was possible, according to that study, to use the short mononucleotide 
markers to infer the clonal characteristics in spatially different samples derived from 
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MSI-H CRCs. However, that assay assessed a limited number (3 tumours with a total 
of 27 specimens) of fresh tissue samples rather than FFPE samples. 
In this chapter, the panel of short mononucleotide markers that was developed 
and validated in previous chapters in addition to extra 6 markers, will be used to 
investigate whether short repeats can be used to analyse clonality of CRCs. For this 
purpose, 2 groups of MSI-H CRC samples were prepared for analysis; FFPE and 
fresh frozen tumour samples. For both groups, specimens from different positions 
within the same tumour were collected to investigate the clonal variability between 
them in terms of microsatellite profiles.  
6.1.2. Aim 
 In this chapter, the aim is to: 
 Assess the utility of short mononucleotide (7-12bp) markers to study the clonal 
characteristics of different samples from the same primary CRC or between 
primary tumour and its secondary metastasis. 
6.2. Results 
6.2.1. Collection of MSI-H CRC fresh tissue samples 
Twelve groups of fresh CRC tissue samples were obtained from the 
Department of Cellular Pathology (Royal Victoria Infirmary, Newcastle Upon Tyne 
Hospitals NHS Foundation Trust, UK). Each group was composed of 8 fresh tissue 
specimens retrieved from different locations within the same CRC tumour as 




 Figure ‎6-1: The orientation of specimens retrieved from fresh CRC tumours.  All specimens 
were retrieved in a clockwise orientation. The nearest tumour edge to the antimesentric border was 
considered as the 12 ‘clock. Specimens retrieved by needle were denoted as “N”, while specimens 
retrieved by scalpel were denoted as “S”. 
All fresh tissue samples were tested for MSI status using the Promega MSI 
test (MSI Analysis System, Version1.2: Promega, Madison, WI, USA) as explained in 
Chapter 2 section  2.8. A single tumour, out of the 12 tested CRC fresh tissue 




Figure ‎6-2: Electropherogram showing the fragment analysis of 2 fresh CRC tumours.  (A) 
MSS tumour and (B) MSI-H tumour (PR32516/14). For each tumour, matched normal tissue sample 
was tested in parallel. X-axis refers to mononucleotide markers that are included in the panel and Y-
axis refers to relative fluorescence intensity. The panel of markers was composed of 5 
mononucleotide markers and 2 pentanucleotide markers. Names of markers are labelled next to each 
individual group of peaks. By careful visual comparison of the allelic profile, very similar profiles are 
observed in tumour A with its corresponding normal sample, while, 3 makers show different profiles in 
the tumour B (arrows).  
Three additional MSI-H samples were obtained from Dr Lisa Redford 
(Newcastle University, UK), so the overall number of fresh MSI-H tumours included in 
the assay was 4, PR32516/14, PR10654/14, PR51896/13 and PR17848/14. From 
each tumour, 9 spatially different specimens were retrieved by a pathologist from 
different orientations as explained in Figure  6-1.  
6.2.2. Collection of FFPE MSI-H CRC samples  
I searched the NHS database looking for all MSI-H colorectal cancers, which 
have more than one FFPE specimen and diagnosed in the time interval from 2000-
2015. The search was limited to those MSI-H CRC tumours, which have been 
referred from the Royal Victoria Infirmary (RVI) and have more than one tissue 
source (e.g. Tumour and lymph node or 2 or more tumours from different positions). 
Eighteen MSI-H CRC tumours were found to fulfil these criteria. Out of those 18, 7 
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tumours were collected and examined as explained in Chapter 2 section  2.2.2 and 







       IHC for MMR  
No. Path. Ref. No. Age Block Position Diagnosis Stage MLH1 MSH2 MSH6 PMS2 MMR mutation 









   1H Caecal  
   1M Ascending colon  
   1N Ascending colon  
2 PR7146/13 53 1P Lymph node Medullary  AC  of 
Sigmoid 
T4N1M0      
NMD    1W Tumour + serosa  
3 PR34630/03 68 3J Tumour Moderately 











NA    3P Apical lymph node  
4 PR049276/12 68 2I Tumor + serosal invasion Medullary AC of right 
colon 
T3N0M0      
 
NMD 
   2H Tumor with Gerota's 
fascia  
 











NA    1K  Tumour  













   1J  Tumour  






T3N0M0      
NA    1Q Tumour+ LN close to 
CRM 
 
   1R Tumour + LN close to 
CRM 
 
   1S Tumour close to CRM  
   1T Tumour  
   1O Tumour + mesocolic fat  
Table ‎6-1: The FFPE CRC tumours that were used to assess ITH. For each tumour, at least 2 samples from different positions were requested.  AC= 







of Immunohistochemistry for Mismatch repair proteins. Dark red boxes indicate absent protein, faint green boxes indicate the presence of protein. NMD= no 
mutation detected. NA indicates no available information. 
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6.2.3. PCR amplification and MiSeq sequencing of the collected samples to 
assess the clonal composition  
 All the 36 fresh tissue specimens (9 specimens from each tumour mass, 4 
tumours in total) and all the 20 FFPE specimens (from 7 FFPE tumours) were 
amplified using a batch of 23 markers (shown in Table  6-2). 
 The primers used in PCR amplification were composed of those that were 
used in the previous chapters (the 17 markers panel) and additional 6 markers. Of 
those 6 additional markers, 3 markers were retrieved from Selective Targets in 
Human MSI-H Tumorigenesis Database website (SelTarbase) (SelTarBase, 
http://www.seltarbase.org). The search in the SelTarbase was limited to those 
markers with a length of 7-12bp that have a high percentage (more than 80%) of 
instability in CRCs. The markers that were retrieved from SelTarbase are ASTE1 
(Woerner et al., 2003), AVIL and IRS2 (Woerner et al., 2010). Another 3 markers 
were chosen from a parallel assay conducted by Dr Lisa Redford (Redford, 2016) as 
they were variable in the majority of the tested specimens. These markers were 
GM29-10, LR17-11 and LR43-12.  
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  Marker Repeat 
Size 
SNP 1 SNP2 Repeat Position 
1 LR49-7 7 rs12903384  Chr15:93619048 
2 IM66-C 7 rs4794136 rs141474571 Chr17:48433967 
3 DEPDC2-G 8 rs4610727  Chr8:68926683 
4 LR20-8 8 rs146973215 rs217474 Chr1:64029634 
5 GM9-8 8 rs79878287  Chr20:6836977 
6 GM11-9 9 rs347435   Chr5:166099891 
7 LR24-9 9 rs192329538    Chr1:153779429 
8 IM16-9 9 rs73367791   Chr18:1108767 
9 GM17-9 9 rs666398   Chr11:95551111 
10 AP003532-2-9 9 rs138081624  Chr11:127625067 
11 AVIL-10 10  rs141859389  Chr12:58202497 
12 GM29-10 10  rs2687195   Chr3:70905560 
13 GM7-11 11 rs2283006   Chr7:93085748 
14 GM14-11 11 rs6804861  Chr3:177328818 
15 ASTE1-11 11 rs753405495  Chr3: 130733047 
16 LR48-11 11 rs368641323  rs11105832 Chr12:77988097 
17 LR11-11 11  rs13011054   Chr2:217217871 
18 LR17-11 11  rs1009977  rs1009978 Chr14: 55603031 
19 LR36-12 12 rs17550217  Chr4:98999723 
20 LR44-12 12 rs7905384 rs7905388 Chr10:99898286 
21 IM49-12 12 rs7642389   Chr3:56682066 
22 IRS2-12 12 rs57032199  Chr13: 110407562 
23 LR43-12 12  rs6881835 rs10051666 Chr5:86199061 
Table ‎6-2: The list of primers that were used in the clonal assessment of CRC samples 
alongside with the included SNPs in the amplicons.All tumour specimens were then amplified 
and sequenced and deletion frequency calculated as explained in Chapter 2. In fresh 
CRC tumours, for each specimen, deletion frequencies for all markers were 
compared to those in the associated normal specimen. This baseline calculation was 
done for all amplicons which showed an overall sequencing reads of ≥ 100 paired 
end reads. The amplicons with less than 100 sequencing reads were excluded from 
the baseline calculations. Out of the tested 36 fresh CRC specimens, 94% (34/36 
samples) were amplified and sequenced to adequate depth (i.e. >100 sequencing 
reads) in ≥ 20 markers. A single specimen was sequenced for only 17 markers and 
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another specimen sequenced for <20 markers. On the other hand, 90 % of FFPE 
specimens (18/20) were sequenced to adequate depth in ≥ 20 markers. 
 The average depth to which all tumours in both groups were sequenced was 
approximately the same (4971 per/ amplicon for fresh tissue samples and 5119 per/ 
amplicon for FFPE samples). When a specific marker failed to be amplified in a 
particular specimen from a particular tumour, the marker was excluded from further 
analysis for all specimens of that tumour. To establish instability of each marker, 
cutoff values that used in threshold set 7 (developed and validated in Chapter 4 and 
Chapter 5, respectively) were used as shown in Table  6-3. The only exceptions are 
the 10bp markers, where there is no validated cutoff value for such a repeat length 
(as there was no 10bp marker in the 17 marker panel). For the 10bp markers, the 
cutoff value was set to a deletion frequency of 0.14 as this value yielded the least 
false positive rate (= 0 %) in a previous analysis (Redford, 2016).  
Marker group 7bp 8bp 9bp PolyG/C 10bp 11bp 12bp 
Cutoff value 0.05 0.05 0.08 0.1 0.14 0.30 0.30 
Table ‎6-3: Cutoff values for calling instability in the clonality assay.  The same cutoff values 
used in threshold set 7 were used with the addition of new cutoff value for the 10bp markers. 
For purposes of phylogenetic tree construction, Mesquite software 
(http://mesquiteproject.wikispaces.com/) was used as explained in Chapter 2 
section  2.10.8. 
6.2.4. Clonal composition of the FFPE tumours 
6.2.4.1. Clonal composition of the tumour PR53139/13 
 The tumour PR53139/13 was examined by a certified pathologist (Dr Helen 
Turner, Department of Cellular Pathology, RVI, Newcastle Hospitals NHS Foundation 
Trust, UK) and reported as moderately differentiated adenocarcinoma. Four 
specimens from 4 different blocks were retrieved from that tumour (1H, 1J, 1M and 
1N).  The specimens 1H and 1J were originated from the Caecum while both 1M and 
1N were from the ascending colon. The histopathological diagnosis for all specimens 
was the same. The malignant cell population was reported to be <5% in both 1J and 
1H specimens while it was estimated to be 30% in specimen 1M and 40% in 
specimen 1N. The four specimens were successfully amplified and sequenced 
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across 22 markers. All the tested specimens have shown instability, but in different 
number of markers for each specimen as shown in Table  6-4. 







No. of unstable 
markers 
1J 22 2442 <5% 5 
1H 22 3106 <5% 9 
1M 22 4437 30% 15 
1N 22 7587 40% 16 
Table ‎6-4: Number of unstable markers and sequencing coverage for the 4 specimens of 
the tumour PR53139/13. The coverage depth expressed in paired end read (per) / amplicon.  
The least number of unstable markers was observed in the specimen 1J, 
where only 5 markers (out of the 22 successfully sequenced markers) showed a 
deletion frequency above threshold values. The marker IRS2-12 showed the highest 
deletion frequency among the unstable markers in that specimen (= 70%), most of 
deletions for that marker (67%) were 2bp deletion while 3bp deletion was observed in 
3% and no 1bp deletion was recorded as shown in Appendix Figure  8-4. The 
existence of the low number of unstable markers in the specimen 1J can either be 
due to low tumour cell contents (reported as <5%) or it could represent the nearest 
specimen to the original trunk from which other specimens (branches) were 
originated. 
 In the specimen 1H, 4 additional markers (GM11-9, AP0035322-9, GM14-11 
and LR44-12) showed deletion above the threshold values. The markers GM11-9 
and AP0035322-9 showed only 1bp deletions (39% and 10%, respectively), while 
marker GM14-11 showed 2bp deletion (44%) in addition to 1bp deletion (3%). The 
deletion frequency in all the remaining 5 unstable markers was higher than the 
frequencies observed in the 1J specimen, except for the marker IRS2-12 where the 
2bp deletion is lower than that observed in the 1J specimen (48% compared to 76% 
in the 1J sample). 
The specimen 1M showed deletion frequency above the length specific 
threshold in 15 markers. Compared to specimen 1H, the markers DEPDC2-G, GM9-
8, LR24-9, AVIL-10 and IM49-12, showed deletion frequency above the threshold 
while they were stable in both 1H and 1J as shown in Figure  6-3. In the specimen 
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1N, an additional marker (LR11-11) showed a deletion frequency above threshold, 
giving rise to a unique deletion in that particular sample.  
According to the number of unstable markers in each of the 4 tested 
specimens, a phylogenetic tree was constructed as shown in Figure  6-3. One 
possible conclusion is that the specimen 1J contains cells that belong to the nearest 
clone to the original ancestral tumour clone (as it has the lowest number of unstable 
markers). The specimen 1H stands out as a branch as it has more unstable markers 
than 1J but lower than both 1M and 1N. Furthermore, it shares 4 mutations with other 
specimens. This indicates that the specimen 1H contains cells of a descent clone 
from 1J but developed before the emergence of the clone whose cells are existed in 
specimens 1M and 1N. Both 1M and 1N specimens are likely to contain cells of a 
descent clone from the clone existed in specimen 1H as shown in Figure  6-3.  
Although the recorded tumour cell content in both specimens 1J and 1H was 
very low (<5% for both), it was possible to detect at least 5 unstable markers in both 
specimens with relatively high deletion frequency (up to 70%). One possible 
explanation is that the tumour cell population was underestimated. Another possibility 
is that the coverage depth to which these specimens were sequenced (2000- 3000 
per/amplicon) was high enough to detect such low prevalence mutations. 
Overall, this indicates that the origin of the tumour PR53139/13 is likely to be 
located in the Caecum than in the ascending colon. However, the reported low 
tumour cell population in both 1J and 1H specimens (both are <5%) might contribute 
to the relatively low number of unstable markers in both specimens compared to 
specimens 1M and 1N. This assumption is supported by the clear positive relation 
between the number of unstable markers and the estimated tumour cell population 




Figure ‎6-3: The clonal characteristics of the tumour PR53139/13. Images of the histological 
sections were shown in the upper pane with their corresponding specimen identifier. All slides have 
the same diagnosis (moderately differentiated adenocarcinoma). (A) Deletion frequencies of 16 
markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to stable 
markers in the 4 tested specimens (leftmost column). The total number of unstable markers in each 
specimen is shown in the rightmost column. (B) Schematic representation of specimen locations in 
this tumour, where samples 1J and 1H were derived from the Caecum while specimens 1M and 1N 
were derived from the ascending colon. (C) The phylogenetic tree of the tested specimens. The 
newest clones are likely to be represented in specimens 1M and 1N. The horizontal timeline shows 
that the further the branching, the newer is the specimen.    
6.2.4.2. Clonal composition of the tumour PR32079/14 
The tumour PR32079/14 was reported as a poorly differentiated 
adenocarcinoma of the caecum with some medullary and focal neuroendocrine 
features. Six specimens were retrieved from different positions of the tumour (1O, 1P, 
1Q, 1R, 1S and 1T). Of them, two specimens contained an associated lymph node 
(1Q and 1R). Of these 6 specimens, 2 specimens (1O and 1Q) were reviewed by the 
pathologist and the malignant cell population was estimated to be 40% for both 
specimens. Among the 23 tested markers, 3 specimens (1P, 1S and 1T) were 
successfully amplified and sequenced for 23 markers, 2 specimens (1Q and 1R) for 
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22 markers and a single specimen (1O) for 21 markers with average coverage of 
4699 per/ amplicon as shown in Table  6-5.  






No. of unstable 
markers 
1O 21 2873 40% 14 
1P 23 7748  14 
1Q 22 5801 40% 13 
1R 22 3665  12 
1S 23 4487  9 
1T 23 3623  13 
Table ‎6-5: Number of unstable markers in the 6 specimens of tumour PR32079/14.The 
tumour cell population was assessed for only 2 samples. The coverage depth expressed in pairs end 
read (per) / amplicon.  
Based on the number of unstable markers for all specimens, the phylogenetic 
tree was constructed as shown in Figure  6-4. All specimens showed at least 9 
unstable markers (i.e. Have a deletion frequency above the length-specific cutoff 
values) as shown in Table  6-5. The least number of unstable markers was observed 
in the specimen 1S, indicating that this specimen is likely to contain cells from the 
nearest clone to the ancestral tumour clone.  
The specimen 1R have had an extra 3 unstable markers compared to the 
specimen 1S, while, specimen 1Q showed 13 unstable markers. In the specimen 1Q, 
the marker DEPDC2-G showed 38% deletion frequency, making it the only observed 
difference from specimen 1R. The specimen 1P exhibited 14 unstable markers and 
shares all the 13 unstable markers in the specimen 1Q. It has an additional unique 
instability in the marker IM66-C (13% deletion frequency). 
The specimen 1T had 13 unstable markers, sharing all the 12 unstable 
markers that existed in the specimen 1R. This specimen had an additional unstable 
marker (45% deletion frequency in the marker LR43-12). The marker LR36-12 shows 
a new event represented by the emergence of a new 5bp deletion in the specimen 
1T as shown in Appendix Figure  8-3.  
The specimen 1O showed instability in 14 markers, sharing all the unstable 
markers in the specimen 1T. This specimen shows an additional instability in the 
marker DEPDC2-G with a 15% deletion frequency.  
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Overall, the above characteristics of individual specimens indicate that the 
specimen 1S contains cells that likely belong to the oldest clone (the nearest one to 
the common ancestor) among the tested specimens. Specimens 1R, 1T, 1Q, 1O and 
1P contain cells that likely belong to downstream branches from the 1S specimen as 
shown in the phylogenetic tree in Figure  6-4. However, variability in the percentage of 
tumour cell population among specimens is another possibility for the variation in 
deletion profile. 
 
Figure ‎6-4: The clonal characteristics of the tumour PR32079/14.Upper images represent the 
histological sections of corresponding specimens (1O and 1Q). Both slides showed the same 
histological features (poorly differentiated adenocarcinoma of Caecum). (A) Deletion frequencies of 15 
markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to stable 
markers in the tested specimens (leftmost column). The total number of unstable markers in each 
specimen is shown in the rightmost column. (B) The phylogenetic tree based on the instability profile 
of the tested specimens. The horizontal timeline shows that the further the branching, the newer is the 
specimen.    
6.2.4.3. Clonal composition of tumour PR7146/13 
 The tumour PR7146/13 was reported as a stage III medullary 
adenocarcinoma arose from the Sigmoid with evidence of lymph node involvement 
(T4N1Mx). Two specimens were retrieved from that tumour, 1P and 1W. The 
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specimen 1P was from an involved lymph node while the specimen 1W was from the 
tumour itself. Out of the 23 tested markers, specimen 1P was amplified for 22 
markers with an average coverage of 7400 per/amplicon while the specimen 1W has 
amplified only 17 markers with an average coverage of 8400 per/amplicon. Both 
specimens (1P and 1W) showed instability of 9 markers as shown in Figure  6-5. This 
indicates that both specimens (the tumour and the lymph node) likely contain cells 
that belong to a single clone with a similar age. 
 
Figure ‎6-5: The clonal characteristics of the tumour PR7146/13.(A) Deletion frequencies of 9 
markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to stable 
markers in the tested specimens (leftmost column). The total number of unstable markers in each 
specimen is shown in the rightmost column. (B) Bar charts represent the variant allele frequencies of 
the 9 markers in both specimens. 
6.2.4.4. Clonal composition of the tumour PR34630/03 
 The tumour PR34630/03 was reported as stage III moderately differentiated 
adenocarcinoma of the Sigmoid with lymph node involvement (T4N1Mx). Two 
specimens were retrieved from that tumour, 3J which obtained from the tumour mass 
itself and 3P which obtained from an involved apical lymph node. Out of the 23 tested 
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markers, 21 markers were successfully amplified and typed in both specimens. 
Seven markers were unstable in at least one specimen of that tumour. In the 
specimen 3P (the lymph node), 7 markers showed a deletion frequency above the 
threshold while the specimen 3J (the tumour) showed instability in 11 markers as 
shown in Figure  6-6. Interestingly, almost all markers showed deletion frequencies in 
the specimen 3J higher than in the specimen 3P. This indicates that specimens 3P 
and 3J contain cells likely belong to clones that are distant from each other and the 
clone whose cells are existed in the specimen 3P represent the nearest between 
them to the ancestral clone. 
 
Figure ‎6-6: The clonal characteristics of the tumour PR34630/03.(A) Deletion frequencies of 
11 markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to stable 
markers in the tested specimens (leftmost column). The total number of unstable markers in each 
specimen is shown in the rightmost column. (B) Variant allele frequencies of the 11 markers in both 
specimens.  
6.2.4.5. Clonal composition of the tumour PR049276/12 
 The tumour PR049276/12 was reported as a stage II moderately 
differentiated adenocarcinoma of the caecum. Two specimens were retrieved from 
that tumour, 2I that represents tumour with serosa and 2H, which represents tumour 
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with Gerota’s fascia (renal fascia). The malignant cell population was reported to be 
40% in the specimen 2I and 60% in specimen 2H. The specimen 2I was successfully 
amplified and sequenced across 21 markers while specimen 2H was sequenced 
across 19 markers with approximately double sequencing depth compared to 
specimen 2I (6655 per/ amplicon for specimen 2H compared to 3524 per/amplicon 
for specimen 2I).  
 Both specimens have shown instability in 11 markers, of them, 10 markers 
were unstable in both specimens. The specimen 2I showed instability in the shared 
10 markers and an additional single marker (the marker IM49-12). In the other 
specimen (2H), in addition to the 10 shared unstable markers, one additional marker 
was unstable (GM14-11) as shown in Figure  6-7. There was new 3bp deletion alleles 
observed in 3 markers (GM14-11, LR36-12 and IM49-12) in the specimen 2I. Thus, 
these specimens contain cells that likely belong to separate clones originated from a 
single trunk.  
 
Figure ‎6-7: The clonal characteristics of the tumour PR049276/12.  (A) Deletion frequencies 
of 12 markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to 
stable markers in the 2 tested specimens (leftmost column). The total number of unstable markers in 
each specimen is shown in the rightmost column. (B) Bar charts represent variant allele frequencies of 
the 13 markers of both specimens.  
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6.2.4.6. Clonal composition of the tumour PR53996/14 
 The tumour PR53996/14 was reported as stage I adenocarcinoma of the 
colon, and 2 specimens (1J and 1K) were retrieved from the archived tumour blocks. 
The malignant cell population was reported to be 30% for both specimens. Out of the 
23 tested markers, the number of the markers that were successfully amplified and 
sequenced is 22 for specimen 1J and 20 for specimen 1K. Both specimens (1J and 
1K) showed a shared instability in 9 markers while each specimen showed 
instabilities in additional 2 different markers.  
In the specimen 1J, in addition to the 9 shared markers, 2 unstable markers 
(LR24-9 and LR43-12) were observed. In the specimen 1K, on the other hand, 11 
unstable markers were observed, including the 9 shared markers and additional 2 
markers (LR49-7 and LR17-11). The specimen 1K showed new events represented 
by the existence of 3bp deletion allele in 2 markers (ASTE1-11 and AVIL-10) and 4bp 
deletion allele in the marker IRS2-12 (Figure  6-8).  
As the additional (non- shared) unstable marker were not the same in both 
specimens, instabilities of these markers could indicate that both specimens contain 
cells that belong to 2 independent branches from a common trunk. However, the 
normal cell contamination is still a possible reason for the difference in instability 




Figure ‎6-8: The clonal characteristics of the tumour PR53996/14. (A) Deletion frequencies of 
13 markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to stable 
markers in the 2 tested specimens (leftmost column). The total number of unstable markers in each 
specimen is shown in the rightmost column. (B) Variant allele frequencies of the 13 unstable markers 
of both specimens.  
6.2.4.7. The clonal composition of the tumour PR45703/14 
 The tumour PR45703/14 was reported as a stage I adenocarcinoma of the 
caecum and 2 specimens from 2 different tissue blocks were retrieved, 1H and 1J. Of 
the 23 tested markers, the number of markers that were amplified and sequenced is 
18 markers for specimen 1H and 20 markers for specimen 1J. Both specimens 
shared a deletion in 10 markers. The specimen 1H showed an additional unique 
mutation in the marker IM16-9. Furthermore, this specimen showed a higher 3bp 
deletion frequency in 2 markers (ASTE1-11 and IRS2-12) compared to those in the 
specimen 1J as shown in Figure  6-9. This mutational profile is likely to indicate that 
both specimens contain cells that belong to 2 clones bifurcated from the same trunk. 
Another possible scenario is that cells within both specimens belong to a single 
clone, but contamination with normal cell resulted in the observed difference in the 
IM16-9 instability between the two specimens. This conclusion is supported by the 
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marginal difference between deletion frequencies for the marker IM16-9 in both 
samples. 
 
Figure ‎6-9: The clonal characteristics of the tumour PR45703/14. (A) Deletion frequencies of 
11 markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to stable 
markers in the 2 tested specimens (leftmost column). The total number of unstable markers in each 
specimen is shown in the rightmost column. (B) Variant allele frequencies of the 11 markers in both 
specimens.  
6.2.5. Clonal composition of the Fresh MSI-H CRC samples 
Thirty six specimens were tested from 4 fresh MSI-H tumours using the 23 
short repeats. Details of deletion frequencies of all individual specimens are shown in 
Appendix Figure  8-5, Figure  8-6, Figure  8-7and Figure  8-8. 
6.2.5.1. Clonal composition of the tumour PR10654/14 
 The tumour PR10654/14 involves the Ileocaecal junction. It was tested by 
fragment analysis and found to be MSI-H.  
Of the 23 tested markers, normal tissue specimen did not shown deletions in 
any of the tested markers. For this tumour, 15 markers exhibited deletion frequencies 
above the length specific threshold values. Of those 15 markers, 5 markers were 
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found to be unstable in all the tested tumour specimens. In the 6 O’clock scalpel (6° 
S) specimen, only 5 markers were unstable, indicating that this specimen likely 
contain cells belong to a clone which is the nearest to the original ancestral clone. In 
the scalpel 3 O’clock (3° S) specimen, 6 additional markers showed instability. The 
3°, 6° and 12° O’clock needle biopsies showed a similar deletion profile as all these 
specimens showed instability in 13 markers as shown in Figure  6-10. In the 12° 
O’clock scalpel (12°S) specimen, a new 1bp deletion was observed in the marker 
AP0035322-9. This deletion was not observed in any other specimen, indicating that 
the 12° S specimen likely contains cells belong to a clone derived from a preceding 
branch.  
In the specimen 9 O’clock needle (9°N), an additional deletion in the marker 
LR11-11 was observed. This alteration was not observed in any other specimen, 
indicating this specimen contain cells belong to a clone originates from previous 
clones. A very similar deletion profile was noticed for specimen 9° S, where the same 
markers showed deletion frequencies above the length specific cutoff values in the 
specimen 9° N. The only difference between the 2 specimens (i.e. 9°N and 9° S) was 
the marker LR48-11, where a deletion below the cutoff value in the specimen 9° S 
was found. However, deletion frequency of that marker in specimen 9° S (=29%) was 
very close to the cutoff value (which is 30%). The likely scenario is that contamination 
with normal cells could be the underlying reason for the reduction in deletion 
frequency of this marker in that particular specimen and both specimens contain cells 




Figure ‎6-10: The clonal characteristics of the tumour PR10654/14.(A) Deletion frequencies of 
15 markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to stable 
markers in the 9 tested specimens (leftmost column). The total number of unstable markers in each 
specimen is shown in the rightmost column. (B) A schematic representation of the distribution of 
clones according to the orientation from which they were obtained. Sections with the same colour 
indicate that they have the same deletion profiles and, thus, contain cells that belong to the same 
clone. (C) The phylogenetic tree based on the instability of markers in different specimens rooted to 
the normal specimen. Colours of the branches are corresponding to their clone colours in (B). The 
horizontal timeline shows that the further the branching, the newer is the specimen. 
Overall, the instability profile of the tested specimens indicates that the 
specimen 6° S contains cells that belong to the nearest clone to the ancestral tumour 
cells, while the newest clones would likely be presented in specimens 9° N and 9° S.  
6.2.5.2. Clonal composition of the tumour PR17848/14 
 The tumour PR17848/14 was tested by fragment analysis and found to be 
MSI-H, and 8 specimens were obtained in the same locations as described in 
Chapter 2 section  2.2.2. The normal specimen was retrieved from normal looking 
mucosa and it did not show any degree of deletion in the tested markers. All tumour 
specimens showed deletion frequencies above the cutoff values and each specimen 
showed at least 5 unstable markers. The specimen 6° S showed the least number of 
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unstable markers (5 markers), and thus it is likely to contain cells that belong to the 
nearest clone to the common ancestor.  
 The specimen 9° S contains cells that belong to clone branching from the 
clone presented in the specimen 6° S as it harbors 12 unstable markers. The 
specimen 12° N showed instability in 14 markers, sharing all mutations in the 
specimen 9° S and an additional 2 markers (LR43-12 and AVIL-10). This likely to 
indicate that the specimen 12° N contain cells of a descendent clone from the 
specimen 9° S as shown in Figure  6-11. 
 
Figure ‎6-11: The clonal characteristics of the tumour PR17848/14.(A) Deletion frequencies of 
18 markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to stable 
markers in the 9 tested specimens (leftmost column). The total number of unstable markers in each 
specimen is shown in the rightmost column. (B) A schematic representation of the distribution of 
clones according to the orientation from which they were obtained. Sections with the same colour 
indicate that they have the same deletion profiles and, thus, contain cells that belong to the same 
clone. (C) The phylogenetic tree of the tested specimens. Colours of branches are corresponding to 
their clone colours in (B). The horizontal timeline shows that the further the branching, the newer is the 
specimen.  
The specimen 3° S showed instability in 14 markers, sharing all the deletions 
observed in specimen 9° S and additional 2 branch mutations (LR36-12 and IM49-
12). The specimen 3° N and 12° S share the same instability profile (have 15 
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unstable markers) and they contain cells that are likely belonging to a clone that is 
derived from the same upstream clone (3° S). 
 There is an additional mutation in a single marker (AVIL-10) in specimen 6° 
N and 2 unique mutations in the specimen 9° N, these are in the markers GM7-11 
and GM14-11. These mutations were not observed in other samples and thus, are 
likely to indicate that this specimen (i.e. 9° N) contains cells that are likely to belong 
to the newest clone among the tested specimens.  
The specimens 12° N and 6° N are the only specimens that have shown 
instability in the marker AVIL-10, however, specimen 12° N lacks instability in 2 
markers (LR36-12 and IM49-12) compared to sample 6° N.  
6.2.5.3. Clonal composition of the tumour PR51896/13 
 The tumour PR51896/13 was obtained from a tumour mass involving the 
Ileocaecal valve and assessed by fragment analysis and found to be MSI-H. Of the 
23 tested markers, all specimens showed deletion in at least 2 markers. Specimen 6° 
S showed the smallest number of unstable markers (LR24-9 and AVIL-10), thus this 
specimen is likely to contain cells that belong to the nearest clone to the common 
ancestral clone. The specimen 3° N showed a deletion in additional 9 markers, so 
this specimen lies further away from the parental tumour clone compared to 
specimen 6° S. The specimen 6° N showed a deletion in 12 markers with additional 
marker (GM11-9) compared to the sample 3° N. 
Specimens 12° N and 3° S showed instability in 13 markers and both of them 
have had identical deletion profiles, so they contain cells that belong to a single clone 
originated from the upstream clone.  
 The specimen 12° S showed deletions in 13 markers with the absence of a 
deletion of a single marker that was unstable in the preceding specimen (LR36-12) 
as shown in Figure  6-12. The absence of LR36-12 instability is likely to be explained 
by contamination of the sample with normal cells. The specimens 9° N and 9° S 
exhibit the same number of unstable markers. 
There is a high similarity in the deletion profiles among specimens 9° N, 9° S 
and 12° S, with the only exception is the marker LR36-12 which is stable in one 
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specimen while unstable in the other two. However, this stability is likely to be due to 
contamination with normal cells.  
 
Figure ‎6-12: The clonal characteristics of the tumour PR51896/13. (A) Deletion frequencies of 
14 markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to stable 
markers in the 9 tested specimens (leftmost column). The total number of unstable markers in each 
specimen is shown in the rightmost column. (B) A schematic representation of the distribution of 
clones according to the orientation from which they were obtained. The sections with the same colour 
indicate that they have the same deletion profiles. The samples 9° N and 12° S seems to represent a 
single clone (C) The phylogenetic tree of the specimens based on deletion profiles. Colours of 
branches are corresponding to their clone colours in (B). The horizontal timeline shows that the further 
the branching, the newer is the specimen. The specimens 9° N and 12° S seem to represent the 
newest clone. 
6.2.5.4. Clonal composition of the tumour PR32516/14 
 The tumour PR32516/14 was assessed by fragment analysis and found to be 
MSI-H. Out of the 23 tested markers, the specimens showed instability in 7-13 
markers, with the least number of unstable markers observed in the specimen 6° N. 
The specimen 6° N showed instability in 7 markers and these markers were unstable 
in all descendant samples. 
 The specimens 12° N and 12° S showed similar profile and are likely to 
contain cells belong to a clone that originate from the same upstream clone present 
 168 
 
in specimen 6° N, as they showed an identical deletion profile across markers (both 
have 9 unstable markers) as shown in Figure  6-13.  
 Both of the specimens 9° N and 9° S show a new deletion in marker LR43-
12, so they are likely to contain cells that belong to a clone located downstream to 
the clone presented in specimens 12° S and 12° N.  
Ten markers in the specimen 3° S showed deletion frequency above the cutoff 
values. The specimen 3° N had 12 unstable markers with a single additional marker 
(IM49-12) compared to the sample 9° N. Based on the similarity of deletion profiles, 
specimens 3° N and 3° S seem to contain cells belong to a single clone. 
 There was a unique deletion in the marker GM17-9 in specimen 6° S. 
However, this specimen lacks the deletion in the marker GM29-10 which was 




Figure ‎6-13: The clonal characteristics of the tumour PR32516/14.  (A) Deletion frequencies 
of 13 markers (the upper raw), dark red boxes refer to unstable markers and green boxes refer to 
stable markers in the 9 tested specimens (leftmost column). The total number of unstable markers in 
each specimen is shown in the rightmost column. (B) A schematic representation of the distribution of 
clones according to the orientation from which they were obtained. Places with the same colour 
indicate that they have the same deletion profiles. The samples 12° N and 12° S seems to represent a 
single clone (C) The phylogenetic tree based on the instability of the tested specimens. The colours of 
branches are corresponding to their clone colours in (B). The horizontal timeline shows that the further 
the branching, the newer is the specimen. 
6.3. Discussion 
 Intratumour heterogeneity has its impact on diagnosis, prognosis and 
management of different human tumours (Baisse et al., 2001, Linnekamp et al., 
2015, Hardiman et al., 2016). Microsatellite markers were used previously to analyse 
the ITH and clonal characteristics of different human cancers (Rübben et al., 2004, 
Salipante and Horwitz, 2006, Redford, 2016). The development of the new NGS 
based MSI panel investigated and validated by our group (in previous chapters), 
made it possible to assess the intratumour heterogeneity on a large scale basis. In 
this Chapter, variant allele frequency was used as the main classifier for assessing 
the relationship between different specimens from the same tumour. The markers 
were called unstable based on the criteria and cutoff values proposed and validated 
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in previous chapters. Then, the number of unstable markers for each specimen was 
calculated and compared with that of other specimens for the same tumour. 
Mutations in microsatellites accumulate with time following MMR gene 
knockout, thus the higher the number of mutations the longer the time since MMR 
loss (Ionov et al., 1993, Shibata et al., 1996). Based on the assumption that 
microsatellite instability events are cumulative, mutations common to all specimens 
(of a particular tumour) represent an early event (Tsao et al., 2000). Tumours 
associated with a higher number of unstable markers are likely to represent clones 
which have arisen more recently. It was possible to construct the phylogenetic tree 
for each individual tumour by applying the derived shared characters as a basis for 
constructing trees using the software package Mesquite (version 3.04).  
 During the search of the NHS database, a notable challenge of the search 
process was the lack of adequate pathological data in the database, especially for 
old samples; however, it was possible to retrieve 8 MSI-H CRCs with at least 2 
specimens for each. The higher the number of specimens collected for each tumour, 
the better the ability to construct an evolutionary tree.  
The possibility to disseminate to local or distant lymph nodes in MSI-H 
tumours is considerably lower compared to the MSS samples (Hu et al., 2011, 
Birgisson et al., 2015); this was reflected in the difficulty to find an MSI-H tumour with 
involved lymph node during the search process. However, it was possible to collect 
lymph node specimens for 3 tumours (PR34630/03, PR7146/13 and PR32079/14) 
out of the tested 8 FFPE tumours. In the tumour PR7146/13, both tumour and lymph 
node specimens exhibited the same number of unstable markers (9 markers for 
each). In the other tumour (PR34630/03), lymph node specimen exhibited a different 
number of unstable markers compared to the tumour specimen (7 markers for the 
lymph node vs 11 markers for the tumour specimen). In the 3 tumours, lymph node 
specimens share the unstable markers with the original tumour. This provides 
evidence that microsatellites can be used to assess the clonal characteristics in the 
involved lymph nodes in MSI-H tumours. 
All tumours (FFPE and fresh CRCs) were previously tested by fragment 
analysis and all of them were classified as MSI-H. The instability status was 
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confirmed in our assay based on the previously proposed criteria for calling instability 
in the NGS based MSI assay.  
A notable weakness of the overall approach is the inability to have an exact 
estimation of the tumour cell count within the tested specimen. An approximate 
estimation was made by the examining pathologist. It has been predicted that for 
99.9% sensitivity detection of a heterozygous mutation in a heterogeneous tumour 
sample with 10% malignant cell population, 400-500 high quality sequencing reads 
are required (Fisher et al., 2016, Lin et al., 2014). Assuming this prediction is 
applicable for MSI detection, it is likely for our assay with the relatively high average 
coverage (of ~5000 per/amplicon) to detect microsatellite mutations even with the 
existence of a small percentage of tumour cells. This assumption is supported by the 
ability to detect instability in specimens 1J and 1H of the tumour PR53139/13, 
although both specimens had a very low tumour cell count (less than 5%).  
 For all fresh CRC tumours, 8 specimens from a clockwise orientation in 
addition to a normal specimen were provided. It was possible to construct the 
phylogenetic tree for all fresh tumours. In all fresh tumours, normal specimens were 
stable for all markers. 
 In 3 out of the 4 tested fresh MSI-H CRC tumours (PR10654/14, PR17848/14 
and PR51896/13), the specimen 6° S exhibited the least number of unstable 
markers, while it showed the highest number of unstable markers in the 4th tumour 
(PR32516/14). Given these specimens were retrieved from all the 4 tumours in the 
same orientation and by the same pathologist, this reduces the possibility that the 
sampling technique could be the underlying reason for the low number of unstable 
markers in that particular biopsy in these 3 tumours. 
Results obtained from this Chapter can be used as additional evidence of the 
employability of the panel of markers (as well as the calling system) developed and 
validated in the previous Chapters. It was possible to detect instability in all 
specimens from all tumours, while normal specimens did not exhibit any unstable 
marker. These findings confirm the initial reported phenotypes of the tested tumours 
and strongly support the previous validation of the NGS based MSI assay. 
 The development and validation of short amplicons (~ 150bp) has improved 
the success rate of analysing FFPE samples (90% of samples were successfully 
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amplified and sequenced with ≥20 markers). The ability to investigate the FFPE 
samples adds more advantage as these samples represent the major biological 
resource available in the pathological archives. Furthermore, being NGS based, the 
current approach looks more reliable than other studies (Fisher et al., 2016, Blake et 
al., 2001) as they were using fragment analysis to assess the clonal microsatellite 
alterations. However, the notable shortcoming of the current assay is that it is applied 
to MSI-H CRCs only. The exact estimation of tumour cell percentage and 
contamination with normal cells are additional limitations. However, tumour 
enrichment techniques (e.g. Laser capture microdissection) could be applied in future 
to reduce normal cell contamination.   
6.4. Conclusions  
 The microsatellites can be used as evolutionary markers to assess the 
intratumour heterogeneity. The newly developed microsatellite markers proposed 
and validated by our group could be used to assess the clonality of the CRC 
tumours. The cutoff values that were suggested previously worked very well in 
discrimination between MSI-H and MSS CRC samples. The results of this chapter 
can be used to confirm the utility of microsatellites as convenient markers to assess 
the tumour age in MSI-H CRCs as evident in phylogenetic trees. Moreover, these 
results provide additional evidence for the reproducibility of the NGS based MSI 
assay developed and validated in the previous Chapters. 
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Chapter 7. General Discussion and Future work 
7.1. General discussion 
 Due to the importance for diagnosis, prognosis and treatment, microsatellite 
instability testing has been recommended to be performed for all newly diagnosed 
CRC cases (de la Chapelle and Hampel, 2010, Vasen et al., 2013). Recently, a 
group of scientific societies (Association for Molecular Pathology, American Society 
of Clinical Oncology, American Society for Clinical Pathology and College of 
American Pathologist) released a guideline draft for the assessment of molecular 
biomarkers in CRCs. In that draft, MSI test was recommended for all newly 
diagnosed CRCs (Medscape, 2015). The most widely adopted MSI testing 
methodology is by multiplex PCR of 5 mononucleotide markers (20- 27bp in length) 
followed by fragment analysis and observation of allelic profile of the amplified 
markers in tumour compared to matched normal sample (Suraweera et al., 2002, 
Boyle et al., 2014). Although this approach is the most widely used one, it has 
limitations. It is laborious and the interpretation of results is mainly based on 
subjective inspection of the allelic peaks in addition to suboptimal specificity (Nguyen 
et al., 2013, Berg et al., 2009). For all the above reasons, this test is inconvenient to 
test all the newly diagnosed CRCs in line with the recent recommendations. 
Therefore, there is a need to develop a high throughput approach capable of 
satisfying the increasing need to test more CRCs being referred for MSI analysis. 
 One of the reported caveats of NGS is the high error rate in sequencing long 
homopolymers (Minoche et al., 2011). Long homopolymers were reported to 
generate more sequencing errors (~60% error rate for 13bp repeats), and these 
errors are reduced as the length of repeat decreases (down to error free for 9bp 
repeats) (Clarke et al., 2001). Short mononucleotide repeats (7-12bp), therefore,  
offer a good option to implement such an approach as they are less prone to 
generate sequencing errors compared to longer ones (Redford, 2016). I have 
developed a panel of 17 short (7-12bp) repeats derived from an in silico search of the 
length variable repeats in MSI-H CRCs. Observation of deletion curves for all the 
tested markers in that part of the assay showed that the sensitivity of a given marker 
is always less than specificity at a specific value of deletion frequency (see Chapter 3 
section  3.2.2.1). This indicated that the inclusion of more markers in the final panel 
would be justified to improve the sensitivity. A threshold set of length-specific cutoff 
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values were determined. Variant reads in the MSS samples were more prevalent with 
the longer (11 and 12bp) markers than shorter markers (7-9bp), therefore, rising 
cutoff values for these long markers improved specificity. This also confirmed that 
longer markers are more variable (length variation) compared to short repeats (7-
10bp). This observation is consistent with other studies (Clarke et al., 2001, Fazekas 
et al., 2010, Redford, 2016). Another finding is that including the allelic bias 
information (which is the other parameter used in this assay to identify instability) 
increases the reliability of MSI calling compared to using deletion frequency alone. 
Therefore, a combined score for calling instability (referred to as weighted scoring 
system) was proposed. In the weighted MSI scoring system, a specific score was 
given for each feature (i.e. deletion frequency and allelic bias) and an overall score of 
≥3 was used as cutoff for calling a sample as MSI-H. The use of a cutoff value as 
high as ≥3, appears justifiable as this means that any given sample can only be 
called as MSI-H when at least 2 markers exhibited deletion frequency above the 
length specific threshold, and one of them should have evidence of allelic bias. In the 
absence of allelic bias, 3 markers with deletion frequency above threshold (none with 
allelic bias) are required for a sample to be called as MSI-H. This would reduce the 
possibility of mis-calling a stable sample as MSI-H when the cutoff value is low, as 
there is evidence that all CRC cases (including MSS cases) have a low level of 
instability (Laiho et al., 2002). This weighted scoring system was then validated 
across an independent cohort and yielded a 100% sensitivity and specificity. This 
provides evidence for employability of the 17 markers panel alongside the weighted 
scoring system. Although this system yielded 100% specificity and 96% sensitivity, 
the reliance on heterozygous SNPs to determine the allelic bias represents the main 
drawback of this system. 
7.1.1. Comparison of the current assay with other methods   
In 2012, TCGA published a seminal paper about the genome wide somatic 
alteration in CRCs (Cancer Genome Atlas, 2012). In that study, researchers used 
next generation sequencing to detect mutations and classify CRCs. In addition to 
investigating somatic mutations, they also utilised exome data to analyse MSI (using 
a set of 36 coding mononucleotide markers 6-10bp in length) by quantitative 
comparison of the altered allele to the wildtype allele (variant allele frequency). It was 
possible, from that study, to detect high variant allele frequency of mononucleotide 
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markers in selected genes in tumour samples compared to the corresponding normal 
tissue. Tumours that lack the MLH1 gene function were found to show up to 50-fold 
increase in frameshift mutations in these target genes compared to those with 
wildtype MLH1. Furthermore, it was concluded that the degree of instability of a given 
marker affected by the length of that marker. That study provided the first evidence of 
the possibility to test MSI in short repeats using next generation sequencing. Since 
then, several groups have tried to develop new approaches for MSI testing robust 
enough to cope with the increased number of cases being referred. In 2013, an MSI 
assay based on RNA sequencing data was investigated (Lu et al., 2013). In that 
study, RNA-seq data were gathered and analysed from 20 different cancer cell lines 
with known MSI status. The proportion of insertions in microsatellite loci over all 
insertions (named as PI) and the proportion of deletions in microsatellite loci over all 
deletions (named as PD) were calculated. The ratio between them (PI/PD) was 
referred to as MSI- seq index and used to assess the instability of each microsatellite 
locus. A significant increase in the proportion of indels was observed in the MSI 
samples compared to those in control samples (HapMap samples in that particular 
study), while there was no significant difference between MSS and the control 
samples. The disadvantages of this approach are the dependence on the expressed 
microsatellites, the lack of analytical validation for the proposed MSI-Seq index and 
being an RNA- seq based assay, which is relatively expensive. The work presented 
in this thesis has the advantages on Lu et al’s work in that short repeats were 
analysed in amplicon based MiSeq sequencing and the calling system was validated 
using an independent cohort.  
In 2014, a further NGS based MSI analysis pipeline (called mSING), was 
proposed and assessed (Salipante et al., 2014). NGS data from a total of 324 
different tumours (colorectal, endometrial, ovarian, breast and others) from 3 
independent assays (TCGA exome, ColoSeq UW and Oncoplex UW) were 
retrospectively examined to assess instability in 2957 (for TCGA samples), 146 (for 
ColoSeq UW) and 15 (for Oncoplex UW) mononucleotide markers. These markers 
were 3-36bp in length. The analysis was based on calculation of the variant allele 
frequency. Each variant allele with sequencing reads exceed 5% of the most 
abundant allele was tallied and the variant allele frequency for each marker was 
calculated in the MSS group to create a baseline reference value. Then, mean 
 176 
 
number of alleles for each microsatellite marker and standard deviation were 
calculated for the MSS group. The same calculations were done for the MSI-H group 
of samples and the marker was said to be unstable if the number of alleles is more 
than (mean number of alleles + (3xSD) of the baseline reference) of the MSS group. 
They called this approach mSING (MSI by NGS) and a combined sensitivity and 
specificity of 97.8% and 98.3% was obtained in the tested cohorts. One disadvantage 
of that study is that it lacks a validation assay and the vast majority of the analysed 
markers were derived from the TCGA exome analysis (which has used fresh frozen 
CRC samples). Furthermore, being dependent on the MSS reference value, this 
means that MSS baseline reference value needs to be set in each run separately. 
Advantages of the work presented in this thesis on Salipante’s work are that, all CRC 
samples (during both development and validation) were FFPE, which is the same 
kind of samples that would be referred in routine work, making the assay more 
compatible with current practice in clinical laboratories. In addition, a fixed set of 
length specific cutoff values of deletion frequencies was proposed for calling 
instability, which can be used permanently across different MiSeq runs, without the 
need for normal tissue to be routinely analysed. 
More recently, Gan et al. (2015) used Illumina MiSeq platform to assess the 
utility of both mononucleotides (3 markers 25-34bp in length) and dinucleotides (2 
markers 40bp in length) in microsatellite instability using 2 independent cohorts 
collectively composed of 52 CRC samples. For each marker, the most prevalent 
allele in both tumour and a corresponding normal sample was calculated. Then, the 
marker was classified as unstable if the deviation in the tumour sample compared to 
normal was ≥2bp for mononucleotides and ≥ 4bp for dinucleotide markers. 
Quantitative analysis of the MiSeq data from that study showed that the sensitivity 
and specificity of these mononucleotides were both 100%, while for dinucleotides, 
the sensitivity was 47- 59% and specificity was 96- 100%. Although this study used 
the ultra-deep sequencing of microsatellites, notable disadvantages of this analysis 
were the use of long mononucleotide and dinucleotide markers, the unblinded 
analysis and the comparison with matched normal tissue. Advantages of the work 
presented in this thesis over Gan et al’s work are that  MSI analysis was done using 
a relatively high number of samples (266 FFPE CRC samples in total), of them, 211 
samples were analysed blindly using short (7-12bp) mononucleotide markers. 
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Furthermore, the analysis was done without interrogation of matched normal samples 
which will reduce the cost. In addition, our assay has utilised another feature to 
assess instability and to increase the confidence that the detected alteration is a real 
instability rather than a sequencing artefact. This additional tool called allelic bias and 
to our knowledge, this is the first time this tool has been deployed in detection of 
microsatellite instability.  
7.1.2. Comparison of deletion curves suggests further assessment of 
robustness and reproducibility is required 
Deletion curves are the graphical plotting of deletion frequencies for a given 
marker across all MSI-H and MSS samples. The comparison of deletion curves of the 
17 markers across the 3 different cohorts indicated that 2 markers (LR36-12 and 
GM14-11) showed low specificity in the Spanish cohort as explained in Chapter 5 
section  5.2.3. The marker LR36-12 showed a low specificity in the Spanish cohort 
compared to other cohorts (Specificity= 92%) at 30% deletion frequency. This 
anomaly is likely due to the relatively low depth to which that marker was sequenced 
(average sequencing depth was 188 per/amplicon) compared to other markers 
(ranging from 1619 for marker GM7-11 to 5096 for the marker LR24-9) in that 
particular cohort. This assumption is supported by the fact that there was no such a 
problem with this marker either in Newcastle or in the Edinburgh cohorts, where the 
average depth to which this marker was sequenced in both cohorts was more than 
188 per/amplicon. 
Marker GM14-11, showed a significantly lower sensitivity in the Newcastle 
cohort (= 25%) and showed the lowest specificity in the Spanish cohort (= 89%) at a 
deletion frequency of 30%. For this marker, 4 MSS samples in the Spanish cohort 
were found to be discordant as they showed deletion frequency above 30% (which is 
the cutoff value used for that particular marker). I investigated the possible underlying 
reason for this difference by inspecting the nature of surrounding sequences and 
checking for the existence of SNPs at the primer annealing site. There was a low 
minor allele frequency (MAF) SNP (rs539119173 with MAF= 0.06%) at the primer 
annealing site (as explained in Chapter 5 section  5.2.4.1), so this could be one 
possible reason for the inter-cohort difference. 
I re-tested the marker GM14-11 in 24 samples from 2 different cohorts 
(Spanish and Newcastle cohorts) in an independent MiSeq run with higher library 
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concentration (= 10 pM) compared to the initial test (= 4 pM). Out of the 24 retested 
samples, only 2 samples (S79 and S74) were called differently in the re-analysis 
assay, and both of them were called as stable in the re-analysis while they were 
unstable in the initial assay. For both amplicons with discordant reads, the deletion 
frequency was lower in the re-analysis assay compared to the initial assay as shown 
in Table  7-1. This difference in deletion frequency is more likely owing to the change 
in the library concentration, and consequently sequencing depth (as explained in 




Initial Re-analysis Initial Re-analysis 
MSI status Unstable Stable  Unstable  Stable  
Library Concentration 4 pM 10 pM 4 pM 10 pM 
Deletion Frequency 36% 6% 40% 8% 
Depth (per/amplicon) 253 1756 509 36487 
Table ‎7-1: Specifications of the marker GM14-11 with discordant reads in 2 different 
samples (S74 and S79). There is a notable difference in deletion frequencies between the initial and 
re-analysis in both amplicons, which could be explained by the notable difference in sequencing depth 
for both amplicons. 
Both amplicons were included in the DNA integrity assay shown in Chapter 4 
section  4.2.7 and both of them showed DV100<17% of the tested DNA samples, 
indicating that DNA degradation is an unlikely reason. This supports the notion that a 
specific depth is required to ensure that a correct calling of instability is made. 
7.1.3. Suspicion of polymorphism in 2 independent markers in 2 different 
samples 
All the 17 markers included in the panel were defined as monomorphic 
according to dbSNP 144 build. However, the discovery of private polymorphisms is 
always possible. During the extensive analysis of these markers against the 3 
geographically distinct cohorts used here, 2 markers showed an unusually strong 
allelic bias in 2 different samples from 2 independent cohorts. The marker DEPDC2-
G showed 90% of sequencing reads from +1 genotype (i.e. 1bp insertion) in sample 
S129 (from the Spanish cohort). The other marker is LR48-11 showed 98% of 
sequencing reads from -2 genotype (i.e. 2bp deletion) in the sample E82 from 
Edinburgh cohort. However, I was unable to confirm the polymorphism in both 
instances because this needs a corresponding germline DNA to be tested. Therefore, 
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it is recommended that, whenever there is a suspicion of polymorphism which could 
influence an MSI classification, a normal tissue from the same patient need to be 
tested to confirm or exclude polymorphism. This indicates that allelic bias should be 
carefully interrogated in order to differentiate it from polymorphism.  
7.1.4. Determination of the optimal quality metrics for an NGS based MSI 
approach 
Three library concentrations were tried in the 3 independent MiSeq runs, 4, 8 
and 10 pM. In the first Miseq run, I followed the instructions of the Nextera library 
preparation protocol and a library concentration of 8 pM was used. That run resulted 
in 1700 k/mm2 cluster density and Q30 score (99.9% probability of a base being 
called correctly) of 66.7% as shown in Table  7-2 
When primers are modified (tagged primers targeting ~150bp amplicons), the 
16S metagenomics protocol was used for library preparation. According to that 
protocol, it is recommended to start with 4 pM as initial library concentration. Using 
that concentration resulted in a relatively low cluster density and low overall 
sequencing reads (510 k/mm2 cluster density and 12,610,764 sequencing reads). 
However, using that concentration resulted in the highest quality score (Q30= 
69.1%), which is expected in the view of such a low cluster density. In order to 
improve both data output and cluster density, I tried higher library concentration (10 
pM) in the subsequent MiSeq run. That run yielded a better cluster density and 
overall sequencing reads (1450 k/mm2 and 34,774,582), but at the cost of Q30 score 






Newcastle Spanish Edinburgh 
Library Concentration ( pM) 8 4 10 
No. of amplicons  1,200 2,267 2,595 
Amplicon size (bp) ~300 ~150 ~150 
Sequencing Success rate (%)  97.5% 80% 99% 
Total No. of reads 41,383,441 12,610,764 34,774,582 
% PF 92.7% 94 % 88.8% 
Average  Coverage 
(per/amplicon) 
10,400 2,900 5,100 
Q30 66.7% 69.1% 55.5% 
Cluster density (k/mm
2
) 1,700 510 1,450 
Table ‎7-2: Quality metrics for the 3 MiSeq runs using 3 different library concentrations.  
per= paired end reads. Sequencing success rate= the percentage of amplicons that were 
sequenced to a depth of ≥100 reads. %PF= percentage of sequencing reads that have passed the 
quality filter. 
Based on the information summarized in Table  7-2, it would be possible to 
recommend specific inputs for an optimal assay. A run composed of 96 samples 
amplified across the 17 markers (all have amplicon size ~150bp) in a library 
concentration of 8 pM could therefore be suggested. In theory, the average 
sequencing depth (coverage) expected from such a MiSeq run is 5,000-10,000 
per/amplicon. It would be possible to increase the number of samples being 
analysed, but of course at the cost of average depth. However, it was possible to 
successfully call instability in most amplicons (80%) even in the MiSeq run with the 
lowest depth (the MiSeq run of Spanish samples). Performing such a run, would be 
useful to determine the optimal number of samples that can be analysed in a single 
run at a specific library concentration in the future.  
7.1.5. Cost analysis and turnaround time 
Microsatellite instability becomes increasingly important, especially for CRCs. 
Recently, the cost effectiveness of 8 strategies for detection of Lynch syndrome in all 
early onset (<50 years) CRCs was assessed (Snowsill et al., 2015). In that 
systematic review, the 8 testing strategies ranged from no genetic testing (strategy 1) 
to direct mutation testing (strategy 8) for all newly diagnosed CRCs before the age of 
50. Interestingly, strategy 5 (which represents MSI testing (if positive) > BRAF testing 
(if negative) > mutation testing) was found to be the most cost effective strategy 
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(costing 5,491 GBP/ Quality adjusted life year gained over no testing strategy). This 
strongly supports the cost effectiveness of MSI testing of all newly diagnosed CRC 
patients and increases the demand to develop an accurate and cost effective MSI 
assay. However, further analysis is underway to inform NHS policy and the cost of 
MSI testing is likely to be a pivotal issue in that debate (Tristan Snowsill personal 
communication). 
In order to reduce the overall cost of our assay, primers were designed to be 
incorporated with tag sequences, thus reducing the cost and time required for the 
subsequent library preparation. Moreover, the tagged primers were designed to 
amplify shorter sequences (~150bp) rather than the initial 300bp amplicons that are 
recommended by the Nextera library preparation protocol. Multiplexing the amplicons 
in a single PCR reaction would streamline the assay, reduce the time, effort and cost. 
Previous trials of duplexing 2 amplicons were successful and ongoing trials of 
multiplexing showed the feasibility to amplify the 17 markers in down to 4 separate 
multiplexed reactions. 
A cost analysis was done (shown in Appendix Table  8-3) and according to that 
analysis, the cost of the recommended MiSeq run is expected to be 26.2 GBP/ 
sample and the test results are expected to be reported in 7 days as explained in 
Appendix Table  8-3 and Table  8-4. However, Automation of pre and post PCR steps 
together with use of automated pipeline for data analysis would shorten this 
turnaround time to a single week (i.e. 5 working days only).  
We are in a position now to liaise with the clinical laboratories to perform the 
MSI test developed and validated in this thesis in parallel to their routine test as a 
further step to fulfil the clinical monitoring of the MSI assay. This monitoring would be 
useful to assess the concordance rate of our test with the currently used test and, 
ultimately, making it ready to be commercialized. As our test is designed to be a high 
throughput approach, the collection of 96 samples (that was recommended in 
section  7.1.4) from a single laboratory would be likely to take a long time, so it would 
be worth to setting up the test in a reference genetic laboratory and asking all 
regional laboratories to refer their CRC samples. This will allow gathering the 
required number of samples in a comparatively short time.   
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7.1.6. Future improvements in assay design  
As this test is developed and tested in an NGS platform, it would also be 
possible to include other relevant variants (e.g. BRAF, MMR, KRAS genes) with this 
MSI assay to be done at the same run. This will facilitate the overall approach by 
doing these tests in a single run while they are currently done separately. In addition, 
this will minimise the cost per case dramatically compared to the current multistep 
approach. Recently, both MSI and mutational hot spots of relevant genes (KRAS, 
NRAS, and BRAF) were combined in a single NGS assay in an approach called 
MSIplus (Hempelmann et al., 2015). MSI was assessed in 81 tumours using 
mononucleotide markers (12- 28bp in length) while mutational analysis was done for 
61 tumours. Among them, 15 samples were tested for both MSI and mutational 
hotspots in the target genes mentioned above using the Illumina MiSeq platform. The 
MSIplus approach used the software mSINGS for calling instability developed by 
(Salipante et al., 2014) and the assay was reported to be 97% sensitive and 100% 
specific in the detection of MSI. Advantages of this assay are: the inclusion of 
additional target genes in the same sequencing run, the omission of the need for 
normal tissue control and the high sensitivity and specificity. Disadvantages of the 
MSIplus approach are the use of long repeats and the use of mSINGS that (as 
explained earlier) depend on the establishment of MSS baseline values of variant 
read length. This means that, a baseline needs to be established for each run 
independently. The work in this thesis has the advantages on MSIplus in that: short 
mononucleotides were used and a clearcut threshold set of cutoff values was 
developed and validated. 
The development and validation of the NGS based MSI test done in this thesis 
would provide a basis for further development of the assay to be able to detect 
microsatellite instability in the existence of very low number of tumour cells or 
become a non-invasive approach. In 2011, microsatellite instability was detected in 
saliva in higher abundance than in peripheral blood in MMR gene mutations carriers 
(Hu et al., 2011). This means the test could be offered in a non-invasive approach by 
targeting the cellular components of saliva. However, detection of such a low 
prevalent DNA needs a more sensitive methodology (high sensitivity to detect cells 
existed in a low population). To improve detection of low prevalence variants (e.g. in 
saliva or circulating tumour cells), researchers tried an ultrasensitive targeted 
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sequencing using a modified probe called single molecule molecular inversion probe 
(smMIP) (Hiatt et al., 2013). Such an approach would streamline the assay and make 
the detection of low prevalent variants possible. Furthermore, this approach is highly 
accurate (error rate down to 1 error/10,000 bases) and reduces the impact of low 
quality DNA. It would be worth to try to incorporate the 17 primer pairs developed and 
validated in this thesis with smMIPs to enable the assay to be multiplexed and able to 
detect low prevalence mutations.   
7.1.7. Using short mononucleotide markers to assess intratumour 
heterogeneity 
In chapter 6, 23 short mononucleotides were used to assess the clonal 
characteristics of 56 MSI-H tumour specimens (from 4 fresh and 7 FFPE). It was 
possible to detect intratumour variation in microsatellite instability. Lymph node 
specimens were tested in 3 FFPE tumours (PR7146/13, PR34630/03 and 
PR32079/14). In all the 3 tumours, the lymph node showed shared instability 
(instability in some or all markers) with the corresponding primary tumours. This 
provided evidence of employability of short repeats to assess lineage relationship of 
both primary tumour and its associated metastasis.  
In the tumour PR53139/13, 4 samples (1H, 1J, 1M and 1N) were investigated. 
All the 4 tested specimens showed at least 5 unstable markers. Interestingly, both 1J 
and 1H specimens of that tumour were reported to have <5% tumour cell population 
and exhibited at least 5 unstable markers (in the specimen 1J). A possible 
explanation for the detection of microsatellite instability in spite of the low tumour cell 
content in those samples is that this tumour might be too old (long time since loss of 
MMR genes), thus resulted in a high level of instability. 
In the fresh CRC tumours, 8 specimens were retrieved from each tumour 
together with normal tissue sample from the same patient. It was possible to assess 
the clonal characteristics of all tumours. Furthermore, this enabled me to construct 
the phylogenetic tree for all of them. Three of the 4 tested tumours were examined 
previously for clonal characteristics by Dr Lisa Redford (Redford, 2016). However, in 
that assay, these tumours were investigated across 20 mononucleotide markers (8-
14bp in length), 12 of them were included in my assay. The average depth in 
Redford’s work (1672 per/amplicon) was relatively lower than the depth achieved in 
my work (4971 per/ amplicon). In Redford’s work, the specimen 6° S of the tumour 
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PR51896/13 did not show instability in any of the 20 tested markers, while the same 
specimen showed 2 unstable markers (LR24-9 and AVL-10) in my analysis. This 
difference is, perhaps, due to the relatively low sequencing depth of that specimen 
(1100 per/amplicon) compared to the depth to which the same specimen was 
sequenced in my analysis (5036 per/amplicon). 
Overall, results from the clonality analysis showed that mononucleotide 
markers can be used to identify intratumour heterogeneity and help to identify cells 
from different clones, thus providing a tool to construct a lineage relationship among 
different specimens from the same tumour. Furthermore, the incorporation of primers 
with smMIPs would make the approach more sensitive and enables detection of 




Chapter 8. Appendix 
Case  No. MS Status Homopolymers tested 
G1 MSI-H All 25 markers 
G2 MSI-H All 25 markers 
G3 MSI-H All 25 markers 
G4 MSI-H All 25 markers 
G5 MSI-H All 25 markers 
G6 MSI-H All 25 markers 
G7 MSI-H All 25 markers 
G8 MSI-H All 25 markers 
G9 MSI-H All 25 markers 
G10 MSI-H All 25 markers 
G11 MSI-H All 25 markers 
G12 MSI-H All 25 markers 
G13 MSI-H All 25 markers 
G14 MSI-H All 25 markers 
G15 MSI-H All 25 markers 
G16 MSI-H All 25 markers 
G17 MSI-H All 25 markers 
G18 MSI-H All 25 markers 
G19 MSI-H All 25 markers 
G20 MSI-H All 25 markers 
G21 MSI-H All 25 markers 
G22 MSI-H All 25 markers 
G23 MSI-H GM9,GM11,GM21,GM28,LR15,IM14,LR46,IM41, 
LR24,IM43,IM59,LR49,LR51,GM17,IM16,LR40 
G24 MSI-H GM9,GM11,GM21,GM28,LR15,IM14,IM41, 
LR24,IM43,LR49,LR51,GM17,IM16,LR40 
G25 MSI-H IM19,IM55,IM66,IM67,LR10,GM23,LR20,LR8,LR21 
6 MSS All 25 markers 
9 MSS All 25 markers 
11 MSI-L All 25 markers 
12 MSI-L All 25 markers 
13 MSI-L All 25 markers 
14 MSI-L All 25 markers 
15 MSI-L All 25 markers 
16 MSS All 25 markers 
17 MSS All 25 markers 
18 MSS All 25 markers 
19 MSS All 25 markers 
20 MSS All 25 markers 
21 MSS All 25 markers 
22 MSS All 25 markers 
23 MSS All 25 markers 
24 MSS All 25 markers 
25 MSS All 25 markers 
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Case  No. MS Status Homopolymers tested 
26 MSS All 25 markers 
27 MSS All 25 markers 
28 MSS All 25 markers 
29 MSS All 25 markers 
30 MSS All 25 markers 
31 MSS All 25 markers 
32 MSS All 25 markers 
33 MSS All 25 markers 
34 MSS All 25 markers 
35 MSS All 25 markers 
48 MSS All 25 markers 
49 MSS All 25 markers 
50 MSS All 25 markers 
Table ‎8-1: Samples that were included in the Newcastle cohort  and the markers analysed for 









LR49- 7 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAATTTGGGAAAGGGGCACAA 
LR49- 7 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGTGATGGCCAAGTCCCC 
IM66 - C FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAGGAGGTGCTGGAAATCC  
IM66 - C RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCATCAGCCGCGTCGTAGG 
DEPDC2- G FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTTCACACACATGCAAGCTG 
DEPDC2- G RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAAGGGTAGGGAGATGCAGA 
GM9- 8 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCCGTATTCCAGGAGTAAGAGT 
GM9- 8 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTCAGAGGGAAGGTGGCA 
LR20- 8 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGCATTGCCCCTATATACTGT 
LR20- 8 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTCCCAGTTCTGAATCTAGAAAGA 
GM11- 9 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGTATCTAAGTATTCTCCAGC  
GM11- 9 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACAGTGGGTTTCAAATGTCACTTC 
LR24- 9 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGTAACCAAAGCAGGAAAACATT 
LR24- 9 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCCTCTCTCCCTGGAATAAGT 
IM16- 9 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAATCAGCAGTGTTCATACCTTC 
IM16- 9 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTGTTCACTTTAGTAGGAACTGGT 
GM17- 9 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGAAGTCAGTGCATGTGTCTT 
GM17- 9 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCCACCAAGATTGTAAAATGTGA 
AP0035322- 9 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACTGTGGTTTTAATTTGCATTTCCC 








GM7- 11 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGTGGCTTGTTTTCATTTTGTC 
GM7- 11 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCATATGGGGTTTGGTCACATTTT 
GM14- 11 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTCAATGACTTCCCAGGCTAA 
GM14- 11 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAACATTGTGGATTGCTAGCTG 
LR48- 11 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGGAGGAAGTATCTGGTCTTCT 
LR48- 11 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCACATTTACTTAAGCCCTGG 
LR11- 11 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCCTGTGGTCTGTGAAGCTA 
LR11-  11 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTGCATTTGAACATCGCCTC 
LR36- 12 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGGTGACCCTGAACGTTAA 
LR36- 12 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCTGGGTGTAAATGATGGGAA 
LR44- 12 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGGCCAAGAGTTCAAGACCA 
LR44- 12 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGATGAGAATTAGCATACCTTCCA 
IM49- 12 FP TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGTAGTTGGATCGCTTCAGG 
IM49- 12 RP GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAGCCTCTTGAGTAGCTTGG 
Table ‎8-2: The 17 primer sets that were used in the analysis of both Spanish and Edinburgh cohorts.  All primers were incorporated with 5’ tag 








MiSeq based assay Fragment Analysis assay 















17 17 400 0.04 x 17 (0.68) MSI Analysis system 1 757 50 pairs 19 (40 pairs + 
cotrols for 5 runs) 
Herculase  
(800 rcs for 25 µl) 
1 281 800 0.35 x 20 (7) AmpliTaq Gold DNA 
polymerase (100 rcs) 
1 38 100 0.42 (90 rcs + 
controls) 
MiSeq kit v3 
(600 cycles) 
1 1,035 96 10.8 HiDi formamide 
(25ml) 
1 32 200 0.16 
QIAxcel screening 
kit (2400) 
1 517 2,400 4.3      
AMPure XP  
(60 ml)  
1 721 500 1.4      
Qubit dsDNA  HS 
assay  kit  
1 168 500 0.33      
Nextera XT Index 
kit (96 indexes for 
384 samples) 




   26.2 (96 samples) 
22.3(150 samples) 
    19.58 (40 pairs) 
Table ‎8-3: Cost analysis and comparison between MiSeq based assay and the conventional fragment analysis based assay.  The cost of 
MiSeq analysis of 96 samples is 26.2 GBP/ sample (red coloured text) while the cost could be reduced to 22.3 GBP/ sample when 150 samples are analysed 









Step Time (days) 
DNA extraction and quantitation 2 
PCR * and QIAxcel analysis 4 (1*) 
Library preparation 1 
MiSeq 2 
Data analysis ** 1** 
Overall TAT 11 (7*) days 
Table ‎8-4: Total turnaround time (TAT) expected from the MiSeq based assay.The expected TAT to analyse 96 samples is 11 working days. When 
the 17 markers are amplified in 4 multiplex PCR reactions (rather than 17 reactions) for each sample and data analysis is automated, the TAT would be 
reduced to 7 working days only (shown in asterisks). However, when both pre and post-PCR steps are automated, the TAT is expected to be as short as 5 





















Figure ‎8-3: Deletion frequencies of a subset of 15 markers in the tumour PR32079/14. 1S, 





Figure ‎8-4: Deletion frequencies of a subset of 16 markers in the tumour PR53139/13.  1J, 





Figure ‎8-5: Deletion frequencies of a subset of 14 markers in the tumour PR10654/14. (N) 





Figure ‎8-6: Deletion frequencies of a subset of 18 markers in the tumour PR17848/14. (N) 





Figure ‎8-7: Deletion frequencies of a subset of 14 markers in the tumour PR51896/13.  (N) 





Figure ‎8-8: Deletion frequencies of a subset of 13 markers in the tumour PR32516/14.  (N) 
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